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1 INTRODUCTION 
1.1 The human immune system 
Our body’s integrity is constantly threatened by the invasion of microorganisms and the 
development of neoplastic cells. But we have evolved systems of immune defense to 
eliminate infective pathogens and tumor cells. As in all jawed vertebrates, there are two 
types of defense in humans: the innate and the adaptive (also known as acquired) 
immunity. Multiple interactions between these two branches of the immune system are 
required for cooperative elimination of foreign pathogens and transformed host cells. 
 
 
1.1.1 The two arms of the immune system 
The innate immune system is a phylogenetically very old and evolutionarily conserved 
system. It provides a first line of defense against invading pathogens and is mainly 
mediated by phagocytes such as dendritic cells and macrophages. These cells can 
effectively sense microbial infection, rapidly contain it locally and subsequently induce 
a systemic inflammatory response. In contrast, adaptive immunity is involved in 
elimination of pathogens in the late phase of infection but is highly specific and long- 
lasting by generating an immunological memory. This specificity of the adaptive 
immune system is assured by antigen-specific receptors expressed on the surface of 
T and B lymphocytes. By individual somatic recombination of the genes encoding these 
receptors, a nearly infinite repertoire of receptors with random but narrow specificities 
is generated in a process called gene rearrangement. Each T and B cell expresses 
antigen receptors of only a single specificity. In response to a certain pathogen, only 
particular populations of lymphocytes are selected to clonally expand, which is the 
basis for immunological memory. 
 
Unlike the adaptive immune system, the innate immune system is not a single entity. It 
is a collection of distinct subsystems that carry out different functions in host defense. 
Mucosal epithelia and the skin, for example, form physical barriers and also produce 
antimicrobial peptides and mucins preventing pathogen attachment and entry. Another 
module, the acute phase proteins and complement produced by hepatocytes are a 
cascade of serum proteins leading to opsonization and lysis of pathogens as well as 
chemotactic attraction of leukocytes. Phagocytes take up and process antigens to later 
present these to cells of adaptive immunity. However, the innate immune response is 
not completely nonspecific as originally assumed, but rather is able to discriminate 
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between self and a variety of pathogens. The innate immune system recognizes 
microorganisms via a limited number of germ line-encoded pattern-recognition 
receptors (PRR), in contrast to the huge repertoire of randomly rearranged receptors 
utilized by the acquired system. 
 
 
1.1.2 Pattern-recognition receptor families 
Pattern-recognition receptors recognize microbial components known as pathogen-
associated molecular patterns (PAMP) and were first hypothesized twenty years ago 
by Charles Janeway [Janeway, 1989]. PRR are germ line encoded, non-clonal and 
expressed constitutively on all cells of a given type. Each receptor has a broad 
specificity and the potential to bind to a variety of molecules that share a common 
motif. These pathogen-associated molecular patterns are generally unique to 
microorganisms and thereby allow discrimination between self (host) and non-self 
molecules. They are invariant among a class of microorganisms and have essential 
roles in microbial physiology, hence limiting the ability to evade immune recognition 
through adaptation and alteration of these molecules. In addition to PAMP, innate 
receptors have the potential to also recognize endogenous molecules that are released 
by host cells as a result of infection, damage or necrosis. The recognition of these 
molecules is tightly linked to the pathogenesis of chronic inflammatory and autoimmune 
diseases. 
 
 
1.1.2.1 Membrane-bound receptors 
The best characterized class of PRR is the family of Toll-like receptors (TLR). In 1996, 
it was demonstrated that Drosophila carrying mutations in a receptor called ‘toll’ were 
highly susceptible to fungi infection as they showed defective induction of anti-fungal 
peptides [Lemaitre et al., 1996]. Later, a human homologue of toll – now known as Toll-
like receptor 4 – was discovered and shown to induce innate immunity by production of 
inflammatory cytokines and expression of co-stimulatory molecules [Medzhitov et al., 
1997]. These and other studies led to the identification of the family of membrane-
bound TLR. So far, 13 members of the TLR family have been described [Akira et al., 
2006]. TLR1 to 9 are conserved between humans and mice although TLR8 is 
non-functional in mice as well as TLR10 due to a retrovirus insertion. TLR11 to 13 were 
lost in the human genome. Regarding their cellular location, the members of the TLR 
family can be divided into two subpopulations: On the one hand, TLR1, 2, 4, 5, 6 and 
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11 are expressed on the cell surface and thereby recognize components of microbial 
membranes or fungal cell walls such as lipids, lipoproteins or proteins. On the other 
hand, TLR3, 7, 8 and 9 are localized in the membrane of intracellular vesicles such as 
endo-/lysosomes and the endoplasmatic reticulum. This subpopulation of receptors 
predominately recognizes microbial nucleic acids such as bacterial DNA containing 
unmethylated CpG motifs (CpG-DNA) thus differing from mammalian DNA. Table 1.1 
gives an overview of TLR and their most important ligands. 
 
TLR PAMP/activator Species Reference 
TLR1 Heterodimers with TLR2   
TLR2 
Triacyl lipopeptides 
  
Diacyl lipopeptides 
 
Zymosan 
Bacteria 
 
Mycoplasma 
 
Fungus 
[Takeuchi et al., 1999] 
 
[Takeuchi et al., 2001] 
 
[Ozinsky et al., 2000] 
TLR3 dsRNA Virus [Alexopoulou et al., 2001] 
TLR4 
Lipopolysaccharid (LPS) 
 
Envelope proteins 
Bacteria 
 
Virus 
[Poltorak et al., 1998] 
 
[Kurt-Jones et al., 2000] 
TLR5 Flagellin Bacteria [Hayashi et al., 2001] 
TLR6 Heterodimers with TLR2   
TLR7 ssRNA RNA virus [Hemmi et al., 2002] 
hTLR8 ssRNA RNA virus [Heil et al., 2004] 
TLR9 
CpG DNA 
 
DNA 
 
Malaria hemozoin 
Bacteria 
 
DNA virus 
 
Parasites 
[Hemmi et al., 2000] 
 
[Lund et al., 2003] 
 
[Coban et al., 2005] 
hTLR10 Not determined   
mTLR11 
Not determined 
 
Profilin-like molecule 
Uropathogenic 
    bacteria 
 
Parasites                    
[Zhang et al., 2004] 
 
[Yarovinsky et al., 2005] 
mTLR12 Not determined    
mTLR13 Not determined   
   
   
Table 1.1: Overview of Toll-like receptors and their main ligands 
 
TLR are predominantly expressed in tissues involved in immune function, such as 
spleen and peripheral blood leukocytes, as well as those exposed to the external 
environment such as epithelia and fibroblasts in the gastro intestinal (GI) tract, skin, 
urinary tract and the lung. Their expression profiles vary amongst tissues and cell 
types. Focusing on immune cells, myeloid cells constitutively express TLR1 and 6; 
macrophages preferentially express TLR2, 3, 4 and 8. B cells express TLR7, 9 and 10 
while CD4pos T cells and natural killer cells were reported to express TLR2; some 
publications describe the expression of TLR2, 3, 5, and 9 on T cells [Ishii et al., 2006; 
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Kabelitz, 2007]. Notably, TLR expression on dendritic cells (DC) shows considerable 
differences between mice and men: human myeloid DC express all TLRs except TLR9 
while plasmacytoid DC only express TLR1, 6, 7, and 9. Murine DC subsets have a 
broader distribution of TLR expression, with mouse plasmacytoid DC expressing all 
TLR but TLR3 and 4. In contrast to human DC, TLR7 and 9 are expressed by most 
subsets of murine DC [Mazzoni and Segal, 2004]. 
 
Dectin-1 is another recently discovered membrane-bound PRR which is TLR-
independent but synergistic as they share partially common signaling pathways. Like 
other members of the diverse family of C-type lectins – many of which have yet 
unknown functions – Dectin-1 is a transmembrane receptor present on dendritic cells 
and macrophages [Robinson et al., 2006]. Dectin-1 specifically binds to β -glucans 
which are glucose polymers found in the cell walls of fungi [Brown et al., 2003]. It has 
been shown that recognition of β-glucans is TLR-2 independent [Ikeda et al., 2008] and 
subsequent signaling is unique to Dectin-1 [Gross et al., 2006]. However, recent data 
suggests that Dectin-1 and TLR2/TLR6 signaling combine to synergistically enhance 
the responses triggered by each receptor in anti-fungal immunity [Gantner et al., 2003; 
Dennehy and Brown, 2007]. 
 
 
1.1.2.2 Cytosolic receptors 
The TLR family and other transmembrane receptors detect PAMP either on the cell 
surface or the lumen of intracellular vesicles such as endosomes. Now, recent studies 
revealed the existence of a cytosolic branch of innate immunity to detect intracellular 
PAMP. These cytosolic detection PRR include retinoic acid-inducible gene-I (RIG-I)-like 
receptors and nucleotide-binding oligomerization domain (NOD)-like receptors. 
 
RIG-I-like receptors - also known as RIG-I-like helicases - constitute a family of 
cytoplasmatic RNA helicases that are critical for host antiviral responses. The 
RIG-I-like receptor family has three known members present in both immune and non-
immune cells: RIG-I, melanoma differentiation associated gene 5 (MDA5) and 
laboratory of genetics and physiology 2 (LGP2). RIG-I and MDA-5 sense double-
stranded RNA (dsRNA), either from genomic RNA of dsRNA viruses or as a replication 
intermediate from single-stranded RNA (ssRNA)-viruses, both leading to potent 
production of type I interferons (IFN) in infected cells [Kawai and Akira, 2009]. Foreign 
RNA is also recognized by TLR3, 7 and 8, which are located in cell endosomes. 
Recognition of viral RNA by these receptor families is cell-type dependent. In myeloid 
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DC, macrophages and fibroblasts, RIG-I-like receptors are the major sensors for viral 
infection, while in plasmacytoid DC, TLR play a more important role [Kato et al., 2005]. 
 
Despite a structural similarity between RIG-I and MDA5, they detect specific viral 
species, presumably through recognition of distinct structures of viral RNA [Kato et al., 
2006]. Notably, RIG-I was demonstrated to bind to ssRNA bearing a 5’-triphosphate 
moiety (3p-RNA) [Hornung et al., 2006; Pichlmair et al., 2006]. Self RNA is either 
capped or contains base modifications suggesting a discrimination mechanism 
between self and non-self RNA. Recently, it was shown that RIG-I binds preferentially 
to short dsRNA while MDA-5 recognizes preferentially long dsRNA [Kato et al., 2008]. 
 
LGP2 was initially implicated to serve as a negative regulator of virus-induced immune 
responses [Yoneyama and Fujita, 2008], but later studies suggested a two-sided role in 
regulation of RIG-I and MDA5 depending on the type of RNA virus [Venkataraman et 
al., 2007]. 
 
Another large family of cytosolic PRR, the NOD-like receptors, comprises at least 23 
human and 34 murine members; for most of which the physiological function remains 
unclear [Ting et al., 2008]. Best characterized are NOD1 and NOD2 as well as NALP3. 
NOD1 and NOD2 recognize distinct structural motifs of bacterial cell walls derived from 
peptidoglycans [Chamaillard et al., 2003; Girardin et al., 2003; Girardin et al., 2003]. 
NALP3 is one of several large caspase-1-activating cytosolic protein complexes called 
inflammasomes [Martinon et al., 2002]. They can recognize not only a wide variety of 
PAMP but different endogenous signs of cell stress and injury, conveniently called 
danger-associated molecular patterns. Activation of the inflammasome leads to potent 
release of cytokines of the interleukin-1 family [Franchi et al., 2009]. 
 
Recent studies suggested a yet undefined cytosolic DNA sensor promoting anti-viral 
and inflammatory responses independent of TLR9 and RIG-I-like receptors [Ishii and 
Akira, 2006; Stetson and Medzhitov, 2006]. DNA-dependent activator of IRF (DAI) has 
been proposed to be this sensor [Takaoka et al., 2007]. However, DAI-deficient mice 
showed an unaffected immune response against double stranded-DNA, suggesting a 
redundant or non-essential role of DAI [Ishii et al., 2008]. Very recently, several groups 
have identified AIM2 as a new receptor for cytoplasmatic DNA, which forms an 
inflammasome with the ligand and activates caspase-1 [Burckstummer et al., 2009; 
Fernandes-Alnemri et al., 2009; Hornung et al., 2009]. 
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1.1.3 Signaling of pattern-recognition receptors 
Signaling pathways via TLR, RIG-I-like helicases, NOD1 and 2 as well as Dectin-1 
culminate in the activation of nuclear factor (NF)-κB and/or mitogen-activated protein 
kinases (MAPK) and activated protein 1 (AP-1), respectively, all transcription factors 
which regulate the expression of various immune and inflammatory genes. 
Furthermore, some TLR and the RIG-I-like receptors also activate members of the 
interferon regulatory factor (IRF) family of transcription factors inducing expression of 
type I IFN separately from inflammatory genes [Kawai and Akira, 2006]. Figure 1.1 
gives a basic overview of PRR and their main target transcription factors; details are 
given in the text. 
 
TLRs belong to a superfamily called the Toll/IL-1 receptor (TIR) family. The TLR 
signaling cascade is initiated by the ectodomain binding to a ligand and subsequent 
dimerization of the receptor. Receptor dimers facilitate the recruitment of four different 
TIR domain-containing cytosolic adapter molecules, the myeloid differentiation primary 
response gene 88 (MyD88), TIR-containing adapter inducing IFN-β (TRIF), TIR 
domain-containing adapter molecule (TIRAP) and TRIF-related adapter 
molecule (TRAM) [Kawai and Akira, 2007]. These adapter molecules are specifically 
recruited to their respective receptor in order to elicitate appropriate immune responses 
depending on the type of PAMP recognized. MyD88 is utilized by all TLR except TLR3 
and ultimately activates NF-κB and MAPK to control inflammatory responses by 
triggering the production of a variety of pro-inflammatory cytokines such as IL-1, IL-6, 
IL-10, IL-12 and tumor necrosis factor (TNF)-α. TIRAP is exclusively recruited to TLR2 
and 4 to act as a link to MyD88 [Horng et al., 2002]. In contrast, TRIF is only used by 
TLR3 and 4, initiating an alternative pathway eventually leading to NF-κB and MAPK 
activation as well as IRF3-mediated induction of type I IFNs. TRAM uniquely serves to 
link TRIF to TLR4, but not TLR3 [Yamamoto et al., 2003]. 
 
Thus, TLR4 recruits two adapter molecule complexes: TIRAP/MyD88 which leads to 
production of pro-inflammatory cytokines and TRAM/TRIF inducing the same cytokines 
as well as type IFNs. Notably, this is a biphasic activation pathway. TLR4 first engages 
TIRAP/MyD88 leading to NF-κB and MAPK activation and is subsequently internalized 
and relocated to the endosome where it promotes a second-phase NF-κB and MAPK 
activation as well as IRF3-mediated type IFN induction [Kagan and Medzhitov, 2006; 
Kagan et al., 2008; Tanimura et al., 2008]. 
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Beside TLR3, TLR7, 8 and 9 recognize nucleic acids and are therefore capable of 
effectively inducing type I IFN. Signaling mechanisms leading to the induction of type I 
IFN differ depending on the TLR activated. They involve the interferon regulatory 
factors, a growing family of transcription factors known to play a vital role in antiviral 
defense, cell growth and immune regulation. Four IRF function as direct transducers of 
TLR signaling. TLR3 and TLR4 activate IRF3 and IRF7 via the adapter TRIF [Doyle et 
al., 2002], while TLR7, 8 and 9 activate IRF5 and IRF7 via MyD88 [Schoenemeyer et 
al., 2005]. In myeloid DC, TLR9 additionally activates IRF1 [Schmitz et al., 2007]. IRF8 
cooperates with the other transcription factors to facilitate target gene expression. 
 
RIG-I-like helicases signal via the adaptor IFN-β promoter stimulator 1 (IPS-1) which is 
bound to the mitochondrial membrane eventually resulting in activation of NF-κB, 
MAPK, IRF3 and 7. IPS-1 is also known as mitochondrial anti-viral signaling (MAVS) 
CARD adapter inducing IFN-β (Cardif) or virus-induced signaling adapter (VISA) 
[Kawai and Akira, 2009]. The yet undefined cytosolic dsDNA sensor apart from recently 
discovered AIM2 inflammasome, shares at least partly common pathways with these 
receptor molecules culminating in activation of transcription factors NF-κB and IRF3 
[Yanai et al., 2009].  
 
 
Figure 1.1: Overview of pattern-recognition receptors and their main target transcription 
factors relevant to this work. This schematic overview is reduced to receptors, TIR domain-
containing adapter molecules and main target transcription factors that vary between the 
different PRR.  
Introduction 
8 
1.2 Dendritic cells: mediators between innate and adaptive 
immunity 
1.2.1 Dendritic cell function 
Antigen-presenting cells (APC) that process antigenic material and present it on their 
surface to other cells of the immune system act as mediators between the innate and 
adaptive immune system. There are three main types of APC that can activate T cells: 
dendritic cells, macrophages, and B cells. The most important APC is the highly 
specialized dendritic cell, named for their branch-like projections [Steinman and Cohn, 
1973]. Dendritic cells are present in virtually all peripheral body tissues, forming a 
network and constantly sampling their environment by taking up extracellular 
components through phago- or endocytosis. The ingested microbial pathogens, dead 
or dying cells, immune complexes and other antigens are processed and presented by 
major histocompatibility complex (MHC) molecules at the cell surface [Rossi and 
Young, 2005]. Once they have made contact with a danger signal, they mature and 
migrate to regional lymph nodes. Here, a critical interaction with T cells from the 
adaptive branch of the immune system takes place. Depending on their level of 
activation, dendritic cells will induce tolerance towards the presented antigen or will 
initiate a specific T cell immune response. Induction of such an adaptive immune 
response is achieved in a two-step process: T cells need to bind their cognate antigen 
by T cell receptor-MHC complex interaction (signal 1) and must then be additionally 
activated by DC co-stimulatory molecules (signal 2). Recent studies have shown that 
the co-stimulatory potential of DC plays a critical role in inducing an effective T cell 
response. Immature DC only present an antigen without appropriate co-stimulation, 
thus inducing tolerance to this antigen or anergy, respectively [Dhodapkar et al., 2001]. 
Only fully matured DC which also supply an adequate second signal, will induce a 
potent T cell-mediated immune response [Shortman and Heath, 2001]. 
 
These findings move DC to the center of adaptive immunity; as it is the DC who 
determine the fate of T cells deciding between anergy and activation by their co-
stimulatory function. The mechanism of this regulation remained poorly understood 
until Charles Janeway’s hypothesis of pattern-recognition receptors that link innate and 
adaptive immunity proved true. Further studies showed that effective maturation of DC 
and subsequent triggering of a potent immune response is mainly achieved by 
stimulation with microbial cell components [Medzhitov and Janeway, 1997]. However, 
endogenous danger signals can also alert dendritic cells. Only necrotic but not 
apoptotic cells lead to DC maturation although both are processed and presented to T 
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cells by DC [Gallucci et al., 1999]. As described previously (chapter 1.2.1), potential 
danger signals are identified by pattern-recognition receptors recognizing highly 
conserved PAMP. Considering their main function as the body’s scavenger cells it is 
not surprising that DC express a broad spectrum of PRR [Kadowaki et al., 2001; Krug 
et al., 2001]. 
 
 
1.2.2 Dendritic cell subtypes 
Since their initial description by Steinman and Cohn, it has become evident that DC are 
a heterogeneous population and comprise many distinct DC subtypes. Although all DC 
share the capability of antigen uptake, processing and presentation to naïve T and B 
cells, the DC subtypes differ considerably in terms of location, migratory pathways, 
detailed immunological function and dependence on infections or inflammatory stimuli 
for their generation. DC subtypes in the steady state, that is in the absence of infection, 
include type I interferon-producing plasmacytoid DC (pDC), migratory DC located in 
peripheral tissues such as Langerhans cells, and lymphoid tissue-resident myeloid DC 
(mDC), also called conventional DC [Shortman and Liu, 2002]. In mice, mDC can be 
further subdivided according to their expression of CD8α on the cell surface [Vremec et 
al., 2000]. These two subsets differ in their immune functions, with only the CD8pos 
mDC being able to cross-present exogenous antigens on MHC I complexes [den Haan 
et al., 2000]. DC among other APC usually present antigens acquired from the 
extracellular environment on class II MHC complexes binding to T-cell receptors on 
CD4pos T helper cells, whereas class I MHC molecules bear peptides synthesized in the 
cytosol and activate CD8pos cytotoxic T cells. However, CD8pos mDC are capable of 
cross-presenting exogenous antigens on class I MHC complexes, thus allowing the 
induction of a cytotoxic T-cell response to pathogens that do not infect the DC 
themselves [Groothuis and Neefjes, 2005; Rossi and Young, 2005]. 
 
Lymphoid tissue-resident DC collect and present antigens in a single lymphoid organ 
without migrating. In contrast, migratory DC are the classical DC that act as sentinels in 
peripheral tissues and migrate to the lymph nodes through the lymphatics, bearing 
antigens from the periphery. Plasmacytoid DC represent a rare but important cell type 
and are characterized by fast production of high amounts of type I interferons in 
response to viral infections. Immature pDC are present in the blood, bone marrow and 
secondary lymphoid organs and can be recruited to the skin, gut, lung and 
cerebrospinal fluid under stimulatory conditions. Moreover, pDC are known to infiltrate 
many tumors. 
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1.3 Effector cells of adaptive immunity 
1.3.1 T and B cell function 
Conventional T (most αβ T cells) and B cells (also known as B2 cells) are the major 
cellular components of the adaptive immune response characterized by their huge 
arsenal of antigen-specific receptors generated by gene rearrangement. In contrast, 
there are so-called innate-like lymphocytes, that are B1 cells, marginal-zone B cells, 
natural-killer T cells and subsets of ɣδ T cells whose assembly process is not entirely 
random [Medzhitov, 2007]. Their receptor diversity is biased towards a characteristic 
set of specificities for each subset of innate-like lymphocytes [Bendelac et al., 2001]. 
Accordingly, effector function of these lymphocytes and the sites where they reside are 
often predetermined. 
 
T cells are involved in cell-mediated immunity whereas B cells are primarily responsible 
for humoral immunity, which is for the production of antibodies. Once properly activated 
by APC (see chapter 1.2.1), these cells mount specific immune responses that are 
tailored to maximally eliminate specific pathogens or pathogen-infected or transformed 
cells. B cells respond to pathogens by producing large quantities of antibodies which 
then mark and/or neutralize foreign pathogens like bacteria and viruses. There are two 
groups of conventional T cells: T-helper (TH) cells, which are characterized by the 
co-receptor CD4 on the cell surface, and cytotoxic T cells, which express CD8. TH cells 
are the middlemen of adaptive immunity and can differentiate into several types of 
effector cells, characterized by the production of distinct sets of cytokines [Glimcher 
and Murphy, 2000; Reinhardt et al., 2006]. TH1 cells produce IFN-γ and thereby boost 
the cellular immune system by maximizing the killing efficacy of macrophages and the 
proliferation of cytotoxic T cells. TH2 secrete IL-4, 5 and 13 and enhance humoral 
immune responses by induction of B cell proliferation, antibody class switching and 
increased antibody production. Recently described TH17 cells produce IL-17 and are 
involved in protection against extracellular bacteria and fungi [Harrington et al., 2005; 
LeibundGut-Landmann et al., 2007]. Regulatory T (Treg) cells are a specialized 
subpopulation of TH cells that act to suppress immune responses and thereby maintain 
immune homeostasis and tolerance to self-antigens. They are commonly characterized 
by their expression of CD4, CD25 and the transcription factor forkhead box p3 (foxp3) 
[Vignali et al., 2008]. Cytotoxic T cells kill infected or otherwise damaged and 
dysfunctional cells and thereby play an important role in immune response against 
intracellular pathogens and tumor cells. 
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1.3.2 Lymphocytic migration patterns 
Since lymphocytes respond to pathogens only upon direct contact with antigens 
derived from these pathogens, they are forced to migrate to sites where antigen is 
found. The repertoire of naïve T cells – that are T cells that have never encountered 
their cognate antigen – consists of 25 to 100 million distinct clones [Arstila et al., 1999]. 
However, the number of identical cells whose T-cell receptors recognize the same 
individual antigen is very limited; several thousand at most [von Andrian and Mackay, 
2000]. Clearly, a complex guidance system must be at work to accomplish this task. 
 
To facilitate the encounter between APC and the rare antigen-specific lymphocytes, the 
immune system is compartmentalized so that activation of naïve lymphocytes is 
concentrated to secondary lymphoid organs, for example spleen and peripheral lymph 
nodes (PLN) which stand in contrast to internal lymph nodes found in thoracic and 
abdominal body cavities. The secondary lymphoid organs of the gastro-intestinal tract 
form a somehow separate group and are made up of mesenteric lymph nodes (MLN) 
and Peyer’s patches (PP). The PP are large lymphoepithelial structures localized within 
the small intestinal wall in humans while murine PP are distributed in the small and 
large bowl.  
 
Naïve lymphocytes constantly patrol secondary lymphoid organs in search for their 
cognate antigen presented by APC. They enter these sites via the blood stream and 
leave in the lymph fluid. Upon activation by antigen contact, they relocate to peripheral 
sites and exert their effector activities. To achieve these tasks, lymphocytes must travel 
between lymphoid and non-lymphoid organs via the blood stream and finally exit the 
circulation to enter antigen-containing tissues. Therefore, in a process called the 
multi-step adhesion cascade, lymphocytes are captured (“tethering”) and interact 
loosely with the endothelial cells (“rolling”), then undergo “activation” and establish firm 
arrest (“sticking”) on the epithelial surface to finally transmigrate into a tissue 
(diapedesis) [Springer, 1994]. The molecules involved in the different steps vary not 
only depending on the lymphocyte population but first and foremost on target-tissue 
and inflammatory context [von Andrian and Mackay, 2000]. Generally, initial tethering 
and rolling is mediated by selectins or α 4 integrins. Chemokines presented on the 
vascular endothelium interacting with corresponding chemokine receptors (CCR) 
activate further integrins on lymphocytes which then mediate rolling, sticking and 
diapedesis. 
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1.3.2.1 Homing of naϊve T and B cells 
By their set of surface migratory molecules, naïve lymphocytes are mainly excluded 
from nonlymphoid peripheral tissues, but effectively migrate to secondary lymphoid 
organs where they can meet their cognate antigen and undergo activation. Basically, 
lymphocytes use L-Selectin (also named CD62L) to tether and roll on specialized 
microvessels found in PLN, MLN and PP known as high endothelial venules (HEV) 
[Bargatze et al., 1995]. L-Selectin binds to a molecule called peripheral lymph node 
addressin (PNAd) which is found on HEV. In addition, the chemokines CCL19 and 
CCL21 are expressed on HEV, interacting with CCR7 on lymphocytes and thereby 
triggering activation of the integrin lymphocyte function-associated antigen 1 (LFA-1) 
and lymphocyte arrest in HEV [Warnock et al., 1998]. In contrast, HEV in PP do not at 
all and in MLN only partially express PNAd in the lumen. Instead, they express high 
levels of mucosal addressin cell adhesion molecule-1 (MAdCAM-1). MadCAM-1 can 
interact with both L-Selectin and the α4β7 integrin [Berlin et al., 1993]. α4β7 which is also 
called leukocyte Peyer’s patches adhesion molecule 1 (LPAM-1) is expressed only at 
low levels on naïve lymphocytes but plays a critical role in their migration to MLN and 
PP [Wagner et al., 1996]. Table 1.2 shows the most important molecules involved in 
lymphocyte migration. 
 
Target tissue PLN MLN / PP Skin Intestinal lamina propria 
Cell subset Naïve  Naïve Effector Effector 
Tethering/ 
Rolling  
L-Selectin 
PNAd 
L-Selectin 
PNAd 
  
α4β7 
MAdCAM-1 
P-/E-Lig 
P-/E-Selectin 
α4β1 / α4β7 
MAdCAM-1 
Integrin 
activation 
CCR7 
CCL19/21 
CCR7 
CCL19/21 
CCR4 
CCL17 
 
CCR10 
CCL27 
CCR9 
CCL25 
  
Others in 
colon? 
Firm adhesion LFA-1 ICAM-1 
LFA-1 
ICAM-1 
 
α4β7 
MAdCAM-1 
LFA-1 
ICAM-1 
 
α4β1 
VCAM-1 
α4β7  
MAdCAM-1 
    
   
Table 1.2: Overview of steady-state lymphocyte homing receptors and endothelial 
vascular addressins. Corresponding pairs of migratory molecules are shown with endothelial 
structures depicted in italic. The table describes the situation in the non-inflamed steady state. 
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1.3.2.2 Homing of antigen-experienced T and B cells 
Upon activation in secondary lymphoid organs, lymphocytes change their set of surface 
migratory molecules and then migrate more efficiently to nonlymphoid tissue and sites 
of inflammation. In addition, antigen-experienced T and B cells often display tissue 
specificity to improve their chances of reencountering their cognate antigen. 
 
T and B cells that migrate to the small intestine express the integrin α 4β7 and the 
chemokine receptor CCR9 [Zabel et al., 1999]. These traffic molecules, as well as their 
corresponding ligands are essential for efficient lymphocyte homing to the small bowel 
[Hamann et al., 1994]. The main α4β7 ligand, MAdCAM-1 and the CCR9 ligand CCL25 
are expressed on intestinal lamina propria (LP) venules and epithelial cells, 
respectively. Unlike CCR9, α 4β7 is also important for lymphocyte migration into the 
colon. Other yet unknown chemoattractant pathways have been suggested for T and B 
cell migration to colon mucosa [Kunkel and Butcher, 2002]. 
 
In contrast, skin-tropic lymphocytes express E- and P-selectin ligands (E-Lig, P-Lig) as 
well as CCR4 and/or CCR10. Non-inflamed skin venules constitutively express their 
corresponding partners E- and P-selectin as well as CCL17 and CCL27. These traffic 
molecules are critical for efficient lymphocyte homing into the skin. 
The best understood tissue-selective homing pathways are in the intestine and skin, 
but there may be other selective migration streams, such as to the lungs, joints and 
central nervous system [Salmi et al., 1992]. Indeed, the large number of leukocyte-
adhesion receptors and endothelial counterparts as well as chemokines and 
corresponding receptors allow hundreds of possible combinations, comparable to a 
postal code system. In this context, endothelial adhesion molecules with a predominant 
role in tissue-specific cell migration are often called “vascular addressins” while their 
counterparts on T and B cells are called “homing receptors” [Butcher and Picker, 1996]. 
 
 
1.3.2.3 Tissue-specific homing: imprinting mechanisms 
Previous studies have suggested that lymphocytes acquire homing receptors randomly 
or independently of their site of activation [Davenport et al., 2000]. However, a 
considerable amount of evidence indicates that the tissue where T and B cells 
encounter their cognate antigen influences the traffic pattern they acquire. Several 
studies showed that T cells activated in MLN express higher levels of α4β7 and CCR9 
while skin-specific receptors E- and P-Lig are preferentially induced in skin-draining 
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PLN [Campbell and Butcher, 2002]. Thus, local environments within lymph nodes 
differentially direct T- and B-cell expression of adhesion and chemoattractant 
receptors. 
 
Subsequent reports have shown that DC underlie the differential regulation of homing 
receptors in mesenteric versus peripheral lymph nodes and that DC are sufficient to 
imprint tissue-specific homing on T and B cells. DC from PP [Mora et al., 2003] or MLN 
[Johansson-Lindbom et al., 2003; Mora et al., 2005] induce α4β7 and CCR9 on 
activated T cells. In contrast, high levels of skin-specific E- and P-Lig were induced by 
DC from PLN [Dudda et al., 2004]. Regarding their tissue-specific homing commitment, 
T and B cells can also be reprogrammed when they are re-stimulated under different 
homing conditions [Mora et al., 2005]. 
 
Recently, it has been demonstrated that the selective capacity of intestinal DC to 
generate gut-specific lymphocytes involves retinoic acid (RA). RA is an oxidative 
metabolite of dietary vitamin A (retinol) and is essential for numerous physiological 
processes including embryonic growth and development, reproduction, maintenance of 
epithelial surfaces and immunity. Its major physiologically active metabolite, all-trans 
RA, is sufficient to induce α4β7 and CCR9 on activated T cells even in the absence of 
DC [Iwata et al., 2004] which then effectively home to the GI tract. Blocking RA-
receptors significantly reduces the induction of α4β7 and CCR9 by intestinal DC. 
Compatibly, intestinal DC are not homogeneous in their capacity to imprint gut-
specificity as recent studies showed that only CD103pos MLN-derived DC imprint gut 
homing on T cells [Johansson-Lindbom et al., 2005]. That is consistent with their higher 
expression of retinol aldehyd dehydrogenase (RALDH) messenger RNA (mRNA), a 
key enzyme in the synthesis of retinoic acid [Coombes et al., 2007].  
 
Upon stimulation by intestinal DC, B cells are not only imprinted with a gut-homing 
phenotype, upregulating α4β7 and CCR9, but also with a specific set of antibodies. 
Intestinal DC induce IgA class-switching on activated B cells in a partially RA 
dependent manor [Mora et al., 2006]. IgA is the principle immunoglobulin isotype in 
secretions, the most important being those in the endothelium lining the GI and 
respiratory tract. In contrast to T cells, gut-specific B cells have been implicated with 
CCR10 and its ligand CCL28 which is expressed by most mucosal epithelial cells. 
However, it is still heavily debated whether IgA-secreting B cells need both CCR9 and 
CCR10 for optimal migration to the small bowel or whether these chemokines play a 
redundant role in B cell gut-homing [Hieshima et al., 2004; Feng et al., 2006]. 
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Recent studies have shown that vitamin D3, which is mainly produced in sun-exposed 
skin, induces T cell tropism for the skin [Sigmundsdottir et al., 2007]. With vitamin A 
which enters the body exclusively through the diet being linked to gut migration, 
evolution has cleverly co-opted tissue-specific, external environmental stimuli to imprint 
homing. DC play a dual role in this process, processing both local antigen and the 
environmental signals themselves for presentation to lymphocytes [Sigmundsdottir and 
Butcher, 2008]. Adapted to the GI tract, antigens sampled in the lamina propria are 
taken up by CD103pos DC and are transported via draining lymphatic vessels to MLN or 
PP. Here, by simultaneous presentation of antigen and co-stimulatory molecules as 
well as secretion of RA, DC imprint gut-homing specificity on T and B cells. However, it 
is poorly understood how DC themselves are educated to acquire tissue-specific 
imprinting potential such as their RA-secreting capacity. 
 
 
1.4 Pattern-recognition receptor ligands in immunotherapy 
The increasing knowledge of innate immune cells with their pattern-recognition 
receptors and their central role in triggering inflammatory signals has moved PRR in 
the focus of immunotherapy. Their ligands make up attractive immunomodulators in 
clinical use for different reasons: In contrast to distinct cytokines like IFN-α or IL-1, PRR 
ligands lead to a co-ordinated immune response which resembles the natural situation. 
Secondly, selective activation of professional APC and subsequent induction of 
antibody production and cellular immunity make PRR ligands to an eligible adjuvant for 
both prophylactic and therapeutic vaccinations. Furthermore, induction of a TH1-
weighted immune response with potent production of type I IFN defenses against 
intracellular pathogens and prevents allergic reactions which are based upon TH2-
directed immune conditions. Finally, PRR ligand-induced TH1-accentuated stimulation 
of adaptive immunity supports immunological defense of host tumor cells. 
 
Therefore, PRR ligands are the subject of intensive research in immunotherapy and 
many have found their way to clinical trials or have been established in routine 
therapies. Because their function and ligands have been characterized in most detail, 
Toll-like receptors have played a pioneer role in different approaches in the human 
system. Many TLR ligands are now tested as vaccine adjuvants to boost long-lasting 
adaptive immune responses. Synthetic TLR4 ligands are part of the commercial 
hepatitis B virus vaccine Fendrix [Baldridge et al., 2004] and CpG-ODN are used in 
combination with the vaccines Engerix-B1 (for use against hepatitis B virus) and 
Fluarix1 (for use against influenza) in late phase II trials [Cooper et al., 2004; Cooper et 
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al., 2004]. Because of their potent induction of type I IFN and thereby profound antiviral 
effect, TLR7 and 8 agonists have especially been used to target infectious diseases. 
Synthetic TLR7 agonists showed promising effects in chronic hepatitis C infections 
[Horsmans et al., 2005] while imiquimod, another synthetic TLR7 ligand now approved 
for topical application in the treatment of papilloma-virus-induced genital wards, had 
initially contributed to the increased interest in the TLR field [Beutner et al., 1998]. 
 
Furthermore, TLR ligands are an integral part of anti-cancer immunotherapy research 
and here our work group is especially interested in the function of TLR7 and 9 ligands 
in murine tumor models [Bourquin et al., 2007; Bourquin et al., 2008; Wurzenberger et 
al., 2009]. TLR ligands have been used as anti-cancer monotherapy, in combination 
with anti-tumor antibodies or as adjuvants in cancer vaccines. In monotherapy, 
unspecific activation of the immune system can fight tumor growth which leaded to the 
approved use of imiquimod in superficial basal cell carcinoma [Geisse et al., 2004]. 
Inducing type I IFN and IL-12, TLR agonists can indirectly increase antibody-dependent 
cellular cytotoxicity by macrophages and natural killer (NK) cells thereby boosting the 
effect of anti-tumor antibodies. Two clinical trials have shown encouraging results 
combinating CpG-ODN with rituximab (an anti-CD20 monoclonal antibody) in the 
treatment of patients with non-Hodgkin’s lymphoma [Friedberg et al., 2005]. Probably 
the most promising approach in tumor immunology is to immunize cancer patients with 
autologous, patient-derived DC loaded with tumor antigens ex vivo. TLR agonists 
promote maturation of DC that can then present cancer-specific antigens and produce 
type I IFN and inflammatory cytokines, which in turn promote direct cellular effector 
functions. Both mechanisms might participate in breaking the tolerance towards cancer 
cells that often secrete immunosuppressant cytokines, and eventually lead, in certain 
cases, to activation of tumor-specific adaptive immunity [Romagne, 2007]. However, 
recent studies suggest that tumor cells also bear TLR and that their signaling may 
promote tumor growth and immune evasion [Huang et al., 2005; Kelly et al., 2006]. 
 
 
1.5 Objectives 
The ability of T and B cells to traffic to distinct tissue compartments is vital for the 
maintenance of immune homeostasis and the generation of an effective immune 
response. It is mediated by adhesion molecules, also called homing receptors, on 
lymphocytes that have cognate ligands at peripheral or mucosal sites such as the gut. 
Intestinal lymphocytes express the gut-homing receptors α 4β7 integrin and chemokine 
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receptor CCR9 that mediate lymphocyte migration to the gastrointestinal tract, thus 
promoting regional immunity. The imprinting of α 4β7 and CCR9 on T and B cells is 
effected by intestinal dendritic cells during T cell activation. The expression of the 
correct pattern of adhesion molecules is crucial for mounting efficient gut-tropic 
immune responses but also the induction of chronic inflammatory autoimmune 
diseases such as Crohn’s disease and ulcerative colitis. 
 
From a therapeutic perspective, controlling the expression pattern of adhesion 
molecules that direct lymphocyte homing to the gastrointestinal tract represents an 
attractive tool for the manipulation of localized immune and inflammatory responses. 
Understanding the regulation of homing receptors such as α4β7, is thus a vital 
prerequisite for their therapeutical utilization. Little is known however, about the 
expression patterns of these gut-homing receptors during a systemic inflammatory 
state. Using Toll-like receptor ligands to induce innate immune activation such as is 
seen during infection, this work was designed to answer the following questions: 
 
(1) Does stimulation of Toll-like and other innate immune receptors change the gut-
homing phenotype of T and B cells? 
(2) If so, which are the cellular and molecular mechanisms involved? 
(3) What is the resulting effect of Toll-like receptor stimulation on lymphocyte migration 
patterns in vivo? 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Technical equipment 
Balance (LP 6209)  Sartorius, Göttingen, Germany 
Cell culture CO2 incubator (BD 6220)  Heraeus, Hanau, Germany 
Cell culture laminar flow  Heraeus, Hanau, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Centrifuge 5424  Eppendorf, Hamburg, Germany 
DynaMag 15/50 magnet Invitrogen Dynal, Carlsbad, USA 
FACSCalibur, FACSCanto II  Becton Dickinson, San Jose, USA 
LightCycler 2.0 System  Roche, Mannheim, Germany 
Microscope Axiovert 25  Zeiss, Jena, Germany 
MiniMACS, QuadroMACS  Miltenyi, Bergisch Gladbach, Germany 
Mithras LB940 multilabel plate reader  Berthold, Bad Wildbad, Germany 
Multifuge 3L-R  Heraeus, Hanau, Germany 
Nanodrop ND-1000  NanoDrop, Wilmington, USA 
Omnifuge 2 ORS  Heraeus, Hanau, Germany 
pH meter  WTW, Weilheim, Germany 
Power Supply 200/2.0  Biorad, Munich, Germany 
Refrigerators (4°C, -20°C, -80°C)  Thermo Scientific, Waltham, USA 
Shaker  NeoLab, Heidelberg, Germany 
Thermocycler T3  Biometra, Göttingen, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
Vortex VF2  Janke & Kunkel, Staufen, Germany 
 
 
2.1.2 Chemicals, reagents and buffers 
Agarose LE Biozym, Hess. Oldendorf, Germany 
Aqua ad injectabilia Braun AG, Melsungen, Germany 
Bovine serum albumine (BSA) Sigma Aldrich, Steinheim, Germany 
Collagense D Roche, Mannheim, Germany 
Chloroform  Sigma Aldrich, Steinheim, Germany 
DNase II Roche, Mannheim, Germany 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich, Steinheim, Germany 
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Dulbecco’s PBS (1x)  PAA, Pasching, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSSafe  Becton Dickinson, San Jose, USA 
Heparin-Natrium 25000 I.E./5 ml  Braun AG, Melsungen, Germany 
Isoflurane (Forene®)  Abbott, Zug, Switzerland 
Isopropanol (70 Vol%)  Apotheke Innenstadt, LMU Munich 
Paraformaldehyde (PFA)  Sigma Aldrich, Steinheim, Germany 
Sodium azide (NaN3)  Sigma Aldrich, Steinheim, Germany 
Sodium chloride (NaCl 0.9%) Apotheke Innenstadt, LMU Munich 
Trypan blue Sigma  Aldrich, Steinheim, Germany 
Trypsin (10x)  PAA, Pasching, Austria 
 
MACS buffer  Cell Fixation buffer 
2 mM EDTA  2% PFA 
10% FCS in PBS 
in PBS  
 
ELISA coating buffer ELISA assay diluent 
0.2 M sodium phosphate  10% FCS  
in water  in PBS 
pH 6.5 pH 7.0 
 
ELISA wash buffer 
0.05% Tween 20 
in PBS 
 
 
2.1.3 Cell culture materials, reagents and media 
β-Mercaptoethanol  Sigma-Aldrich, Steinheim, Germany 
DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]- Roche, Mannheim, Germany 
 3N-trimethylammonium-methylsulfate 
Dulbecco's modified Eagle´s medium  PAA, Pasching, Austria 
 (DMEM), high glucose 
Fetal calf serum (FCS)  GibcoBRL, Karlsruhe, Germany 
Hank's balanced salt solution (HBSS)  PAA, Pasching, Austria 
Iscove's modified Dulbecco's medium PAA, Paschin, Austria 
 (IMDM)   
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L-glutamine 200mM  PAA, Pasching, Austria 
MEM-NEAA (non-essential amino acids)  GibcoBRL, Karlsruhe, Germany 
Phosphate buffered saline (PBS)  PAA, Pasching, Austria 
Penicillin / Streptomycin (100x)  PAA, Pasching, Austria 
Roswell Park Memorial Institute (RPMI)  PAA, Pasching, Austria 
 1640 medium 
Sodium pyruvate  PAA, Pasching, Austria 
 
RPMI complete medium  IMDM complete medium 
10% FCS 10% FCS 
2 mM L-glutamine 2 mM L-glutamine 
100 IU/ml penicillin 100 IU/ml penicillin 
100 µg/ml streptomycin 100 µg/ml streptomycin 
1 mM sodium pyruvate 1 mM sodium pyruvate 
1% non-essential amino acids (MEM-NEAA) 1% MEM-NEAA 
3.75 x 10-4 % β-mercaptoethanol in IMDM 
in RPMI 1640  
          
DMEM complete medium Cryo medium 
10% FCS 50% DMEM complete medium 
2 mM L-glutamine 40% FCS   
100 IU/ml penicillin 10% DMSO   
100 µg/ml streptomycin       
 
Cytokines and growth factors 
anti-CD3ε (clone 500A2,  BD Biosciences, San Diego, USA 
 syrian hamster IgG2,κ) 
Flt3-Ligand, human recombinant tebu-bio,Offenbach, Germany 
granulocyte-macrophage colony-stimulating tebu-bio, Offenbach, Germany 
 factor (GM-CSF), mouse recombinant   
Interleukin 1-β, mouse recombinant Biolegend, San Diegeo, USA 
IFN-α, human, recombinant InvivoGen, San Diego, USA 
Interleukin-2, mouse recombinant  R&D Systems, Wiesbaden, Germany 
Interleukin-4, mouse recombinant  R&D Systems, Wiesbaden, Germany 
Interleukin-6, mouse recombinant  R&D Systems, Wiesbaden, Germany 
Interleukin-10, mouse recombinant R&D Systems, Wiesbaden, Germany 
Interleukin-12p40, mouse recombinant BioLegend, San Diego, USA 
Interleukin 17, mouse recombinant  Biolegend, San Diegeo, USA 
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Blocking antibodies: 
  Description Isotype Clone Distributor 
anti-IL-2 Rat IgG2a JES6-1A12 R&D Systems 
anti-IL-6 Rat IgG1 MP5-20F3 R&D Systems 
anti-IL-10 Rat IgG1 JES052A5 R&D Systems 
anti-IL12p40 Rat IgG2a, κ C17.8 BioLegend 
anti-IFN-α Rat IgG1 RMMA-1 PBL Biomedical Lab 
anti-TGF-β Rat IgG2a A75-2 BD Biosciences 
anti-TNF-α Rat, IgG1, κ MP6-XT22 BioLegend 
 
Disposable plastic materials for cell culture experiments were purchased from Becton 
Dickinson (Heidelberg, Germany), Bibby Sterilin (Stone, Staffordshire, Great Britain), Corning 
(Corning, USA), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, Germany), Greiner 
(Frickenhausen, Germany), Henke-Sass Wolf (Tuttlingen, Germany), Nunc (Rochester, USA) 
or Sarstedt (Nümbrecht, Germany). 
 
 
2.1.4 Oligonucleotides, TLR ligands and other stimuli 
CL097 InvivoGen, San Diego, USA 
CpG 1826 (CpG)  Coley, Langenfeld, Germany 
Curdlan Roche, Mannheim, Germany 
Flagellin InvivoGen, San Diego, USA 
Lipopolysaccharide (LPS) Sigma, St. Louis, USA 
 (Salmonella enterica ssp. enterica)     
PAM3CysSerLys4 (PAM3CSK) tebu-bio, Offenbach, Germany 
polyI:C InvivoGen, San Diego, USA 
5’-triphosphate 2.2ds RNA Eurogentec, Köln, Germany 
9.2s double right RNA CureVac, Tübingen, Germany 
 
Listing of all oligonucleotides used in this work: 
Description Nucleotide sequence (5’ --> 3’) 
CpG 1826 TCCATGACGTTCCTGACGTT 
9.2s double right RNA UGUCCUUCAAUGUCCAA 
Poly A 20 RNA AAA AAA AAA AAA AAA AAA AA 
5’-triphosphate 2.2ds RNA GCAUGCGACCUCUGUUUGA 
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2.1.5 Kits  
Cell Trace CFSE Cell Proliferation Kit  Molecular Probes, Eugene, USA 
Cell Tracker Violet BMQC dye Molecular Probes, Eugene, USA 
 
RNA isolation, reverse transcription, qRT-PCR 
High pure RNA isolation kit Roche, Mannheim, Germany 
Transcriptor first strand cDNA Roche, Mannheim, Germany 
 synthesis kit 
LightCycler TaqMan Master kit Roche, Mannheim, Germany 
Universal ProbeLibrary Roche, Mannheim, Germany 
 
Magnetic-activated cell sorting 
CD3 Dynabeads, murine Invitrogen Dynal, Carlsbad, USA 
CD8a Micro Beads, murine Miltenyi, Bergisch Gladbach, Germany 
CD8 T Cell Isolation Kit, murine Miltenyi, Bergisch Gladbach, Germany 
CD11c Micro Beads, murine Miltenyi, Bergisch Gladbach, Germany 
CD19 Micro Beads, murine Miltenyi, Bergisch Gladbach, Germany 
CD45R/B220 Micro Beads, murine Miltenyi, Bergisch Gladbach, Germany 
 
Cytokine ELISA sets 
IL-2 murine  BD Bioscences, San Diego, USA 
IL-6 murine  BD Bioscences, San Diego, USA 
IL-10 murine  BD Bioscences, San Diego, USA 
IL-12p40 murine  BD Bioscences, San Diego, USA 
 
Cytokine ELISA antibodies 
Detection of murine IFN-α: 
Capture Ab: Anti-IFN-α (RMMA-1)  PBL, New Brunswick, USA 
Detection Ab: Anti-IFN-α (polyclonal,  PBL, New Brunswick, USA 
 rabbit anti mouse) 
HRP-conjugated F(ab´)2 fragments  Biomeda, Foster City, USA 
 (donkey anti rabbit) 
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2.1.6 FACS antibodies 
Description Isotype Clone Distributor 
anti-CD3 Rat IgG2b 17A2 BD/ Pharmingen 
anti-CD4 Rat (DA) IgG2a, κ RMA4-5 BD/ Pharmingen 
anti-CD8a Rat (LOU/Ws1/M) IgG2a, κ 53-6.7 BD/ Pharmingen 
anti-CD11b Rat (DA) IgG2b, κ M1/70 BD/ Pharmingen 
anti-CD11c Armenian Hamster IgG1a, λ2 HL3 BD/ Pharmingen 
anti-CD19 Rat, IgG2a, κ 1D3 BD/ Pharmingen 
anti-CD25 Rat (Lewis) IgM, κ 7D4 BD/ Pharmingen 
anti-CD45R/B220 Rat IgG2a, κ RA3-6B2 BD/ Pharmingen 
anti-CD69 Armenian Hamster IgG1, λ3 H1.2F3 BD/ Pharmingen 
anti-CD80 (B7-1) Armenian Hamster IgG2, κ 16-10A1 BD/ Pharmingen 
anti-CD86 (B7-2) Rat (Louvain) IgG2a, κ  GL1 BD/ Pharmingen 
anti-foxp3 Rat IgG2b, κ TH6 BD/ Pharmingen 
anti-LPAM-1 (α4β7) Rat IgG2a, κ DATK32 BD/ Pharmingen 
anti-MHC II Rat IgG2b NIMR-4 Southern Biotech 
 
 
2.1.7 Software 
Adobe Illustrator CS3  Adobe System, San Jose, USA 
CellQuest  BD Biosciences, San Diego, USA 
Endnote X2  Thompson Reuter, Carlsbad, USA 
FlowJo  Tree Star, Ashland, USA 
Microsoft Office  Mircosoft, Redmond, USA 
SPSS 16  SPSS, Chicago, USA 
 
 
2.2 Animal experimentation 
2.2.1 Animals 
Female C57BL/6 mice were purchased from Harlan-Winkelmann (Borchen, Germany). 
IL-6-deficient, IL-12p40-deficient and IFN-γ-deficient mice were purchased from Jackson 
Laboratories (Bar Harbor, MA). IL-10-deficient mice, IFN-α receptor (IFNaR)-deficient mice, 
IRF3/7-deficient mice and p50-deficient mice were kindly provided by Prof. J. Heesemann 
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(Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Ludwig-Maximilian 
University Munich, Germany), Prof. H.J. Anders (Medizinische Poliklinik Innenstadt, Ludwig-
Maximilian University Munich, Germany), PD Dr. A. Krug (Department of Internal Medicine II, 
Klinikum Rechts der Isar, Technical University Munich, Germany) and PD Dr. S. Frantz 
(Medizinische Klinik und Poliklinik I, University Würzburg, Germany). Mice were 8-12 weeks 
of age at the onset of experiments. Animal studies were approved by the local regulatory 
agency (Regierung von Oberbayern, Munich, Germany). 
 
 
2.2.2 Organ and single cell preparation 
2.2.2.1 Isolation of splenocytes 
Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Spleens were 
resected and pressed through a 40 µm cell strainer to disintegrate tissue structure. Single 
cell solutions were centrifuged (400 G, 7 minutes) and resuspended in erythrocyte lysis 
buffer. Red blood cell debris was removed by a second centrifugation step. Splenocytes 
were kept in IMDM complete medium for subsequent experiments. 
 
 
2.2.2.2 Preparation of lymph node and Peyer’s patch cells 
Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Cervical, 
brachial, axillary, inguinal and popliteal lymph nodes pooled as peripheral lymph nodes as 
well as mesenteric lymph nodes and Peyer’s patches were resected. Tissues were 
enzymatically digested with collagenase D (1 mg/ml) and DNase I (0.05 mg/ml) in IMDM 
complete medium at 37°C and moderate stirring for 25 to 35 minutes. The digested tissues 
were passed through a 40 µm-pore cell strainer. Single-cell suspensions were washed with 
PBS and were then kept in IMDM complete medium for later experiments. 
 
 
2.2.2.3 Isolation of lung, liver, small bowel and colonic cells 
Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Small bowel, 
colon, lung and liver were resected. For the intestine, remaining feces, complete mesenteries 
and Peyer’s patches were carefully removed. In a first step, organs were disintegrated 
manually. Then, tissues were enzymatically digested and passed through a cell strainer as 
described above (see chapter 2.2.2.2). Digestion and separation with the cell strainer were 
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repeated once. Red blood cells were then lysed with erythrocyte lysis buffer. Single-cell 
solutions were kept in IMDM complete medium for subsequent experiments. 
2.2.2.4 Preparation of bone marrow cells 
Mice were anesthetized with isoflurane, sacrificed by cervical dislocation and femur and tibia 
were bilaterally dissected. Remaining muscle tissue was removed and bones were externally 
cleaned with isopropanol. Bone marrow was extracted by flushing RPMI complete medium 
through the bones and passing the cell suspension through a 40 µm cell strainer. After 
resuspension of centrifuged cells, erythrocytes were lysed by PharmLyse ammonium 
chloride buffer. Cells were then washed with PBS and kept in RPMI complete medium for 
later experiments. 
 
 
2.2.3 Immunostimulation of mice 
To determine the role of Toll-like and other pattern-recognition receptors in tissue-specific 
regulation of the homing receptor α 4β7, mice were treated with different immunostimulants. 
On the one hand, 100 µg CpG-oligodesoxyribonucleotides (ODN) were solved in 120 µl PBS 
and injected subcutaneously. On the other hand, 20 µg oligoribonucleotide (ORN) 9.2dr with 
a phosphothiorated (PTO) ribose-backbone to prevent enzymatic degredation, were 
incubated with 100 µg DOTAP - a liposomal transfection reagent - and 40 µl PBS for 20 min 
and were then injected intravenously into the retro-bulbar venous plexus. In some 
experiments, CpG-ODN were injected intraperitoneally or intravenously. These mice were 
treated with 100 µg CpG solved in 100 µl PBS or 20 µg CpG complexed with 100 µg DOTAP 
and 40 µ l PBS, respectively. 48 hours after the injection, mice were sacrificed and spleen, 
PLN, MLN and PP were preparated as described above (see chapter 2.2.2). For analysis of 
α4β7 surface expression, cells were stained with fluorochrome-coupled antibodies and 
analyzed by flow cytometry.  
 
 
2.2.4 Tumor experiments 
The experimental use of DC as vectors for anti-tumor and infectious disease immunotherapy 
is limited by their trace levels and accessibility in normal tissue and terminal state of 
differentiation. For this reason we used a murine B16 melanoma cell line secreting the 
hematopoietic growth factor Flt3-Ligand (B16-FL, see chapter 2.3.2). Mice were 
subcutaneously injected with 5 x 106 B16-FL tumor cells. Secondary lymphoid organs were 
harvested after eleven to 14 days. At this time spleens were 3- to 5-fold enlarged over that of 
untreated mice because of extramedullary hematopoesis with all lineages of hematopoietic 
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cells fully represented [Shurin et al., 1997]. Tumor-secreted Flt3-Ligand provoked a time-
dependent and reversible accumulation of DC in spleen, bone marrow, lymph nodes and 
liver. These cells exhibited veiled and dendritic processes and were as efficient as rare, 
mature DC isolated from the spleens of untreated mice at presenting antigen to T cells, or in 
priming an antigen-specific T cell response in vivo [Maraskovsky et al., 1996]. Thus, 
Flt3-Ligand secreted by the B16-FL melanoma cell line proved to be a valuable tool to 
expand the number of functionally mature DC in vivo for utilization in subsequent 
experiments.  
 
Single-cell solutions were preparated from secondary lymphoid organs as described above 
and dendritic cells were sorted by magnetic cell sorting. Purified DC from spleen, PLN, MLN 
and PP were kept in IMDM complete medium for subsequent experiments. 
 
 
2.2.5 Lymphocyte in vivo migration assay 
In order to assess in vivo migration patterns of lymphocytes after CpG stimulation, 
fluorescence-marked splenocytes were adoptively transferred into recipient mice. Therefore, 
splenocytes were cultured in IMDM complete medium with or without added 
CpG-ODN (4 µg/ml). After 48 hours, cells were incubated for 15 minutes with 1 mM or 
0.1 mM CFSE at 4°C. Thereafter, cells were centrifuged over complete RPMI medium and 
extensively washed. 2 - 4 x 107 cells from both preparations (stimulated CFSEhigh and 
unstimulated CFSElow splenocytes) were mixed and injected intravenously into each recipient 
mouse. An aliquot was saved to assess the input ratio. Four to six hours after injection, 
recipient tissues were harvested. For the intestine, complete mesenteries and PP were 
carefully removed before further preparation. Single cell suspensions were generated by 
mechanical disintegration, following enzymatic digestion and filtration through cell strainers 
as described earlier. Each tissue cell preparation was analyzed for adoptively transferred 
lymphocyte subpopulations with flow cytometry and CFSEhigh / CFSElow ratios were 
measured. The homing index (HI) was calculated as the ratio of [CFSEhigh]tissue / [CFSElow]tissue 
to [CFSEhigh]input / [CFSElow]input. 
 
 
2.2.6 T cell adoptive transfer assay 
To assess antigen-specific T cell responses in vivo, OT-I transgenic T cells were adoptively 
transferred into naïve recipient mice. In OT-I transgenic mice, all CD8pos T cells have the 
same T cell receptor that recognizes the model antigen ovalbumin. CD8pos T cells were 
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purified by magnetic sorting (see chapter 2.3.4) from splenocyte single cell suspensions of 
wild-type and OT-I transgenic mice. OT-I CD8pos T cells were fluorescently labeled with 
CFSE while WT CD8pos T cells were marked with the fluorochrome Cell Tracker Violet (see 
chapter 2.4.1.4). The labeled CD8pos T cells were mixed at equal numbers and 5 - 10 x 106 
cells were injected intravenously into naïve WT recipient mice. One day after the adoptive T 
cell transfer, mice were immunized intraperitoneally with 100 µg LPS and 500 µg endotoxin-
free ovalbumin. Two to three days after immunization, mice were killed and secondary 
lymphoid organs were obtained. The surface expression of α 4β7 on antigen-specifically 
activated OT-I CD8pos T cells and unspecific WT CD8pos T cells was analyzed by flow 
cytometry. 
 
 
2.3 Cell culture 
2.3.1 General culture conditions and cell viability testing 
Culture of all cell lines was carried out in incubators at 37°C, 5% CO2/air mixture and 95% 
atmospheric humidity using disposable tissue culture flasks. All cell and reagent 
manipulations were performed using sterile technique under a laminar flow hood. Cell 
numbers and viability were tested by trypan blue exclusion. With decreasing membrane 
integrity of dying cells the dye is absorbed where as trypan is not able to penetrate living 
cells. Thus, dead cells show unique blue intracellular staining under the light microscope. 
After appropriate dilution cell numbers were determined by counting in a Neubauer 
hemocytometer. 
 
 
2.3.2 B16-FL tumor cell line 
The B16 melanoma cell line expressing Flt3-Ligand (B16-FL) was provided by 
Prof. T. Mempel (Bosten, USA). These B16 melanoma cells of C57BL/6 background were 
prepared by transfection of murine Flt3-Ligand cDNA using the retroviral vector MFG [Shi et 
al., 1999]. The cell line was cultured in DMEM complete medium and repeatedly checked for 
signs of cell death and microbial contamination by light microscopy. Medium was substituted 
every two to three days according to cell growth. Additionally, tumor cells were regularly 
transferred to new culture flasks. Therefore, adherent growing cells were detached with 1% 
trypsin-EDTA solution, washed with PBS and then re-disseminated. A possible 
mycoplasmatic contamination was excluded by frequently repeated tests. 
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2.3.3 Generation of bone marrow-derived dendritic cells 
Immature murine DC were raised from bone marrow as described previously (Brasel et al., 
2000; Brawand et al., 2002), with some modifications. Preparation of bone marrow cells was 
described above (see chapter 2.2.2.4). Following washing with PBS, cells were diluted to 
1 x 106 cells/ml in RPMI complete medium. To generate myeloid DC (GM-DC) GM-CSF (20 
ng/ml) and interleukin 4 (20 ng/ml) were added to the culture assay. After four days, fresh 
medium supplemented with GM-CSF and IL-4 (40% of original volume) was added to the 
culture. Differentiated dendritic cells were harvested on day 7 to 8. Therefore, culture 
medium was gathered and flasks were rinsed with cold PBS to detach loosely adherent cells. 
DC (CD11cpos cells) generally represented > 75% of the preparation. 
 
A second protocol was used to generate a mixture of myeloid and plasmacytoid dendritic 
cells. Here, bone marrow precursors were cultured at 2 - 3 x 106 cell/ml in complete RPMI 
medium supplemented with recombinant Flt3-Ligand (20 ng/ml). Culture and harvesting of 
differentiated cells (FL-DC) were identical to the GM-DC protocol. Dendritic cells (CD11cpos) 
generally represented > 80% of the preparation’s cells with a typical proportion of 40% being 
pDC (B220pos) and 60% being mDC (B220neg, CD11bpos). For subsequent sorting of DC 
subpopulations, see chapter 2.3.4. 
 
 
2.3.4 Cell purification with magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) is a sorting technique used to isolate viable and 
functionally active cells with minimal interference with subsequent experiments. Cells are 
labeled with magnetic beads, superparamagnetic particles of approximately 50 nanometers 
in diameter. These are composed of a biodegradable matrix; thus it is not necessary to 
remove them from purified cells after the separation process. The magnetic beats are coated 
with antibodies specific for the desired surface antigen. Hence, the beads attach to cells 
expressing this particular antigen. Labeled cells are then transferred into a plastic column 
which is placed in a high-gradient magnetic field induced by a strong permanent magnet. The 
field is strong enough to retain cells attached to the superparamagnetic beads while 
unlabeled cells pass through and can be collected. After removal from the magnetic field, 
retained cells are eluted from the column. Using this method, cells can be sorted positively or 
negatively. Positive selection means that the desired target cells are magnetically labeled 
and isolated as the magnetically retained cell fraction. Negative selection or so-called 
untouched isolation is performed by depletion of undesired cells. Non-target cells are 
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magnetically labeled and eliminated from the cell mixture. The non-magnetic, untouched cell 
fraction contains the target cells. 
 
In this work, materials and reagents were used from Miltenyi Biotec if not stated otherwise. 
CD8pos T cells were negatively sorted using a CD8pos T cell isolation kit. B cells were purified 
by positive sorting with CD19 beads. Plasmacytoid DC were sorted from FL-DC by positive 
selection using B220 microbeads, while mDC differentiated by Flt3L were obtained by 
depleting B220pos plasmacytoid DC from FL-DC. Splenic DC were separated from total 
splenocytes using CD11c beads. 
 
According to the manufacturer’s protocol, cells were washed with MACS buffer then 
incubated with the microbeads at 4°C for 15 min and washed again twice. LS columns were 
rinsed with 3 ml MACS buffer, loaded with labeled cells diluted in 2 ml of buffer and then 
placed in a MACS separator magnet. Columns were washed three times with 3 ml MACS 
buffer. Effluent was gathered as negative fraction. After removal from the magnetic field, 
positive cells were eluted by flushing the column with 2 ml MACS buffer using the provided 
plunger. For further enrichment of desired cells, previous steps were repeated with already 
purified target cells. According to remaining cell numbers, LS or MS columns were used. MS 
columns were rinsed, loaded, twice washed and eluted with 1ml MACS buffer each. Splenic 
DC were depleted using LD columns. After rinsing with 2.5 ml MACS buffer, LD columns 
were loaded with CD11c-labeled splenocytes diluted in 4 ml buffer. Columns were washed 
once with 2 ml buffer and negative flowthrough was re-applied on another LD column. 
Previous steps were repeated and total effluent was gathered as DC-depleted splenocytes.  
 
Purity of magnetically sorted T and B lymphocytes was > 95 %. After DC-depletion, residual 
dendritic cells made up < 0.045 % of total splenic cells. Figure 2.1 shows defined cell 
populations after lymphocyte purification and DC depletion, respectively. T cells are gated on 
the lineage marker CD3 and CD8 to define cytotoxic T cells (Figure 2.1 A). B cells are shown 
as CD19 / B220 double-positive cells. Splenic DC are gated on their lineage marker CD11c 
and B220 to distinguish plasmacytoid and myeloid dendritic cells (Figure 2.1 B). 
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Figure 2.1: Purity of defined splenic cell populations after magnetic-activated cell sorting. 
Representative flow cytometry data is shown as dot plots. T cells are gated on the lineage marker CD3 
and CD8 to define cytotoxic T cells. B cells are shown as CD19 / B220 double-positive cells. Splenic 
DC are gated on their lineage marker CD11c and B220 to distinguish plasmacytoid (B220pos) and 
myeloid (B220neg) dendritic cells. Numbers show percentage of the indicated subset relative to all 
viable cells. 
 
 
2.4 Immunological methods 
2.4.1 Flow cytometry 
Flow cytometry - also called fluorescent-activated cell sorting (FACS) - is a technique used 
for counting, examining and eventually sorting cells and any other given microscopic 
particles. Beforehand prepared single-cell suspensions are necessary for flow cytometry 
analysis. Various antibodies conjugated with fluorochromes can be attached to the cellular 
antigen of interest. The cell suspension is aspirated through a capillary into a flow cell where, 
surrounded by a narrow sheath fluid stream, they pass one-by-one through a focused laser 
beam. The light is either absorbed or scattered when hitting a cell. Such absorbed light of the 
appropriate wavelength will be re-emitted as fluorescence if the cell contains a naturally 
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fluorescent substance or if the cell is labeled with one or more fluorochrome-conjugated 
antibodies at surface or intracellular structures. Light scatter is dependent on the internal 
structure of the cell and its size and shape. Light scattered at a low angle depends on 
relative cell size and is recorded as so-called forward scatter (FSC). Whereas light scattered 
orthogonal to the fluid stream depends on cell granularity as well as surface configuration 
and is logged as side scatter (SSC). Fluorescence and light scatter signals are detected and 
amplified by multiple photodiodes. Optical filters help to block unwanted light and permit light 
of the desired wavelength to reach the photodetector. 
 
 
2.4.1.1 Multicolor flow cytometry 
In this work, flow cytometry analysis was performed with a FACSCalibur or a FACSCanto II, 
respectively. In both devices, cells are illuminated by an argon-ion laser at a wavelength of 
488 nm. The FACSCalibur three-color capability system facilitates detection of the following 
fluorochromes: fluorescein isocyanate (FITC), phycoerythrin (PE) and peridinin chlorophyll 
protein (PerCP). The FACSCanto II allows for the additional detection of the Cy7-coupled 
tandem-dye PE-Cy7. A second red diode laser (633 nm) was used to excite allophycocyanin 
(APC) or the tandem-dye APC-Cy7. With the FACSCanto II, a third violet diode laser (405 
nm) allows for the usage of the fluorescent dyes Pacific Blue and -Orange amongst others. 
 
The emission spectra of the available fluorochromes for flow cytometry overlap and despite 
appropriate optical filters, this ‘spillover’ of light to photodetectors allocated to other dyes can 
compromise data acquisition. To minimize the potential of spectral overlap, a special 
combination of fluorochromes was selected for 8-color analysis with the FACSCanto II. The 
following table gives fluorescent dyes and the commonly coupled antibodies in these assays. 
 
Fluorochrome Excitation laser [nm] 
Peak 
excitation [nm] 
Peak emission 
[nm]   Common target 
Pacific Blue 405 401 452      anti-CD80 
Pacific Orange 405 405 551      anti-CD4 
FITC 488 494 519      anti-CD3 
PE 488 496, 564 578      anti-α4β7 
PerCP-Cy5.5 488 482 695      anti-CD19 
PE-Cy7 488 496, 564 785      anti-CD69 
APC 633 650 660      anti-CD11 
APC-Cy7 633 650 785      anti-CD8a 
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2.4.1.2 Analysis of cell surface antigens 
For analysis of surface antigens, cells were diluted at 1 x 106 to 2 x 106 in PBS supplemented 
with 10% FCS. A mixture of up to four flourochrome-conjugated monoclonal antibodies 
directed against antigens of interest were added at a concentration of 0.5 to 0.7 µ l/ml. Cells 
and staining antibodies were incubated for 25 minutes at 4°C. Cells were then washed twice 
with PBS and finally re-suspended in PBS supplemented with FCS for subsequent analysis. 
For intermediate storage, cells were suspended in fixation buffer and kept at 4°C. During the 
staining process, exposure of cells to light was kept to a minimum.  
 
Flow cytometry data of a given surface antigen is expressed as percentage of cells staining 
positive for the flourochrome-coupled antibody directed against the antigen of interest or as 
the mean fluorescence intensity (MFI). The MFI is calculated directly by the flow cytometer 
and is a non-dimensional index for the amount of cell-bound fluorescent dye. Therefore, the 
MFI reflects expression levels of the investigated antigen. In the research field of lymphocyte 
migration, the MFI is commonly used to illustrate expression levels of homing receptors like 
α4β7. 
 
 
2.4.1.3 Analysis of intracellular antigens 
For some experiments, intracellular transcription factor foxp3 was analyzed to characterize 
regulatory T cell subsets using a Treg staining Kit (BD Biosciences). In a first step, surface 
antigens including CD4 were stained as described above (chapter 2.4.1.1). Externally bound 
antibodies were fixated and the cell membranes were permeabilisized to later allow the anti-
foxp3 antibody to penetrate the cell. Therefore, cells were incubated in the kit’s 
fixation/permeabilisation buffer for 30 minutes at 4°C. After being washed with buffer, cells 
were incubated with 0.5 µl anti-foxp3 antibody at 4°C for another 30 minutes. Finally, cells 
were washed again twice and suspended in PBS supplemented with 10% FCS for 
subsequent FACS analysis. 
 
 
2.4.1.4 CFSE staining 
Very often used to trace cell movement and growth, carboxyfluorescein diacetate 
succinimidyl ester (CFSE) in its pre-active form is a colorless molecule that passively diffuses 
into cells. Here, its two acetate groups are cleaved by cytosolic esterases to yield highly 
fluorescent carboxyfluorescein succinimidyl ester. The succinimidyl ester groups then react 
with intracellular amines, forming stable fluorescent conjugates. These conjugates are 
Materials and methods 
33 
retained by the cells throughout maturation and are inherited to daughter cells during mitotic 
cell division. Thus, labeled cells are marked and cell divisions can be traced by decreasing 
fluorescence intensity. A similar fluorescent cell tracer is the Cell Tracker Violet and the 
simultaneous use of both markers is possible as their excitation spectra differ strongly (peak 
excitation: CFSE 492 nm, Cell Tracker Violet 415 nm). They are therefore excited and 
detected by two different laser systems of the flow cytometer. 
 
Generally, cells were suspended in PBS at 2 x 107 cells/ml. For imprinting and adoptive 
transfer experiments, CFSE or the Cell Tracker Violet were added at a concentration of 5 µM 
and cells were incubated for 15 min at 37°C. For the in vivo homing assay, cells were either 
stained with 10 µM or 1 µM CFSE and incubated for 3 minutes at 4°C. Then, cells were 
washed extensively and re-suspended in IMDM complete medium for subsequent 
experiments. 
 
 
2.4.2 Enzyme-linked immunosorbent assay 
The Enzyme-linked immunosorbent assay (ELISA) is a method used to detect a particular 
antigen of interest in a given sample by antigen-specific, enzyme-linked antibodies. Binding 
of the antibody in the presence of antigen leads to the subsequent conversion of a colorless 
substrate to a colored reagent by the coupled enzyme. 
 
In this work, cytokines from murine cell culture supernatants were investigated by so-called 
sandwich ELISA. Herefore, ELISA detection plates were coated with antibodies binding the 
particular cytokine. Fixated cytokines were exposed by a second, biotinylated antibody that in 
turn was bound by streptavidin coupled to peroxydase. This enzyme catalyzes the oxidation 
of tetramethylbenzidine with hydrogen peroxide to a blue fluorochrome. The investigation of 
all cytokines except IFN-α was performed with commercially available detection kits 
according to the manufacturers’ protocol. The samples were generally diluted 1:2; for the 
detection of IL-12p40 and IFN-γ, samples were diluted 1:5 or 1:10. 
 
Meassurement of IFN-α was accomplished by a set of antibodies: detection plates were 
coated with 50 µl/well capture antibody in coating buffer (1 µg/ml) and incubated overnight at 
4°C. Unspecific binding on the plates was blocked by 150 µl/well assay diluent, applied for 
3 hours at room temperature. Coated plates were cleaned several times with washing buffer, 
than samples and standard protein dilutions were transferred on the plates and again 
incubated overnight at 4°C. The highest level standard was set at 105 IU/ml, samples were 
applied undiluted. The detection antibody (625 ng/ml) in assay diluent (50 µl/well) was added 
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for 3 h at RT. Following extensive washing, horseradish peroxidase-conjugated F(ab´)2 
fragments (15 µg/ml) were used to identify plate-bound detection antibody. After the 
fragments’ incubation for 3 h at room temperature, tetramethylbenzidine with hydrogen 
peroxide served as substrate for the horseradish peroxidase. Therefore, substrate 
solution (50 µl) was added to each well after washing the plates extensively. The enzymatic 
reaction was stopped by adding sulfuric acid (25 µl/well). All ELISA assays were read-out at 
a wavelength of 450 nm with correctional subtraction at 590 nm. 
 
 
2.5 Molecular biology methods 
Cells in all organisms effectively regulate gene expression and turnover of gene 
transcripts (mRNA). The number of copies of a gene’s transcripts in a cell or tissue is 
determined by the rates of its expression and degradation. In order to reliably detect and 
quantify gene expression from small amounts of mRNA, amplification of the gene transcript 
is necessary. The polymerase chain reaction is a common method for amplifying DNA; for 
mRNA-based PCR the RNA sample is first reversely transcribed to DNA. In this work, PCR 
was used to quantitatively determine mRNA expression of the enzyme retinalaldhyde 
dehydrogenase 2 (RALDH2) by quantitative real-time PCR. 
 
2.5.1 Isolation of cytoplasmatic RNA 
To examine gene expression of RALDH2 in dendritic cells before and after CpG stimulation, 
total RNA was extracted using the High pure RNA isolation kit (Roche). Therefore, DC were 
magnetically purified from PLN, MLN and PP. Dendritic cells as well as additionally prepared 
hepatocytes were stimulated with CpG-ODN and cultured for 18 hours. After being washed in 
cold PBS twice, 1 x 106 cells were re-suspended in 200 µl PBS at each. By adding 400 µl of 
lysis-/binding buffer and shaking for 15 seconds, cells were lysed and RNases were 
inactivated simultaneously. The samples were then transferred into a filter tube and 
centrifuged at 8000 g for 15 seconds. Flowthrough liquid was discarded and 100 µl DNase 
mix was added to the nucleic acids retained in the filter. Disintegrated DNA and the enzyme 
mix were removed from the filter in three consecutive washing steps. First, 500 µl washing 
buffer I and II were added and probes were centrifuged at 8000 g for 15 seconds each. Then, 
another 200 µ l washing buffer II were added and probes were centrifuged at 13,000 g for 2 
minutes to remove any residual washing buffer. Retained RNA was re-suspended in 50 µ l 
elution buffer and eluted from the filter tube by centrifugation at 8000 g for 1 minute. 
Extracted complete RNA was kept at -80°C for further analysis.  
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2.5.2 Reverse transcription 
To be later amplified by polymerase chain reaction (PCR), complete RNA had to be reversely 
transcribed into a so-called copy-DNA single strand (cDNA) using the Transcriptor first strand 
cDNA synthesis kit (Roche). According to the manufacturer’s protocol, the reaction assay 
was composed of the following: 10mM Tris Buffer, 50 mM KCl, 5 mM MgCl2, 1mM 
desoxynucleotide mix, 2.5 µM anchored-oligo(dT)15 primer, 20 U Protector RNase inhibitor 
and 10 U Transcriptor reverse transcriptase. 1 µg of previously isolated RNA was mixed with 
11.8 µ l of the reaction assay and sterile water was added to a final volume of 20 µ l. Probes 
were incubated at 25°C for 10 minutes and then heated to 42°C for another 60 minutes. To 
exclude interference of the reverse transcriptase with subsequent PCR steps, probes were 
finally heated to 95°C for 5 minutes to denaturize the enzyme. Sterile water was added to the 
cDNA to a final volume of 500 µl and probes were kept at -80°C for subsequent amplification 
and analysis. 
 
 
2.5.3 Polymerase chain reaction 
2.5.3.1 Functional principle 
The PCR technique allows amplification of a specific DNA sequence in a complex mix of 
nucleic acids e.g. genomic DNA or previously synthesized cDNA. The specific DNA matrix 
which is to be amplified, is called template. The reaction is facilitated by a thermoresistent 
DNA polymerase and a sequence-specific pair of oligonucleotide primers, which are 
homologue to the template’s ends. The amplification proceeds with the following three 
repetitive steps: thermal separation of both strands in the matrix-DNA (denaturation), specific 
hybridization of the primers with the homologue target sequence in the DNA-templates 
(annealing) and final DNA synthesis beginning at the primers (elongation). In subsequent 
amplification rounds, newly synthesized DNA fragments will act as matrices themselves. 
Thus, multiple repetitive cycles allow exponential accumulation of arbitrary DNA sequences 
located between the both primers origination from only trace amount of template-DNA. 
 
However, quantification of initial DNA amounts by conventional PCR is only possible as long 
as the PCR reaction is in the linear interval of amplification efficacy. Here, in every cycle the 
amount of product is doubled. Later, the DNA polymerase gradually loses its activity and 
consumption of primers and nucleotides slow the reaction to finally reach a plateau when no 
more product accumulates due to exhaustion of reagents and enzyme. This plateau phase is 
reached at varying time points and thus is very hard to be verified. Therefore, an aliquot 
would have to be saved after every PCR cycle and be quantified by gel electrophoresis 
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without altering the conditions in the amplification assay. This verification is obsolete if 
amounts of synthesized DNA can be measured in the reaction assay during the PCR; which 
is possible by quantitative real-time PCR (see chapter 2.5.3.2). 
 
 
2.5.3.2 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) is a technique based on the polymerase chain 
reaction, which is used to amplify and simultaneously quantify one or several targeted DNA 
molecules. The procedure follows the general principle of PCR. As its key feature, amplified 
DNA is quantified as it accumulates in the reaction in real time after each amplification cycle. 
Therefore, a fluorescent dye is added to the PCR probes. The fluorochrome is able to bind 
only to double-stranded DNA. Following every amplification cycle, probes kept in glass 
capillaries were excited by a laser and thus emitted a fluorescent signal proportionally to the 
amount of synthesized DNA. The signal is measured by an appropriate detector and 
electronically stored by a computer. Increasing fluorescence intensity is adjusted to the 
number of amplification cycles. Using adequate reference probes with a known number of 
templates, the original number of copies in the samples of interest can be extrapolated. To 
ultimately conclude quantitative mRNA expression of a certain gene, the measured number 
of copies is normalized to the number of transcripts in a so-called reference gene. Typically, 
an ubiquitaryly expressed gene whose expression is not influenced by the experimental 
assay is chosen as the reference gene and additionally measured in every sample. In this 
work, hypoxanthine-guanine phosphoribosyltransferase (HPRT), an enzyme in purine 
metabolism, is used as the reference gene. 
 
In this work, all qRT-PCR assays were performed using a LightCycler TaqMan Master kit 
with fluorescent hydrolysis probes from the Universal ProbeLibrary Set. Primers were 
designed according to the Universal ProbeLibrary Assay Design Center. The experimental 
assay for each sample was as follows:  
 
Component Volume Final concentration 
LightCycler TaqMan Master mix 2.0 µl 1x 
Hydrolysis probe 0.1 µl 0.1 µM 
Primer sense 0.2 µl 0.5 µM 
Primer antisense 0.2 µl 0.5 µM 
Water, PCR-grade 4.5 µl  
cDNA 3.0 µl  
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Immediately after preparation in a cooling block at 4 °C, all samples were amplificated and 
analyzed on a LightCycler 2.0 system using LightCycler Software 4.1. Vital PCR parameters 
were programmed as follows: 
   
 
Cycles Component Target temperature Hold time  
1 Pre-Incubation 90 °C 10 min 
45 
Denaturation 
   
Annealing 
   
Elongation 
95 °C 
   
60 °C 
   
72 °C 
10 s 
   
30 s 
   
1 s 
1 Cooling 40 °C 30 s 
 
 
2.6 Statistical analysis 
In this work, for multiple experiments all data is given as arithmetic mean values. Variance of 
mean values is indicated as standard error of the mean (SEM). Statistical significance of 
different experimental findings was calculated with the independent two-tailed Student’s 
t-test. Significance was implicated at p levels < 0.05, p < 0.01 and p < 0.001 and was then 
indicated with an asterisk (*, ** and ***). If not stated otherwise, an asterisk illustrates 
significant difference in comparison to the experiment’s unstimulated control group. In some 
figures, statistical significance among several experimental groups is calculated and 
indicated with asterisk-marked brackets. All statistical calculations were performed using 
SPSS software. Mathematical analysis and graphical design were done with Microsoft Office 
and Adobe Illustrator. 
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3 RESULTS 
3.1 Effects of TLR ligands in different immunological 
compartments in vivo 
3.1.1 Activation of lymphocytes in secondary lymphoid organs after systemic 
TLR stimulation 
In our lab, previous experiments have shown varying response rates to immunotherapy 
with TLR9 ligands in murine cancer models from different immunological 
compartments. In particular tumors of the gastro-intestinal tract proved resistant 
against CpG-ODN treatment. Therefore, in a first experiment, we investigated the 
immunostimulatory capacity of CpG-ODN - our most intensively studied TLR ligand - in 
different secondary lymphoid organs. Here we focused on the opposing compartments 
of peripheral immunity (represented by PLN) and intestinal immunity (MLN and PP). 
We considered the spleen to be a ‘neutral’ organ in terms of tissue-specific lymphocyte 
homing as the spleen lacks high endothelial venules and no adhesion pathway appears 
to be essential for homing to that organ [von Andrian and Mackay, 2000]. 
 
Mice were injected with 100 µg CpG-ODN subcutaneously; a dosage and application 
type resembling typical anti-tumor treatment regimens. At the onset of this work TLR7 
ligands – although not as well understood as their TLR9 counterparts - emerged as 
another promising approach in immunotherapy because of the restricted expression 
pattern of TLR9 on human DC. Therefore, another group of mice was treated with 
20 µg RNA intravenously according to the standard experimental therapeutic protocol 
at the time. 48 hours after treatment, mice were sacrificed and secondary lymphoid 
organs were dissected. Activation level of local lymphocytes was reflected by their 
surface expression of CD69, a very sensitive activation marker that is rapidly up-
regulated on most lymphocytes upon unspecific stimulation [Testi et al., 1989]. CD69 
expression levels on T and B cells were examined by flow cytometry. 
 
Naïve mice showed low expression levels of CD69 on CD8pos T cells in most examined 
SLO (Figure 3.1). In surprising contrast, cytotoxic T cells found in PP of these 
untreated mice showed moderate to high expression levels of the activation marker. 
Upon systemic stimulation with TLR7 and 9 ligands, CD8pos T cells showed markedly 
increased expression of CD69 in spleen, PLN and MLN. The immunostimulatory effect 
of CpG-ODN and RNA was comparable and both did not differ between lymph nodes 
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of the peripheral and intestinal compartment. However, cytotoxic T cells in PP which 
already had high expression levels of CD69 in naïve mice, showed no significant up-
regulation of the activation marker upon systemic TLR stimulation. CD8neg TH cells and 
B cells had similar in vivo expression patterns of CD69 upon systemic treatment with 
immunostimulatory oligonucleotides (data not shown). 
 
 
 
Figure 3.1: In vivo immunostimulatory effect of TLR7 and 9 ligands on CD8pos T cells in 
different secondary lymphoid organs. Mice were injected with 100 µg CpG-ODN 
subcutaneously or 20 µg RNA 9.2 intravenously. 48 hours after injection, lymphocyte 
populations from spleen, PLN, MLN and PP were isolated. CD69 surface expression of CD8pos 
T cells was examined by flow cytometry and is expressed as percentage of CD69pos cytotoxic 
T cells. Data show the mean values of individual mice (n = 3) ± SEM. Results are representative 
of 3 independent experiments. **P < 0.01; ns indicates not significant. 
 
 
3.1.2 In vivo expression patterns of the gut-homing receptor α4β7 upon systemic 
TLR stimulation  
In a second step, effects of the most recently used oligonucleotides on lymphocytic 
expression of the gut-homing receptor α 4β7 in vivo were examined. With previous 
experiments showing increased expression of the co-stimulatory molecule CD69 on 
lymphocytes in both peripheral and intestinal SLO after systemic TLR7 and -9 
stimulation, we investigated expression patterns of α4β7 on T and B cells in the same 
lymphoid organs. Therefore, mice were again treated with CpG-ODN subcutaneously 
or RNA 9.2 intravenously. 48 hours later, α 4β7 surface expression was analyzed on 
lymphocytes from spleen, PLN, MLN and PP by flow cytometry. 
 
As expected, naïve mice showed the highest percentage of α4β7pos cytotoxic T cells in 
lymphoid organs of the GI-tract in a representative FACS analysis (Figure 3.2 A, gated 
on CD8pos T cells). CD8pos T cells expressing low levels of the homing receptor were 
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also found in spleen and PLN. Unexpectedly, when mice were treated with CpG-ODN 
or RNA, the proportion of α 4β7pos CD8pos T cells significantly decreased in all 
investigated SLO. The frequency of α4β7pos cytotoxic T cells in MLN and PP reached 
levels similar to the PLN and the spleen. Combined data of repeated experiments 
showed that the reduced proportion of α4β7-expressing CD8pos T cells was similar upon 
systemic stimulation with CpG-ODN and RNA (Figure 3.2 B). CD8neg TH cells and B 
cells showed analog α 4β7 expression patterns after in vivo stimulation with the TLR7 
and 9 ligands (Figure 3.2 C and D). 
 
 
 
Figure 3.2: Effects of TLR7 and 9 ligands on expression patterns of α4β7 in vivo. Mice 
were treated with 100 µg CpG-ODN subcutaneously or 20 µg RNA 9.2 intravenously. 48 hours 
later, lymphocyte populations from spleen, PLN, MLN and PP were isolated. α4β7 surface 
expression was examined by flow cytometry. (A) FACS dot blots of one representative 
experiment are gated on cytotoxic T cells. Numbers indicate percentage of α4β7pos cells. (B) Bar 
graphs show α4β7 mean fluorescence intensity (MFI) in proportion to the unstimulated control 
group on different lymphocyte subsets. Data show the mean values of individual mice (n = 3) ± 
SEM. Results are representative of 2 independent experiments. *P < 0.05; **P < 0.01. 
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3.1.3 The role of different routes of CpG-administration for the expression of the 
gut-homing receptor α4β7  
With previous experiments showing in vivo downregulation of α4β7 on lymphocytes in 
various SLO after subcutaneous CpG stimulation, we investigated which role the route 
of ODN administration played in regulation of the gut-homing receptor. Therefore, we 
treated mice with CpG-DNA intraperitoneally and intravenously. 48 hours after 
stimulation, mice were sacrificed and α4β7 surface expression on lymphocytes from 
spleen, PLN, MLN and PP was analyzed by flow cytometry. 
 
In vivo stimulation with CpG-DNA via intraperitoneal or intravenous injection showed 
downregulation of the gut homing receptor α 4β7 on T cells similar to subcutaneous 
application (Figure 3.3). However, intraperitoneal treatment resulted in slightly reduced 
downregulation of α 4β7 in non-intestinal SLO such as spleen and PLN. Although 
detectable, the surface expression of the homing receptor on CD8pos T cells was not 
significantly reduced when compared to T cells from unstimulated control mice. Taken 
together, these results implicate that the route of CpG in vivo-administration has no 
major effect on α4β7 expression patterns at least in intestinal SLO 
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Figure 3.3: Role of the application route on the effect of immunostimulatory 
oligonucleotides in vivo. Mice were injected with CpG ODN 20 µg intraperitoneally or 20 µg 
complexed with DOTAP intravenously. 48h after injection, lymphocyte populations from different 
lymphoid organs were isolated. α4β7 surface was examined by flow cytometry and is expressed 
as percentage of unstimulated control group for each sample. Data show the mean values of 
individual mice (n = 3) ± SEM. Results are representative of 2 independent experiments. *P < 
0.05; **P < 0.01; ns indicates not significant. 
 
 
3.2 Effects of TLR ligands on α4β7 expression patterns of naïve 
lymphocytes 
3.2.1 Kinetics and dose dependency of TLR7- and TLR9-mediated effects on α4β7 
expression in vitro 
Previous experiments showed reduced frequency of α 4β7-positive lymphocytes in 
secondary lymphoid organs upon systemic TLR7 and TLR9 stimulation in vivo. We 
analyzed this effect in detail by further in vitro-experiments with special emphasis on 
dose dependency and kinetics. Murine spleen cells were generally stimulated with 
CpG ODN, and in addition in one experiment with CL097, a highly water-soluble 
derivative of the imidazoquinoline compound R848 and thus TLR7 and TLR8 agonist 
[Salio et al., 2007]. After 6 hours, cells were washed with PBS to remove free 
oligonucleotides and cultured. Surface expression of α 4β7 was examined on different 
lymphocytes subsets by flow cytometry at various time points. 
 
Upon in vitro-stimulation with CpG-ODN as well as CL097 naïve splenic CD8pos T cells 
showed downregulation of the gut-homing receptor α 4β7. For both immunostimulatory 
oligonucleotides in this experiment a clear dependency between dose and subsequent 
impaired surface expression of α 4β7 on cytotoxic T cells was apparent (Figure 3.4 A). 
Both, T cells treated with CpG-ODN and those treated with CL097 showed mostly 
similar patterns of downregulation. As little as 0.1 µg/ml of the ON is sufficient to clearly 
reduce expression of α4β7 on splenic CD8pos T cells in vitro. Whereas increased doses 
of stimulus indeed lower the expression of the homing molecule, the additional effect 
especially of dosages > 1.0 µ g/ml is less dramatic. CpG-induced downregulation of 
α4β7 in vitro showed a similar dose dependency for CD8neg T cells and B cells (data not 
shown). 
 
Kinetics of α 4β7 surface expression showed temporally analog downregulation on 
CD8pos and CD8neg T cells as well as B cells upon CpG stimulation (Figure 3.4 B). 
Although more accentuated amongst B cells, α4β7 was markedly reduced after 12 hours 
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of stimulated culture on all experimentally included lymphocyte subsets. After 42 hours, 
surface expression of the homing receptor reached a minimum on T and B cells and 
was then stable till the final measurement after 64 hours. 
 
We thus show that the homing receptor α4β7 is downregulated on splenic lymphocytes 
in a dose dependent manner after in vitro-stimulation with CpG-ODN or CL097, 
respectively. The CpG-induced downregulation is clearly detectable as early as 
12 hours after stimulation and surface expression reaches a relative stable minimum 
after 42 hours. 
 
 
 
Figure 3.4: Dose dependency and kinetics of oligonucleotide-induced downregulation of 
α4β7 expression in vitro. (A) Splenocytes were stimulated with CpG-ODN or CL097 (0.1, 1, 5 
or 10 µg/ml) for 6 hours, then washed and cultured. 48 hours later, surface expression of α4β7 
on CD8pos T cells was examined by flow cytometry. Data show the mean values of triplicate 
samples ± SEM. Results are representative of 3 independent experiments. *P < 0.05; 
**P < 0.01. (B) Spleen cells were stimulated with CpG-ODN (5 µg/ml) for 6 hours, then washed 
and cultured. α4β7 expression was examined on lymphocyte subpopulations after 12, 18, 34, 42 
and 62 hours.  
 
 
3.2.2 Effects of different pattern-recognition receptor ligands on lymphocyte α4β7 
expression 
To further evaluate regulation of lymphocytic α4β7 surface expression we investigated 
the role of Toll-like receptors beyond TLR7 and 9 as well as other pattern-recognition 
receptors in the modulation of the gut-homing receptor. Hence, we stimulated murine 
spleen cells with PAM3CSK4 (a synthetic peptidoglycan stimulating TLR2) [Aliprantis et 
al., 1999], polyI:C (synthetic analog of dsRNA, TLR3) [Alexopoulou et al., 2001], LPS 
(bacterial cell wall component, TLR4), Flagellin (TLR5), CL097 (TLR7), CpG-DNA 
(TLR9), Curdlan, 3p-RNA 2.2 or low-dose polyI:C, the latter two complexed with 
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Lipofectamin. Curdan is a bacterial β-glycan and ligand for Dectin-1, a TLR-
independent but synergistic PRR [Yoshitomi et al., 2005]. 3p-RNA 2.2 and low-dose 
polyI:C both complexed with the transfection agent Lipofectamin are ligands for the 
intracellular, cytoplasmatic RNA-helicases RIG-I and MDA5, respectively [Akira et al., 
2006]. After 48 hours of stimulated culture, α4β7 surface expression on lymphocytes 
was measured by flow cytometry. 
 
In a representative FACS analysis, the vast majority of untreated splenic CD8pos T cells 
expressed low levels of α4β7 after being cultured for 48 hours (Figure 3.5 A, dot blots 
gated on CD8pos T cells). However, the formerly prevailing fraction of α4β7pos cytotoxic 
T cells was clearly diminished after treatment with all investigated PRR ligands. 
Compatibly, integrated data of three independent experiments (Figure 3.5 B) also 
showed clearly impaired surface expression of the gut-homing receptor on naïve 
splenic CD8pos T cells. Downregulation of α4β7 on cytotoxic T cells was most impressive 
after stimulation by TLR4, 7 and 9 ligands, respectively. Stimulation with ligands of the 
intracellular helicases Rig-I and MDA5 as well as membrane-bound PRR Dectin-1 
resulted in intermediate downregulation of α 4β7 on naïve CD8pos T cells where as 
activation of TLR3 and 5 lead to a less dramatic decrease in surface expression. 
Further experiments showed equivalent downregulation of the gut-homing receptor 
α4β7 on naïve splenic CD8neg TH cells and B cells (data not shown). 
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Figure 3.5: Effects of various pattern-recognition receptors on α4β7 expression in vitro. 
Splenocytes were stimulated with Pam3CSK4 (1 µg/ml), polyI:C (180 µg/ml), LPS (5 µg/ml), 
Flagellin (2 µg/ml), CL097 (5 µ g/ml), CpG-ODN (5 µg/ml), Curdlan (100 µg/ml), 3p-RNA 2.2 
(1 µg/ml) or polyI:C (1 µg/ml), the latter two complexed with Lipofectamin 2000. 48 hours later, 
surface expression of α4β7 on cytotoxic T cells was examined by flow cytometry. (A) FACS dot 
blots of one representative experiment are gated on CD8pos T cells and numbers indicate 
percentage of α 4β7pos cells. (B) The bar graph shows α4β7 mean fluorescence intensity in 
proportion to the unstimulated control group. Data show the mean values of triplicate 
samples ± SEM. Results are representative of 3 independent experiments. **P < 0.01; 
***P < 0.00.1. 
 
 
3.2.3 Role of dendritic cells in TLR-mediated downregulation of α4β7 on naïve 
lymphocytes 
In preceding experiments we had learned that stimulation of murine spleen cells with 
ligands of Toll-like and other pattern-recognition receptors induced downregulation of 
the gut-homing receptor α4β7 on CD8pos and CD8neg T cells as well as B cells. Previous 
studies had described the expression of TLR2, 3, 5, and 9 on T cells; recently reviewed 
in 2007 by Kabelitz et al. However, both direct and indirect mechanisms of TLR-
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mediated activation of T cells were heavily debated and there are still controversies 
whether T cells do have functional TLR and are therefore actually capable of sensing 
pathogen-associated molecular patterns themselves [Kranzer et al., 2000; Lipford et 
al., 2000; Verthelyi et al., 2001]. Hence, we wanted to investigate whether T and B cells 
respond directly to CpG-ODN with altered expression patterns of gut-homing molecules 
or whether the observed downregulation of α4β7 on lymphocytes is mediated by another 
cell population upon TLR stimulation. 
 
In a first step to investigate a possible role of other cell types in regulation of α4β7 
expression, we examined the lymphocytes’ capability to directly respond to innate 
stimuli with altered expression patterns of the gut-homing receptor. Therefore, naïve 
murine splenic CD8pos T cells and B cells were isolated by magnetic-activated cell 
sorting. The purified cells were stimulated with CpG-DNA for 6 hours, then washed to 
remove free ODN and cultured. After 48 hours, their α4β7 surface expression was 
examined by flow cytometry. 
 
These experiments demonstrated that both, purified naïve splenic CD8pos T cells and B 
cells had no significantly different α4β7 surface expression after CpG-stimulation 
compared to an untreated control group (Figure 3.6 A). When strictly isolated, these 
lymphocyte populations did not have the capability to directly respond to a TLR9 
stimulus with previously described downregulation of α 4β7. With these findings, we 
concluded the existence of a stimulus-mediating cell type thereby indirectly controling 
the homing receptor on T and B cells. 
 
With their central role in innate immunity with not only sensing, processing and 
presenting antigen but also local environmental factors to cells of adaptive immunity 
thereby imprinting tissue-specific homing, we suspected dendritic cells to also be a key 
player in the latter findings of indirectly controlled α 4β7 expression on naïve 
lymphocytes after TLR stimulation. To determine the role of DC in regulating α4β7 
expression on naïve T and B cells, murine splenocytes were depleted of DC by 
magnetic-activated cell sorting. These spleen cells were then stimulated with CpG-
ODN for 6 hours, washed and cultured. α4β7 surface expression was examined after 48 
hours by flow cytometry. 
 
Compatible to our previous experiments, CpG-stimulation of complete splenocytes, that 
is without depletion of DC, lead to a distinct downregulation of α4β7 on both naïve T and 
B cells (Figure 3.6 B, left columns). Hereby, reduced expression levels of the homing 
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receptor after TLR9 stimulation were comparable on cytotoxic and helper T cells as 
well as B cells. In contrast, when DC were depleted from spleen cells, neither CD8pos 
and CD8neg T cells nor B cells showed significant reduction of α4β7 expression following 
CpG-stimulation when compared to an untreated control group (Figure 3.6 B, right 
columns). These findings demonstrated that naïve T and B cells within splenic cells but 
in the absence of DC do not downregulate α4β7 upon TLR stimulation, thus suggesting 
that DC are a vital component in regulating the homing receptor on naïve lymphocytes. 
 
 
 
Figure 3.6: Relevance of direct versus indirect effects in mediating downregulation of 
α4β7 surface expression on naïve lymphocytes upon CpG-DNA stimulation. A) Splenic 
CD8pos T cells and B cells were isolated by magnetic-activated cell sorting, stimulated with 
CpG-DNA (3 µg/ml) for 6 hours, then washed and cultured. (B) Spleen cells were depleted of 
dendritic cells, stimulated with CpG-ODN (3 µg/ml) for 6 hours, then washed and cultured. After 
48 hours, α4β7 surface expression was examined by flow cytometry. Data show the mean 
values of triplicate samples ± SEM. Results are representative of at least 3 independent 
experiments. **P < 0.01; ns indicates not significant. 
 
 
On the one hand, there are several additional cell populations like antigen-presenting 
macrophages and other mononuclear cells which also yield a great arsenal of different 
PRR and could therefore be able to mediate TLR signals and induce α4β7 
downregulation on lymphocytes. On the other hand, dendritic cells are an 
inhomogeneous family with members that differ in functions like cytokine production but 
which could – by their expression pattern of PRR – all be capable to communicate 
CpG-dependent regulation of the gut-homing receptor on naïve T and B cells. So, in a 
next step, we investigated whether other cell types played a role in this process or 
whether only dendritic cells alone were responsible for our findings. Simultaneously, 
different DC subsets were compared in their potency to induce downregulation of α4β7 
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upon CpG stimulation. Therefore, different DC subtypes were raised from bone marrow 
precursors. For DC maturation either the two cytokines GM-CSF and interleukin 4 or 
the single factor Flt3-Ligand were used. Bone marrow cells cultured with GM-CSF 
(GM-DC) mature into myeloid DC only, where as Flt3L-derived DC (FL-DC) 
compromise both myeloid and plasmacytoid dendritic cells. The latter two were 
differentiated by MACS sorting with an anti-B220 antibody and then analyzed 
separately. Different DC subsets were stimulated with CpG-DNA for 6 hours, washed 
extensively to remove free ODN and were co-cultured with naϊve splenocytes. After 48 
hours of co-culture, α 4β7 expression was examined on splenic lymphocytes by flow 
cytometry. 
 
When co-cultured with both, myeloid (CD11cpos, B220neg) or plasmacytoid (CD11cpos, 
B220pos) CpG-stimulated dendritic cells, naϊve splenic lymphocytes showed clearly 
impaired surface expression of α 4β7 (Figure 3.7 A). This effect was similar on CD8pos 
and CD8neg T cells as well as B cells. There was no significant difference in 
downregulation of the homing receptor’s surface expression between lymphocytes 
co-cultured with FL-DC and those co-cultured with GM-DC. These findings suggested 
that cell populations other than DC are not required for CpG-induced downregulation of 
α4β7 on naïve splenic T and B cells. Furthermore, both bone marrow-derived mDC and 
pDC can alter the expression pattern of the gut-homing receptor upon a TLR9 stimulus. 
 
In a last step, we excluded possible effects on α4β7 regulation by cells other than DC 
which were present within the splenocytes but unstimulated during the previous 
experiment. We therefore purified splenic CD8pos T cells and B cells which had been 
shown previously not to respond with α4β7 downregulation upon CpG-stimulation. The 
sorted cells were co-cultured with CpG-stimulated GM-DC for 48 hours. Then, α 4β7 
expression on the lymphocytes was measured by flow cytometry. 
 
When only co-cultured with CpG-activated dendritic cells but in the absence of other 
splenocytes, purified splenic CD8pos T cells reacted with significantly impaired α 4β7 
surface expression (Figure 3.7 B). Equally co-cultured B cells showed downregulation 
of the homing receptor to a similar extent. Thus, we demonstrated that dendritic cells 
alone are capable and sufficient to mediate CpG-DNA stimulation to naïve splenic T 
and B cells and hence induce downregulation of α 4β7. This effect could be shown for 
both plasmacytoid and myeloid DCs, independent from whether DC were matured with 
GM-CSF and interleukin 4 or Flt3-Ligand. 
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Figure 3.7 Role of dendritic cells in mediating downregulation of α4β7 surface expression 
on naïve lymphocytes upon CpG stimulation. (A) GM-DC, B220pos FL-DC or B220neg FL-DC 
were stimulated with CpG-ODN (3 µg/ml) for 6 hours, then washed and co-cultured with naïve 
splenocytes. (B) GM-DC were stimulated with CpG-ODN (3 µg/ml) for 6 hours, then washed 
and co-cultured with magnetically purified naïve splenic CD8pos T cells and B cells. After 48 
hours, α4β7 surface expression was examined by flow cytometry. Data show the mean values of 
triplicate samples ± SEM. Results are representative of at least 3 independent experiments. 
*P < 0.05; **P < 0.01; ***P < 0.00.1. 
 
 
3.2.4 Mechanism of DC-mediated downregulation of α4β7 on naïve lymphocytes 
upon TLR stimulation 
With previous experiments showing that DC are responsible for lymphocytic 
downregulation of α 4β7 following CpG stimulation, questions about the underlying 
mechanisms were raised. On the one hand, dendritic cells can stimulate T and B cells 
via direct receptor interaction, e.g. peptide - MHC complexes bind to the T cell receptor 
and subsequently activate naϊve T cells. On the other hand, DC are potent producers of 
a wide arsenal of cytokines and other humoral components. On that account, the 
functional principle of the DC regulatory effect had to be differentiated between a 
cell-cell contact dependent or a soluble factor dominated mechanism. 
 
Therefore, bone marrow-derived GM-DC were stimulated with CpG for 6 hours, 
washed and cultured. After 42 hours, the culture supernatant was gained. Then, 
splenic CD8pos T cells were purified by MACS and co-cultured either alone with CpG, 
CpG-activated and washed GM-DC or the previously gained supernatant from 
CpG-stimulated GM-DC culture. In this experiment T cells and DC were cultured in a 
transwell system separated by a 0.02 µm membrane. These small pores are too small 
for DC and T cells to penetrate the membrane and thus prevent direct cell-cell contact 
between both experimental cell populations. However, the pore size allows humoral 
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factors to pass the barrier. After 48 hours of co-culture, α4β7 surface expression was 
examined on T cells by flow cytometry. 
 
As shown in previous experiments, purified splenic CD8pos T cells did not respond with 
altered expression patterns of α4β7 when stimulated with CpG-DNA in the absence of 
DC (Figure 3.8, left columns). However, CpG-activated DC induced α4β7 
downregulation on co-cultured cytotoxic T cells even when being separated by a 
membrane preventing direct cell-cell interaction (Figure 3.8, middle columns). In the 
same way, only the supernatant from CpG-activated DC culture – supposedly 
comprising all DC produced cytokines – leads to a comparable reduction of the homing 
receptor on co-cultured T cells (Figure 3.8, right columns). Further equivalent 
experiments with purified, splenic B cells co-cultured with TLR9-stimulated DC or their 
supernatant, respectively, showed similar results of downregulated α4β7 (data not 
shown). Thus, we demonstrated that DC do not need direct cell contact to lymphocytes 
but rather release one or multiple soluble factors to induce downregulation of their gut-
homing receptor α4β7.  
 
 
 
Figure 3.8: Role of direct cell-cell contacts versus humoral factors in CpG-induced and 
DC-mediated downregulation of α4β7 surface expression on CD8pos T cells. Sorted splenic 
CD8pos T cells were cultured with or without CpG-activated (3 µ g/ml) GM-DC or the DC 
supernatant gained after 42 hours of CpG-stimulated DC culture. T cells and DC were 
separated in a Transwell system by a 0.02 µm membrane to prevent cell-cell contacts. After 48 
hours, α4β7 surface expression was examined on CD8pos T cells by flow cytometry. Data show 
the mean values of at least triplicate samples ± SEM. Results are representative of 3 
independent experiments ***P < 0.00.1; ns indicates not significant. 
 
 
Knowing that humoral factors play a critical role in DC-induced downregulation of α4β7 
on lymphocytes, we assessed the regulatory capacity of various common DC-released 
cytokines, namely IL-6, IL-10, IL-12p40, IFN-α, TGF-β and TNF-α as well as T cell-
derived IL-2. Therefore, bone marrow-derived GM-DC were stimulated with CpG-DNA 
and were co-cultured with purified splenic CD8pos T cells separated in a Transwell 
system by a 0.02 µm membrane to prevent direct cell-cell contact. Monoclonal 
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neutralizing antibodies targeting the cytokines mentioned above were added to the 
culture. These antibodies bind free cytokines and thereby competitively inhibit 
subsequent cytokine-receptor interactions. Thus, with appropriate levels of neutralizing 
antibody referring to common literature specifications, lymphocyte response to these 
DC-derived cytokines could be completely abrogated. After 48 hours of culture, α4β7 
surface expression on CD8pos T cells was measured by flow cytometry. An adequate 
degree of cytokine inhibition was assured by measuring culture levels of cytokines that 
escaped neutralization by blocking mAbs with an ELISA assay (data not shown). 
 
Consistent with previous experiments, naïve cytotoxic T cells among complete 
splenocytes effectively downregulated α4β7 surface expression when stimulated with 
CpG-DNA in absence of any neutralizing antibodies (Figure 3.9). Presence of anti-IL-6 
antibody in the culture clearly diminished CpG-induced α4β7 downregulation, resulting 
in higher α 4β7 surface expression on anti-IL-6-treated T cells when compared with 
T cells not treated with any neutralizing antibody. Nonetheless, α4β7 expression levels 
of T cells treated with CpG and anti-IL-6 antibody were lower as those from naϊve T 
cells. Hence, blocking the effect of interleukin 6 only partially abrogates CpG-induced 
downregulation of α4β7 on naïve CD8pos T cells. Furthermore, expression of the homing 
receptor on CpG-stimulated T cells treated with anti-IL-10, anti-TGF-β or anti-TNF-α 
was slightly yet significantly reduced when compared with stimulated T cell not treated 
with any blocking antibody. There was no significant modification in downregulation of 
α4β7 expression on CpG-activated T cells when being cultured with anti-IL-2, anti-
IL-12p40 or anti-IFN-α antibodies. Analog experiments using mesenteric lymph 
node-originated intestinal DC instead of bone-marrow derived GM-DC showed similar 
effects of reduced downregulation of α4β7 on naïve CD8pos T cells only with anti-IL-6 but 
no other neutralizing antibody (data not shown). 
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Figure 3.9: Effects of cytokine-neutralizing antibodies in CpG-induced downregulation of 
α4β7 surface expression on CD8pos T cells. Sorted splenic CD8pos T cells were cultured with 
CpG-stimulated (3 µg/ml) GM-DC separated in a Transwell system by a 0.02 µm membrane to 
prevent direct cell-cell contact. Monoclonal blocking antibodies targeting different cytokines 
were added to the culture. After 48 hours, α4β7 surface expression was examined on CD8pos 
T cells by flow cytometry. Data show the mean values of at least triplicate samples ± SEM. 
Results are representative of 3 independent experiments. *P < 0.05; ns indicates not significant. 
The asterisk without brackets indicates comparison to the CpG-stimulated group that was not 
treated with any neutralizing antibody. 
 
 
To confirm and further evaluate the data gained with the blocking antibody assay we 
rearranged the experimental setting using transgenic mice. We therefore obtained 
splenocytes from multiple knockout mice which lack certain pro-inflammatory 
transcription factors, cytokines or their receptors; namely IL-6, IL-10, IL-12, IFN-ɣ, 
NFκB-p50, IRF-3/7 and IFN-α receptor (IFNaR). NF-κB is a signaling molecule 
downstream of various PRR like TLR, cytoplasmatic RNA-sensing helicases or 
Dectin-1 and is compromised of the two heterodimers p50 and p65. It acts as a 
transcription factor which upon activation, translocates into the nucleus and leads to 
induction of pro-inflammatory genes. IRF-3 and 7 are signaling molecules in the 
activation cascade of TLR3, 4, 7 and 9 as well as the cytosolic RNA-helicases. In their 
function as a transcription factors, they are potent inducers of genes leading to 
production of type I interferons. The cytokine-deficient splenocytes were stimulated 
with CpG for 6 hours, then washed and cultured. After 48 hours, α 4β7 expression on 
lymphocytes was measured by flow cytometry. 
 
Figure 3.10 shows α4β7 downregulation on CpG-stimulated splenic CD8pos T cells of 
knockout (KO) and corresponding wild type (WT) mice. α 4β7 surface expression is 
shown as percentage of unstimulated control groups. Varying levels of percentual α4β7 
downregulation amongst the experimental groups can be explained by the different 
strain backgrounds of the knockout mice. This is why, every KO mouse is individually 
compared to its corresponding WT with the same background.  
 
Splenic CD8pos T cells among complete splenocytes from IL-6-deficient mice stimulated 
with CpG downregulated α4β7 to a significantly smaller extent as those T cells obtained 
from corresponding WT mice. This resulted in higher expression levels of the homing 
receptor on T cells of the KO group when compared to the WT. IRF-3/7 and IFNaR 
deficient CpG-stimulated splenocytes showed little but significantly increased 
downregulation of α 4β7 surface expression when compared to corresponding WT 
spleen cells. However, general levels of downregulation were rather low within these 
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strain backgrounds. There was no significant difference in α 4β7 expression upon CpG 
stimulation between KO and WT splenocytes in IL-10, IL-12, IFN-ɣ and NFκB-p50 
groups. Further experiments showed equivalent data for CD8neg T cells and B cells with 
attenuated α4β7 downregulation upon TLR9 activation only in IL-6 knockout mice (data 
not shown). 
 
 
 
Figure 3.10: α4β7 surface expression patterns of transgenic splenic CD8pos T cells 
deficient of cytokines or pro-inflammatory transcription factors following CpG 
stimulation. Splenocytes from different transgenic knockout mice were stimulated with 
CpG-ODN (3 µg/ml) and were cultured. After 48 hours, α4β7 surface expression was examined 
on CD8pos T cells by flow cytometry. Data show the mean values of at least triplicate 
samples ± SEM. Results are representative of 3 independent experiments. *P < 0.05; 
***P < 0.001; ns indicates not significant. The asterisk indicates comparison to the 
corresponding CpG-stimulated wild type group. 
 
 
These data strongly suggest that IL-6 plays an important role in DC-mediated 
downregulation of α 4β7 expression on lymphocytes upon CpG stimulation. 
IL-6-deficiency significantly impairs activated DC capability to induce downregulation of 
the homing receptor. In a next step, we tested whether these CpG-activated cells 
actually produce considerable amounts of IL-6 that could then induce downregulation 
of α 4β7 on co-cultured lymphocytes. Therefore, splenocytes were cultured in the 
presence of different TLR ligands, namely PAM3CSK4 (TLR2), LPS (TLR4), CL097 
(TLR7) and CpG-DNA (TLR9). After 24 hours, the culture supernatant was obtained 
and IL-6 levels were determined by ELISA. Compatible with previous reports that 
murine DC secrete large amounts of different cytokines upon stimulation of TLR 
[Sparwasser et al., 1998], activated splenocytes produced an abundance of IL-6 
(Figure 3.11). The highest secretion of IL-6 by splenocytes was observed after 
stimulation with CpG-DNA. But other TLR ligands also induced considerable amounts 
of IL-6 and these differences could simply resemble unbalanced activation levels due 
to differing TLR ligand activity.  
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Figure 3.11: IL-6 secretion of murine splenocytes following TLR stimulation. Splenocytes 
were stimulated either with Pam3CSK4 (1 µg/ml), LPS (1 µg/ml), CL097 (5 µg/ml) or CpG-
ODN (3 µg/ml) and were then cultured. After 24 hours, IL-6 in the culture supernatant was 
measured by ELISA. Data show the mean values of triplicate samples ± SEM. Results are 
representative of 2 independent experiments. ***P < 0.001. 
 
 
Our data show that CpG-activated splenocytes produce high amounts of IL-6. 
However, expression levels of α4β7 even on IL-6-deficient splenocytes stimulated with 
CpG-DNA are clearly reduced when compared to unstimulated spleen cells. Hence, 
other DC-released factors may contribute to the regulation of α 4β7. To investigate 
whether IL-6 alone is sufficient to induce downregulation of α4β7 on T cells or whether 
other cytokines may act synergistically with IL-6, we cultured splenocytes in the 
presence of recombinant cytokines. After 48 hours, CD8pos T cells were analyzed for 
α4β7 surface expression by flow cytometry. Very interestingly, treatment of splenocytes 
with recombinant IL-6 did not result in significantly reduced expression levels of α4β7 on 
CD8pos T cells (Figure 3.12). Similarly, other common DC-released cytokines did not 
induce downregulation of the homing receptor. These data suggest that IL-6 alone is 
not sufficient to mediate the DC-induced downregulation of α 4β7 on T cells after CpG 
stimulation.  
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Figure 3.12: Effect of recombinant cytokines on α4β7 expression of splenic CD8pos T cells. 
Splenocytes were cultured in the presence of CpG-DNA (3 µg/ml) or different recombinant 
cytokines, namely IL-1β, IL-6, IL-10, IL-12p40 or IL-17 (each with 250 ng/ml). After 48 hours, 
α4β7 expression of CD8pos T cells was measured by flow cytometry. Data show the mean values 
of triplicate samples ± SEM. Results are representative of 2 independent experiments. 
***P < 0.001, ns indicates not significant. 
 
 
3.2.5 Differences in α4β7 regulation of antigen-specific and -unspecific naïve 
CD8pos T cells after TLR4 stimulation in vivo 
Previous studies have proven that tissue-specific homing properties are imprinted on 
lymphocytes during activation of their antigen-specific receptors by DC in secondary 
lymphoid organs [Johansson-Lindbom et al., 2003; Mora et al., 2005]. DC from MLN 
[Stagg et al., 2002] or PP [Mora et al., 2003] but not PLN are capable to imprint gut-
homing specificity on activated T cells in the presence of TLR ligands. Our data now 
show that T cells from different SLO downregulate the expression of α 4β7 upon 
stimulation with different TLR ligands mediated by DC. 
 
Treatment of immune cells with activators of the innate immune system such as CpG-
DNA or other TLR ligands triggers stimulation of T cells without requiring detection of a 
nominal antigen by the Tcell receptor. This cytokine-driven antigen non-specific T cell 
activation is mediated mainly by DC and has been referred to as ‚bystander activation’ 
[Kamath et al., 2005]. This bystander activation has two specified components: On the 
one hand, there is a strongly upregulated expression of the phenotypic activation 
marker CD69 on naïve and memory CD8pos T cells, reported after the application of 
either polyI:C (TLR3), LPS (TLR4) or CpG-DNA (TLR9) in mice. On the other hand, 
there is division of memory CD8pos T cells [Tough et al., 1996; Tough et al., 1997; Sun 
et al., 1998]. Bystander activated T cells have been reported to show increased 
responsiveness to subsequent stimulation via the TCR [Ramanathan et al., 2008]. 
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We hypothesized that the expression of the gut-homing receptor α 4β7 in response to 
stimuli of the innate immune system is differentially regulated on antigen-specifically 
activated versus non-specifically activated, bystander lymphocytes. To investigate this 
question we utilized OT-I transgenic mice in an adoptive transfer model. In these 
animals, all CD8pos T cells have the same T cell receptor that recognizes the model 
antigen ovalbumin. This common model allows for the analysis of antigen-specific 
T cell responses.  
 
CD8pos T cells were purified by magnetic sorting from splenocyte single cell 
suspensions of OT-I transgenic and strain matched wild type (WT) mice. OT-I CD8pos 
T cells were fluorescently labeled with CFSE while WT CD8pos T cells were marked 
with the fluorochrome Cell Tracker Violet. Both CD8pos T cell preparations were mixed 
at equal numbers and 5 - 10 x 106 labeled cells were injected intravenously into naïve 
WT recipient mice. One day after the adoptive T cell transfer, mice were immunized 
intraperitoneally with 100 µg LPS and 500 µg endotoxin-free ovalbumin. Naïve mice of 
the control group did not receive an adoptive T cell transfer and were treated with 
150 µl of PBS intraperitoneally. Two days after immunization, mice were killed and 
secondary lymphoid organs were obtained. The surface expression of α 4β7 on 
transferred antigen-specifically activated OT-I and unspecific WT CD8pos T cells as well 
as endogenous CD8pos T cells of naïve WT mice was analyzed by flow cytometry. 
 
As reported in previous studies [Johansson-Lindbom et al., 2003], CD8pos OT-I T cells 
that are activated in the MLN by their cognate antigen and LPS show a gut-homing 
phenotype with very strong upregulation of α 4β7 (Figure 3.13 right panel). Consistent 
with earlier findings [Agace, 2006], OT-I T cells activated in the spleen show 
intermediate expression of α4β7 while OT-I cells activated in PLN do not upregulate the 
gut-homing receptor (Figure 3.13 left and middle panel). At the same time, transferred 
WT CD8pos T cells, that in generally do not recognize ovalbumin and are therefore 
unspecifically LPS-activated bystander cells, showed strongly reduced expression of 
α4β7 when compared to CD8pos T cells of naïve WT mice. Endogenous CD8pos T cells of 
recipient mice showed downregulation of α4β7 upon stimulation with LPS and 
ovalbumin comparable to previously transferred WT CD8pos T cells (data not shown). 
The downregulation of α4β7 on WT CD8pos T cells in response to TLR4 stimulation 
seems to be a broad reaction pattern as it could be observed in all analyzed secondary 
organs. In summary, these data strongly suggest that antigen-specifically activated 
CD8pos T cells show diverse α4β7 regulatory mechanisms in different SLO while 
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unspecifically LPS-activated bystander T cells respond with a uniform pattern of 
downregulation of the gut-homing receptor α4β7. 
 
 
Figure 3.13: Differences in α4β7 regulation of antigen-specific and -unspecific CD8pos 
T cells after TLR4 stimulation in vivo. CD8pos T cells were sorted out of splenocytes from wild 
type or OT-I transgenic mice by MACS. The two CD8pos T cell preparations were stained with 
either CFSE or the Celltracker Violet, mixed at equal numbers and were adoptively transferred 
into naïve wild type recipient mice. 24 hours after the transfer of 5-10 x 106 T cells, mice were 
immunized with 500 µg ovalbumin and 100 µg LPS ip. Naïve mice in the control group did not 
receive an adoptive T cell transfer and were treated with 150 µl PBS ip. 48 hours after this 
immunization, α4β7 expression was analyzed on transferred wild type and OT-I transgenic 
CD8pos T cells as well as endogenous CD8pos T cells of naïve control mice in different SLO. 
Data show the mean values of duplicate samples per mouse (n=4) ± SEM. Results are 
representative of 2 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ns indicates 
not significant. An asterisk without brackets indicates comparison to CD8pos T cells of 
unstimulated naïve mice. 
 
 
3.3 Imprinting of a gut-homing phenotype 
3.3.1 Toll-like receptor effects on T cell gut imprinting 
Our previous experiments have shown that bystanding naïve lymphocytes activated by 
DC-derived cytokines upon TLR stimulation in the absence of their cognate antigen 
subsequently downregulate the gut-homing receptor α4β7. Now we wanted to 
investigate the effect of TLR stimulation on the process of imprinting gut-homing 
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specificity on T cells itself during antigen-specific T cell receptor simulation by dendritic 
cells. 
 
Therefore, single-cell suspensions gained from peripheral and mesenteric lymph nodes 
were labeled with the fluorescent marker CFSE to later visualize cell proliferation. After 
extensive washing, complete cells were stimulated with CpG-DNA and cultured. 
Soluble anti-CD3ε antibody was added to the culture to simulate T cell receptor 
stimulation (see below). After five to eight days, proliferation and α4β7 expression was 
measured on different T cell subsets by flow cytometry. 
 
The αβ T cell receptor binds its cognate peptide-MHC complex on antigen-presenting 
cells but is not able to signal to the cell that antigen is actually bound. The T cell 
receptor is associated with four signaling chains (two ε, one ɣ, one δ) collectively called 
CD3 which link binding of extracellular antigen to intracellular signaling. A monoclonal 
antibody against the ε chain (anti-CD3ε) activates the signal transducer and 
subsequent intracellular signaling thereby resembling T cell receptor stimulation in the 
absence of the cell’s cognate peptide-MHC complex. The soluble anti-CD3ε used in 
this work - unlike its plate-bound counterpart - is dependent on accessory cells like DC 
to be presented to T cells [Stagg et al., 2002]. The use of an accessory cell-dependent 
stimulus maximizes the potential for modification of the response by accessory cells 
such as DCs during the interaction with T cells. Therefore anti-CD3ε is a DC-
dependent pan-T cell stimulus resembling antigen-specific T cell receptor activation 
which is a prerequisite for tissue-specific T cell imprinting. 
 
Compatible to previous studies [Stagg et al., 2002], the proportion of CD8pos T cells 
expressing α 4β7 was consistently higher in cultured MLN than PLN cell solutions. For 
both cell populations, expression of the homing receptor was progressively upregulated 
with simultaneously decreasing CFSE-intensity which represents the inversely 
increasing numbers of T cell divisions (Figure 3.14 A, showing FACS data of one of 
three representative experiments, gated on CD8pos T cells). As the dye’s fluorescent 
conjugates are retained by T cells throughout maturation and thus are inherited to 
daughter cells during mitotic cell division, proliferating T cell generations could be 
traced by linearly decreasing CFSE intensity. As described previously by Stagg et al. in 
2002, these findings concluded that expression of the gut-homing integrin α4β7 was 
enhanced when T cells are activated in the presence of DC derived from MLN 
compared with activation in the presence of DC from non-mucosal peripheral lymph 
nodes. The proportion of dividing cells expressing α4β7 was consistently greater for 
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MLN than for PLN while the homing receptor was only upregulated on cells that had 
divided and expression progressively increased with the number of cell divisions. 
  
When the single-cell solutions from MLN and PLN were additionally stimulated with 
CpG-DNA, the percentage of α4β7 expressing CD8pos T cells was clearly reduced when 
compared to not CpG-stimulated cell cultures. Cytotoxic T cells activated with 
anti-CD3ε by CpG-stimulated MLN-DC among other cells showed strong proliferation. 
However, these T cells failed to acquire expression levels of α4β7 comparable to T cells 
activated by MLN-DC that were not CpG-stimulated. Thus, these findings suggest that 
TLR9 stimulation attenuated intestinal DC capability to imprint gut-homing specificity on 
cytotoxic T cell during T cell receptor activation. Accordingly, the proportion of 
anti-CD3ε-activated CD8pos T cells with upregulated α4β7 in PLN was slightly reduced 
after CpG stimulation when compared to T cells in the non-CpG PLN group. However, 
this reduction was not significant. 
 
Figures 3.14 B to D show integrated data of at least three experiments for surface 
expression of α 4β7 on anti-CD3ε-activated T cell subsets cultured within MLN or PLN 
single-cell solutions. Expression of the gut-homing receptor is shown for every T cell 
generation as fold increase compared to base-level α4β7 expression on non-responding 
cells. Again, for both PLN and MLN single-cell cultures the proportion of proliferating 
CD8pos T cells expressing α4β7 integrin increased with the number of cell divisions 
(Figure 3.14 B). The difference between PLN and MLN cultures was maintained over 
the full range of cell divisions. Cytotoxic T cells as well as CD8neg TH cells in MLN cell 
suspension clearly upregulated α 4β7 with every cell generation while additional CpG 
stimulation diminished this effect (Figure 3.14 C). There was no significant difference in 
expression of the homing receptor on CD8pos or CD8neg T cells within PLN cell 
suspension when comparing the CpG-stimulated with the unstimulated group. Recent 
studies demonstrated that regulatory T cells similar to other T cell subset are imprinted 
by intestinal DC with a gut-specific phenotype [Siewert et al., 2007]. Our findings 
confirmed that MLN-derived DC are potent inducers of α4β7 also on regulatory T cells 
as Tregs showed predominant upregulation of the gut-homing receptor when cultured 
with MLN- but not PLN-derived cell solutions. Similar to cytotoxic and helper T cells, 
anti-CD3ε-activated proliferating Tregs showed significantly impaired expression levels of 
α4β7 when co-cultured MLN-derived DC were stimulated with CpG-DNA. However, the 
failure to upregulate α 4β7 after CpG-stimulation of MLN-DC was less dramatic among 
Tregs than the other T cell subsets. 
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Figure 3.14: Effects of CpG-DNA on anti-CD3ε-activated MLN and PLN cell cultures. 
Single-cell suspensions from PLN and MLN were labeled with CFSE and stimulated with 
CpG-ODN (4 µg/ml). After extensive washing, cells were cultured in the presence of soluble 
anti-CD3ε antibody for 5 to 8 days. α4β7 surface expression on each T cell generation was then 
measured by flow cytometry. A) FACS dot blots from one representative experiment out of three 
are gated on CD8pos T cells and numbers indicate percentage of α4β7 expressing cells. (B) Data 
show the mean values of triplicate samples ± SEM. Results are representative of at least 3 
independent experiments. The asterisk without brackets indicates comparison to the 
CpG-unstimulated group for each tissue culture. *P < 0.05; **P < 0.01; ns indicates not 
significant. 
 
 
In a next step, we excluded possible side-effects on T cell gut-imprinting by cells other 
than DC. Not less important, we wanted to rule out the source of T cells as a potential 
parameter in different α 4β7-imprinting patterns upon CpG stimulation. Hence, we 
purified dendritic cells from PLN (PLN-DC) and MLN (MLN-DC) using MACS 
technique. Pure DC were stimulated with CpG-DNA and co-cultured with MACS-sorted 
splenic CD8pos T cells in the presence of soluble anti-CD3ε antibody. After 4 to 6 days, 
α4β7 surface expression was measured on T cells by flow cytometry. 
 
Consistent with our previous experiments and studies by Stagg et al. in 2002, purified 
anti-CD3ε-activated CD8pos T cells also showed significantly higher levels of α 4β7 
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surface expression when co-cultured with sorted MLN-DC compared to PLN-DC 
(Figure 3.15). Additionally, splenic CD8pos T cells showed expression levels of the 
homing receptor similar to MLN-originated cytotoxic T cells when co-cultured with 
intestinal DC. Upregulation of the homing receptor on CD8pos T cells was clearly 
diminished when MLN-DC were stimulated with CpG-ODN. T cells co-cultured with 
PLN-DC showed no significant difference in α 4β7 expression levels when DC were 
stimulated with CpG-DNA. 
 
Thus, we demonstrated that CpG-ODN clearly influenced DC-mediated imprinting of 
T cells. MLN-DC which induced high expression levels of α4β7 on co-cultured cytotoxic, 
helper and regulatory T cells, to a great extent lost this ability after CpG stimulation. 
PLN-DC did not induce high levels of the homing receptor on T cells, therefore CpG-
stimulation lead to no significant differences in α4β7 expression levels on co-cultured T 
cells. Imprinting effects by dendritic cells were independent from the source of 
responding T cells. 
 
 
 
Figure 3.15: Effects of CpG-ODN stimulation on T cell imprinting. CD11cpos DC were 
purified from PLN or MLN, stimulated with CpG-ODN (4 µg/ml) and co-cultured with sorted 
splenic CD8pos T cells in the presence of soluble anti-CD3ε antibody. After 4 to 6 days, α4β7 
surface expression was measured on responding T cells by flow cytometry. Data show the 
mean values of triplicate samples ± SEM. Results are representative of at least 3 independent 
experiments. ***P < 0.001; ns indicates not significant.  
 
 
3.3.2 Effects of TLR ligands on the retinoic acid metabolism of dendritic cells 
Previous studies implicate a central role of the vitamin A metabolite retinoic acid in 
imprinting a gut-homing phenotype on lymphocytes as vitamin A deficiency affects α4β7 
expression of T and B cells. Compatibly, vitamin A-deficient mice have a dramatic 
reduction in the number of T cells specifically in the gut mucosa [Iwata et al., 2004]. 
Indeed, vitamin A-derived retinoic acid specifically enhances the expression of the gut-
homing molecules α 4β7 and CCR9 on naïve TH cells upon immobilized antibodies to 
CD3 and CD28; even in the absence of dendritic cells. RA-treated T cells migrate into 
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small-intestinal tissues more efficiently than control cell indicating that RA imprints T 
cells with gut-homing specificity when T cells are activated through the T 
cell receptor/CD3 complex [Iwata et al., 2004]. Iwata et al. also found that RA is 
produced by intestinal DC but not DC from PLN or spleen. Antagonists of the retinoic 
acid receptor suppress the capacity of intestinal DC to induce α4β7 expression on 
T cells, indicating that RA is the physiologic and essential ‘imprinter’ for gut-homing 
specificity on lymphocytes [Iwata, 2009]. With our findings, that stimulation with TLR9 
ligand CpG-DNA attenuates MLN-derived DC capability to imprint gut-homing 
specificity on T cells, we wanted to investigate the effect of TLR9 stimulation on the 
production of retinoic acid by dendritic cells. 
 
RA biosynthesis from vitamin A occurs locally where it is required. The key step, an 
irreversible conversion of retinal to RA is catalyzed by retinal dehydrogenases encoded 
by the Aldh1a gene family, a subfamily of class I aldehyddehydrogenases, which are 
expressed in limited cell types [Napoli, 1999]. Furthermore, expression of these retinol 
aldehyd dehydrogenases (RALDH) show a tissue-restricted pattern and hence may be 
at least partially responsible for the differential regulation of homing molecules in 
intestinal and non-intestinal lymph nodes. In this regard, especially RALDH2 mRNA 
was strongly expressed in MLN-derived DC but only detected at low levels in PLN DC 
[Johansson-Lindbom and Agace, 2007]. Thus, to determine the effect of TLR9 
stimulation on production of retinoic acid by dendritic cells, we wanted to investigate 
the expression patterns of RALDH2 in intestinal and non-intestinal dendritic cells after 
CpG-DNA stimulation by the determination of RALDH2 mRNA levels. 
 
Therefore, mice were injected with Flt3-L-secreting melanoma cells to enhance 
dendritic cell frequency in secondary lymphoid organs (see chapter 2.2.4). Twelve to 
14 days later, mice were sacrificed and DC were purified from PLN and MLN using the 
MACS technique. Sorted DC as well as additionally preparated hepatocytes were 
stimulated with CpG-ODN and cultured. After 18 hours, DC and hepatocytes were 
lysed and complete RNA was extracted and reversely transcribed into cDNA. Then, 
RALDH2 mRNA levels were measured using quantitative real-time polymerase chain 
reaction (qRT-PCR). RALDH2 mRNA levels were normalized to mRNA levels of 
ubiquitary expressed hypoxanthin-phosphoribosyl-transferase (HPRT). 
 
Immature dendritic cells originated from both mesenteric and peripheral lymph nodes 
as well as complete hepatocytes all expressed measurable levels of RALDH2 mRNA. 
As described by Johansson-Lindbom and Agace in 2007, RALDH2 mRNA levels were 
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most prominent among MLN-derived DCs while PLN-DC and hepatocytes expressed 
only low levels of the enzyme’s mRNA (Figure 3.16). However, when stimulated with 
CpG-ODN, both DC populations significantly upregulated RALDH2 mRNA levels when 
compared to constitutively expressed mRNA of the housekeeping gene HPRT. After 
CpG stimulation, both intestinal and non-intestinal DC showed similarly high expression 
of RALDH2 mRNA. Hepatocytes also increased expression of RALDH2 mRNA after 
TLR9 stimulation. However, the extend of upregulation was less intensive on 
hepatocytes as compared to dendritic cells. 
 
 
 
Figure 3.16: Effect on CpG-DNA stimulation on RALDH2 mRNA levels in dendritic cells 
and hepatocytes. Hepatocytes and sorted CD11cpos DC from PLN and MLN were stimulated 
with CpG-ODN (4 µg/ml) and cultured for 18 hours. Cells were then lysed and complete RNA 
was extracted and reversely transcribed into cDNA. Finally, RALDH2 mRNA levels were 
measured by quantitative real-time PCR and are expressed relative to HPRT mRNA levels for 
each sample. Data show the mean values of triplicate samples ± SEM. Results are 
representative of two independent experiments. **P < 0.01; ***P < 0.001. 
 
 
3.3.3 Opposing effects of retinoic acid and TLR ligands on T cell gut-homing 
specificity 
With conflicting findings that CpG-DNA stimulation attenuates intestinal DC gut 
imprinting capacity which is known to be RA-dependent but simultaneously enhances 
their expression of RALDH mRNA – the key enzyme in RA synthesis – we wanted to 
investigate the effect of CpG-stimulated dendritic cells on RA-induced upregulation of 
α4β7 on lymphocytes. 
 
According to protocols from previous studies [Iwata et al., 2004], complete splenocytes 
were therefore activated with anti-CD3ε and additional anti-CD28. CD28 is expressed 
on T cells in association with their antigen-specific Tell receptor. CD28 binds to co-
stimulatory molecules on antigen-presenting cells and thereby delivers the essential 
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second signal alongside T cell receptor-peptide-MHC complex interaction. Thus CD28 
signaling drives activation and proliferation of T cells that encounter specific antigen 
presented by dendritic cells or other professional APC. Combined activation of CD3ε 
and CD28 results in a pan-T cell stimulus and proliferation independent of accessory 
cells such as DC. Such activated T cells were cultured with different concentrations of 
retinoic acid to induce a gut-homing phenotype. CpG-DNA was added to the culture to 
stimulate dendritic cells. Three to four days later, α 4β7 surface expression on T cells 
was measured by flow cytometry. 
 
Compatible with findings of Iwata et al. in 2004, retinoic acid induced high expression 
of the gut-homing integrin α 4β7 on CD8pos and CD8neg T cells that were activated by 
anti-CD3ε and anti-CD28 (Figure 3.17). Upregulation of the homing receptor was 
observed with RA concentrations as low as 0.1 nM and grew in prominence with 
increasing culture concentration of the vitamin A-metabolite. As described previously, 
the induction of α4β7 on anti-CD3ε/CD28-activated T cells was independent of dendritic 
cells as DC-depleted splenocyte cultures showed unaffected upregulation of the 
gut-homing molecule (data not shown). Splenocytes that were cultured in the presence 
of additional CpG-DNA, showed impaired induction of α4β7 on cytotoxic and helper 
T cells. Culture concentrations of the TLR9 ligand of 0.3 µg/ml did not result in 
significantly altered expression levels of the gut-homing receptor on T cells, while CpG 
concentrations of 3.0 µg/ml entailed impaired upregulation of α4β7 on T lymphocytes. 
Even in the presence of CpG-DNA, retinoic acid induced α 4β7 on T cells in a 
dose-dependent manner although this induction was clearly decreased in its 
magnitude. 
 
Thus we demonstrated that CpG stimulation of spleen cells significantly reduces 
RA-mediated DC-independent upregulation of α 4β7 on anti-CD3ε/CD28-activated 
T cells amongst splenocytes. CpG-DNA concentrations of 3.0 µg/ml are sufficient to 
attenuate induction of the gut-homing receptor by RA but fail to totally abrogate 
imprinting effects of retinoic acid concentrations > 1 nM. 
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Figure 3.17: Competitive effects of retinoic acid and TLR ligands on T cell gut-homing 
specificity. Splenocytes were activated with anti-CD3ε and anti-CD28 antibodies and cultured 
in the presence of different concentrations of retinoic acid. Variable amounts of CpG-DNA were 
added to the cultures. After three to four days, α4β7 surface expression on T cells was measured 
by flow cytometry. Data show the mean values of quadruplicate samples ± SEM. Results are 
representative of two independent experiments. The asterisk indicates comparison to the 
CpG-unstimulated group for each RA concentration. **P < 0.01; ns indicates not significant. 
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3.4 Effects of TLR ligands on lymphocyte homing in vivo 
Previous experiments have shown that after stimulation with Toll-like and other pattern-
recognition receptors, dendritic cells release IL-6 amongst other cytokines inducing 
significant downregulation of the gut-homing receptor α4β7 on naïve lymphocytes. In a 
next step, we investigated whether this downregulation of α4β7 has functional 
consequences and results in altered migration patterns of responding T and B cells in 
vivo. Therefore, we utilized short term homing experiments as used previously to 
investigate lymphocyte migration patterns in vivo [Mora et al., 2003; Iwata et al., 2004]. 
 
Splenocytes were cultured with or without CpG-ODN for 48 hours. Both cell 
preparations were labeled with the fluorescent marker CFSE. Two different CFSE 
concentrations were used to later distinguish the two experimental groups. This 
resulted in two clearly distinct CFSE labeling intensities with CpG-stimulated 
splenocytes being CFSE highly positive (CFSEhigh) and naive spleen cells showing low 
CFSE fluorescence intensity (CFSElow). After extensive washing, both cell preparations 
were mixed an injected intravenously into naïve recipient mice. An aliquot was saved to 
assess the input ratio ( [CFSEhigh]input / [CFSElow]input ). Four to eight hours after the 
adoptive transfer, mice were sacrificed and preparated organs screened for the 
injected splenocytes by flow cytometry. For all adoptively transferred lymphocyte 
subpopulations CFSEhigh / CFSElow ratios were measured in each tissue preparation 
and normalized to the input ration. Therefore, the homing index (HI) was calculated as 
the ration of [CFSEhigh]tissue / [CFSElow]tissue to [CFSEhigh]input / [CFSElow]input. 
 
With a homing index close to 1.0, CD8pos T cells showed no altered migration to spleen 
and peripheral lymph nodes after CpG-stimulation in in vivo-short term homing 
experiments (Figure 3.18). In MLN and PP, secondary lymphatic organs of the gastro-
intestinal tract, the HI of cytotoxic T cells was significantly reduced after TLR9 
activation. In the same way, CD8pos T cell homing to small bowl and colon was clearly 
diminished after CpG-stimulation. T cell migration to liver and lung showed no relation 
to the innate stimulus. CD8neg T cells showed similar migratory. However, migration of 
CD8neg T cells to gut lymphatic and effector organs was reduced to a less extent after 
CpG-stimulation when compared to CD8pos T cells. Regulatory T cells too, showed 
reduced migration to MLN and PP after CpG stimulation. Small bowl and colon as well 
as the lung could not be analyzed for Tregs due to technical reasons. Notably, Tregs 
showed increased migration to PLN when stimulated with CpG-ODN. B cell migration 
patterns were basically similar to those of CD8pos T cells. 
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Thus, we demonstrated that the observed downregulation of α 4β7 on lymphocytes 
mediated by DC after CpG-stimulation results in altered migration patterns in vivo. 
When adoptively transferred after CpG-stimulation T and B cells migrated significantly 
less to the GI-tract and associated secondary lymphoid organs. CpG-ODN has no 
significant effect on migratory behavior to spleen, PLN, liver and lung except for Tregs 
which show increased migration to PLN after CpG stimulation. 
 
 
 
Figure 3.18: CpG-ODN stimulation has an effect on lymphocyte gut-homing in vivo. 
Splenocytes were cultured with or without CpG-ODN (4 µg/ml) for 48 hours and stained with 
CFSE (1mM or 0.1 mM). Both cell preparations were mixed and injected intravenously into 
recipient mice. After 4 hours adoptive transfer, organs were analyzed for the injected 
splenocytes. The homing index (HI, the ratio of [stimulated CFSEhigh cells] / [unstimulated 
CFSElow cells] corrected to the input ration) in recipient tissues was determined by flow 
cytometry. Data show the mean values of individual recipient mice (n = 3) ± SEM. Results are 
representative of 3 independent experiments. The asterisk indicates comparison to HI for 
spleen homing. *P < 0.05; **P < 0.01; ***P < 0.001; ns indicates not significant.  
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4 DISCUSSION 
4.1 TLR stimulation of dendritic cells affects gut-tropic homing 
of both naïve and antigen-experienced bystander lymphocytes 
During their recirculation, blood-borne lymphocytes make a series of interactions with 
endothelial cells. Naïve lymphocytes preferentially leave the blood stream to organized 
lymphoid tissues where they edge their way through the vessel wall and enter the 
tissue stroma to scavenge the connective tissue network in search for their specific 
antigen [von Andrian and Mempel, 2003]. If a lymphocyte does not find its antigen, it 
leaves the lymphatic organ via efferent lymphatic vessels and reenters the systemic 
blood circulation. The then still naïve lymphocyte is free to continue its journey to any 
other secondary lymphoid organ. But in the rare event that a naïve T or B cell finds its 
cognate antigen in the lymphoid organ, its migratory pattern changes profoundly. The 
lymphocyte starts to rapidly proliferate and differentiate and its numerous descendents 
then enter the blood circulation via the efferent lymphatic vessels. However, these 
activated effector and memory cells – now imprinted in specific tissue 
microenvironment – preferentially leave the blood stream in the same type of lymphatic 
tissue in which their ancestry has initially been activated. Even more fundamentally, 
they have acquired new properties in terms of homing molecules which allow them to 
leave the blood stream in non-lymphoid peripheral tissue which is associated with and 
mainly draining into the lymph node where tissue-specific imprinting took place. Here 
they exert their effector function in fighting pathogens or transformed host cells. 
 
Intestinal homing involves recirculation to organized lymphatic tissues (such as MLN 
and PP) and to the non-lymphoid lamina propria of the intestinal wall. Some of the 
lymphocytes that enter the lamina propria are further attracted to the epithelium of the 
gut where they constitute the unique population of intraepithelial lymphocytes; a 
characteristic feature shared by all mucosal sites [Salmi and Jalkanen, 2005]. MLN and 
PP serve as primary target organs for the entry of naïve lymphocytes while lamina 
propria and associated epithelium function as the ‘peripheral’ effector target organs for 
activated gut-specific lymphocytes. 
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4.1.1 The gut-specific integrin α4β7 has a special status amongst homing 
receptors 
As described above, efficient homing to lymphoid and peripheral sites requires organ-
specific homing receptors interacting with endothelial adhesion molecules. Although 
numerous such molecules are involved in lymphocyte interaction with vascular 
endothelium at different steps of the adhesion cascade, only a few of them guarantee 
tissue specificity of the homing process. These homing receptors are best 
characterized for the dichotomous systems of skin and intestinal homing. The integrin 
α4β7, the gut-specific molecule besides CCR9 and questionable CCR10, has an 
outstanding position amongst the inhomogeneous family of homing molecules. 
Uncommonly, α4β7 is highly involved in lymphocyte recirculation to both operational 
units of the intestinal immune compartment: lymphoid tissues and peripheral effector 
sites [Butcher and Picker, 1996]. Furthermore, the α4β7 integrin facilitates – in contrast 
to all other homing molecules – several steps of the adhesion cascade. 
 
Key players in lymphocyte homing to the skin are CCR4, CCR10 and the cutaneous 
lymphocyte antigen (CLA). CLA is a carbohydrate modification of P-Selectin 
glycoprotein ligand-1 that binds to P- and E-Selectin which are constitutively expressed 
on endothelium of skin venules [Fuhlbrigge et al., 1997]. Therefore, CLA is vital for 
lymphocyte recirculation to the skin. However, other sets of homing molecules mediate 
the initial migration of T and B cells to skin-draining peripheral lymph nodes where they 
may meet their cognate antigen and be imprinted with skin-specificity. In contrast, the 
integrin α 4β7 not only plays a critical role in both recirculation of antigen-experienced 
cells to the intestinal lamina propria (their peripheral effector organ) and of naïve 
lymphocytes to intestinal lymphatic tissue but also is important in more than one step of 
both these extravasation processes [Hamann et al., 1994]. Thus, while initial 
interactions like tethering and rolling of naïve lymphocytes in high endothelial venules 
of peripheral lymph nodes are exclusively mediated by interaction of L-Selectin with the 
endothelial adhesion molecule PNAd, HEV in mesenteric lymph nodes and PP also 
express MAdCAM-1 which binds α 4β7 on incoming lymphocytes [Berlin et al., 1993]. 
After chemokine activation, α 4β7-MAdCAM-1 interaction also facilitates final adhesion 
to the endothelium and allows subsequent diapedesis. As in gut lymphoid organs, 
tissue-specific recirculation of antigen-experienced effector lymphocytes to the 
intestinal lamina propria is dependent of this integrin for several steps: α4β7-MAdCAM-1 
interaction facilitates initial tethering and rolling as well as gut-specific adhesion of 
lymphocytes to the endothelium in lamina propria venules [Berlin et al., 1995]. 
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Thus, α4β7 has a special role amongst homing receptors as it mediates tissue-specific 
recirculation of lymphocytes to both lymphoid and effector organs of the intestinal 
compartment. Hence, transgenic mice that lack the β7-unit of the heterodimeric integrin, 
not only have hypocellular PP, but also significantly reduced numbers of lymphocytes 
in the intestinal lamina propria [Wagner et al., 1996]. Furthermore, in short-term in vivo 
assays, these β7-deficient mice showed reduced lymphocyte migration to lamina 
propria and PP. However, efficient recirculation to PP required both α 4β7 and the 
‘standard’ lymph node receptor L-Selectin, as double-knockout mice showed more 
severly decreased PP-homing than mice which lacked only one of the homing 
receptors.  
 
 
4.1.2 Interleukin-6 release by dendritic cells upon CpG stimulation affects 
expression of the gut-homing receptor α4β7 on bystander lymphocytes 
The α4β7 integrin is expressed at low levels on naïve T and B cells which is enough to 
allow them to enter and scan MLN and PP in search of their specific antigen [Bargatze 
et al., 1995]. Due to the simultaneous expression of further homing molecules such as 
L-Selectin, the same naïve lymphocytes can also leave the blood stream to peripheral 
non-mucosal lymph nodes. It is therefore coincidence which lymph node is scanned by 
a single lymphocyte and the spreading of the entirety of naïve lymphocytes among the 
lymphoid tissues of different immune compartments is a matter of random statistical 
distribution. 
 
In the present work we show that dendritic cells induce strongly reduced expression of 
the gut-homing receptor α 4β7 on lymphocytes upon stimulation of various PRR. This 
downregulation seems to be a broad reaction pattern on T and B cells following 
different stimuli of the innate immune system. However, this regulatory effect was 
limited to antigen-unspecifically activated bystander cells. While several reports have 
characterized the expression patterns of α4β7 on antigen-specifically activated 
lymphocytes [Johansson-Lindbom et al., 2003; Mora et al., 2005], we give evidence for 
the first time, that bystander activated CD8pos T cells in different SLO show 
downregulation of the gut-homing integrin α 4β7. Because of the very nature of the 
transgenic OT-I mouse model with only CD8pos T cells having the unique TCR to 
recognize the model antigen ovalbumin, we could not investigate the regulatory 
mechanisms of α4β7 on antigen-specific CD4pos T cells and B cells. 
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In this context, we demonstrated that DC-produced IL-6 was partly responsible for 
reduced surface expression of α 4β7 on T and B cells. However, lymphocytes from 
transgenic mice which lacked functional IL-6 still showed distinct downregulation of 
α4β7 upon stimulation with CpG-DNA. Furthermore, CD8pos T cells did not respond with 
significantly impaired expression levels of the homing receptor when stimulated in vitro 
with recombinant IL-6 only. We hypothesize that DC-produced IL-6 alone is not potent 
in mediating the downregulation of α4β7 on lymphocytes upon CpG stimulation by itself. 
TLR stimulation of DC results in a broad array of secreted cytokines. Together with at 
least one additional yet unknown factor, IL-6 might synergistically downregulate the 
surface expression of α 4β7 on bystander T and B cells. However, other factors that 
synergize with IL-6 in the regulation of α4β7 still have to be identified in further studies. 
 
IL-6 has a wide spectrum of biological activities that help to coordinate a systemic 
response to infection. IL-6 is released by dendritic cells and macrophages after 
engagement of their pathogen-recognition receptors with microbial or viral PAMP. 
Additional minor sources of IL-6 are endothelial and epithelial cells as well as TH cells. 
Locally, the interleukin activates T and B cells. Systemic effects of IL-6 are the release 
of acute phase proteins by hepatocytes, mobilization of neutrophilic granulocytes from 
the bone marrow and an increased body temperature facilitated by protein and energy 
mobilization in fat and muscle tissue [Horn et al., 2000]. With decreased viral and 
bacterial replication at elevated body temperatures, all these effects aim to efficiently 
eliminate infections.  
 
Additional factors released by DC upon TLR stimulation that cooperated with IL-6 to 
induce downregulation of α 4β7 on bystanding naïve lymphocytes could not yet be 
identified. Other cytokines commonly produced by DC such as IL-10 or IL-12 as well as 
T cell-derived IL-2 and IFN-ɣ proved not to be involved in α4β7 surface expression 
levels. IFN-α, TNF-α and TGF-β seemed rather to attenuate but not to facilitate 
downregulation of the gut-homing integrin upon TLR stimulation. We also investigated 
CpG-DNA stimulation of splenocytes that were deficient for one or several transcription 
factors involved in TLR9 signaling. Both the NF-κB p50-subunit as final transcription 
factor in the MyD88-dependent pathway as well as IRF-3 and 7 in the TRIF-dependent 
signaling were not absolutely required for DC to respond to CpG-DNA with release of 
cytokines that induced downregulation of α4β7 on lymphocytes. These findings may be 
caused by overlapping functions of the different signaling pathways in production of 
IL-6 and other pro-inflammatory cytokines. Furthermore, additional yet unidentified 
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DNA-receptors have been suggested that may contribute in this setting [Ishii and Akira, 
2006].  
 
 
4.1.3 Functional aspects of TLR-induced downregulation of α4β7 in short-term 
homing experiments 
4.1.3.1 Lymphocyte recirculation to the gut is effectively reduced after TLR9 stimulation 
Studies using neutralizing antibodies specific for the α4β7-integrin or knockout mice 
have shown the important role of this homing receptor in mediating the entry of T and B 
cells into intestinal lymphoid organs as well as into the lamina propria of small and 
large bowel [Hamann et al., 1994; Lefrancois et al., 1999]. However, CD8pos cytotoxic T 
cells that were deficient for the β7-subunit could enter the mouse small intestine and 
provide immunity to infection with rotavirus, indicating that the α 4β7-integrin was not 
absolutely required for T-cell entry into the intestinal mucosa [Kuklin et al., 2000]. In 
this work we now demonstrate that stimulation of splenic DC with CpG-ODN results in 
downregulation of α 4β7 surface expression on co-cultured T and B lymphocytes. In 
subsequent short-term homing experiments these spleen-originated lymphocytes were 
significantly impaired in their ability to enter intestinal sites. Upon DC-stimulation with 
the TLR9 ligand, naïve bystander lymphocytes showed unchanged homing to the 
spleen and PLN while they failed to efficiently recirculate to MLN and PP when 
compared to unstimulated control cells. 
 
Antigen-experienced lymphocytes are more diverse than naïve T and B cells with 
respect to their migratory properties and are hence subdivided into central memory, 
effector memory and effector cells [Sallusto et al., 1999]. The distinct patterns of 
recirculation of these subgroups represent different levels of immune surveillance. 
Central memory lymphocytes maintain L-Selectin and, like naïve T and B cells, can 
migrate into secondary lymphoid organs where they rapidly respond upon reactivation. 
In contrast, effector and long-lived effector memory cells do not express L-Selectin and 
cannot recirculate to SLO. However, they efficiently migrate to non-lymphoid peripheral 
tissues where they exert their immune function. With the short-term homing 
experiments in this work, we demonstrate that adoptively transferred splenic T and B 
cells fail to home to the small or large bowel after in vitro-pretreatment with CpG-ODN. 
In contrast, untreated donor lymphocytes, even though in low absolute numbers, 
efficiently relocate to the small and large intestine. As naïve T and B cells are generally 
excluded from non-lymphoid organs [Johansson-Lindbom and Agace, 2007], the 
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transferred lymphocytes that recirculated to the small and large intestine supposedly 
represent effector memory T and B cells. Indeed, previous studies demonstrated that 
approximately 29 % of spleen-derived memory T cells in naïve mice show a gut-
specific phenotype with high expression of α4β7 [Campbell and Butcher, 2002]. Taken 
together, these findings suggest that not only naïve bystander but also antigen-
experienced bystander effector memory lymphocytes downregulate α4β7 surface 
expression and show impaired ability to recirculate to intestinal sites when pre-treated 
with CpG-ODN and adoptively transferred into naïve recipient mice.  
 
4.1.3.2 Homing to the colon: TLR9 affects segregated recirculation to this organ 
While the small bowel and the colon share the importance of α 4β7-MAdCAM-1 
interactions for efficient lymphocyte homing to these effector organs of intestinal 
immunity [Lefrancois et al., 1999], there seem to be additional still unknown factors that 
mediate recirculation to the large bowel. Despite the fact that PP-originated DC induce 
high levels of α4β7 surface expression on CD8pos T cells, these in vitro-activated T cells 
have the capacity to enter the small intestinal lamina propria but show poor migration to 
the colon mucosa [Mora et al., 2003]. Furthermore, the colon lacks CCR9pos cells and 
its ligand CCL25 is nearly exclusively expressed in the small intestine [Papadakis et al., 
2000]. Consistently, CCR9 blockade decreases adhesion of T lymphocytes in the small 
but not in the large bowel [Hosoe et al., 2004]. Notably, CCL28 is highly expressed by 
colonic epithelial cells, although its corresponding receptor CCR10 has been reported 
only on mucosal B but not T cells [Kunkel et al., 2003]. 
 
Thus, it seems that lymphocyte homing to the large bowel depends on additional 
homing molecules besides α 4β7 that are not sufficiently induced by DC from PP. 
Furthermore, other chemoattractant pathways than CCR9/CCL25 may play a role in 
directing lymphocyte migration to the colon mucosa. It remains to be determined 
whether T and B cells primed in vitro by DC from colon-draining lymph nodes efficiently 
home to the colonic mucosa. Notably, in competitive homing experiments, CD8pos T 
cells activated with appendix-DC migrated very inefficiently to the colon (Mora and von 
Andrian, unpublished data). In our short-term homing experiments we now 
demonstrated that DC-released cytokines upon TLR9 stimulation not only impaired the 
capability of adoptively transferred lymphocytes to enter the small intestine but also to 
enter the colon. But as lymphocyte recirculation to the colon, too, is highly dependent 
of the α4β7-integrin, our findings could not give evidence for TLR-induced regulation of 
the yet unknown colon-homing molecule(s).  
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4.1.3.3 Steady state versus inflammation: impact on current research models 
In current short-term in vivo research models, lymphocytes are pretreated in vitro, then 
are fluorescently or radioactively labeled and adoptively transferred into naïve mice. 
After varying periods of several hours to few a days, recipient mice are sacrificed and 
the localization of transferred cells is determined to analyze their homing patterns. But 
lymphocyte recirculation to lymphoid and peripheral effector organs is not only 
dependent on their expression of homing receptors but also on the endothelium’s 
equipment of adhesion molecules. These vascular addressins are very differently 
regulated and expressed during inflammation, which results in significant changes 
between homeostatic and inflammatory states in the relative potency of these 
molecules to mediate lymphocyte recruitment to specific compartments. 
 
Inflammation-induced chemokines and endothelial adhesion molecules play a role in 
mediating lymphocyte trafficking to the inflamed gut. Although expression of both 
CCL25 [Hosoe et al., 2004] and MAdCAM-1 [Briskin et al., 1997] enhances with 
inflammation, the effects of the interaction with their ligands CCR9 and α4β7 appear to 
be less important compared to the now rapidly increasing involvement of inflammation-
induced pathways including vascular cell adhesion molecule-1 (VCAM-1) and vascular 
adhesion protein-1 (VAP-1) [Salmi et al., 1993; Sans et al., 1999]. These adhesion 
molecules are not tissue-specific and are expressed at low levels in vessels of non-
inflamed gut tissue but are induced with ongoing inflammation. As inflammation 
develops, signals that drive organ-specific recirculation may become diluted by generic 
inflammation-associated processes; an important concept to consider when the impact 
of certain homing molecules is examined in steady-state experimental settings 
[Eksteen et al., 2008]. Although a definite role of homeostatic homing molecules α4β7 
and CCR9 has been shown in lymphocyte recirculation during ongoing 
inflammation [Picarella et al., 1997; Petrovic et al., 2004], it will be important to 
distinguish the relative contribution of tissue-specific versus non-specific traffic 
molecules to lymphocyte homing in different inflammatory settings.  
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4.2 Imprinting tissue tropism by dendritic cells and the role of 
Toll-like receptor ligands 
4.2.1 The different effects of TLR ligands on T cell gut-imprinting in vitro and in 
vivo  
Dendritic cells mediate the selective generation of gut- and skin-tropic lymphocytes 
during antigen presentation. This process depends on soluble signals derived from 
regionally imprinted DC. Expression of the gut-specific α4β7-integrin and the skin-tropic 
ligands of P- and E-Selectin are induced at low levels on T cells activated by a wide 
range of DC such as those derived from the spleen; this can be considered as a kind of 
‘default’ setting [Agace, 2006]. This default expression of homing molecules can be 
divergently regulated by soluble factors selectively released by intestinal and skin-
derived DC. Intestinal DC produce soluble factors that enhance the expression of α4β7 
and CCR9 while suppressing skin-homing molecules. This seems to be – at least in 
part – mediated by retinoic acid. On the other hand, skin-derived DC and Langerhans 
cells produce soluble factors that enhance the expression of ligands for P- and E-
Selectin and suppress the expression of α4β7 and CCR9. Several studies support these 
findings as murine TCR-transgenic T cells stimulated either with antigen-pulsed DC 
isolated from intestinal lymph nodes or anti-CD3 antibody in the presence of these DC 
expressed high levels of α4β7 and CCR9 [Stagg et al., 2002; Johansson-Lindbom et al., 
2003; Mora et al., 2003]. DC were necessary and sufficient for in vitro-induction of 
these gut-homing molecules as DC-depleted mesenteric lymph node-cells failed to 
imprint gut-specificity on co-cultured cytotoxic T cells [Johansson-Lindbom et al., 2003]. 
 
In this work we demonstrate that stimulation of DC with a TLR9 ligand attenuated their 
ability to imprint gut-specificity upon T cells in vitro. T lymphocytes activated with 
soluble anti-CD3ε antibody and co-cultured with DC showed significantly impaired 
surface expression of the gut-homing integrin α 4β7 if DC were previously stimulated 
with CpG-DNA. These findings applied for PLN-derived as well as MLN-derived DC. 
The unorthodox fact that DC from peripheral non-mucosal lymph node can imprint low 
levels of gut-homing molecules in vitro after all has been described previously [Dudda 
et al., 2005]. Recent studies suggest that splenic DC possess the enzymatic machinery 
to generate functional ligands of the retinoic acid-receptor at concentrations sufficiently high 
to induce low expression of α4β7 in vitro. However, T cells activated by TLR4 ligands in vivo 
in the splenic environment failed to express α4β7. Thus, additional mediators within non-
mucosal environments appeared to suppress α4β7 induction [Svensson et al., 2008].  
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Further reports showed that the expression of intestinal and cutaneous homing receptors is 
induced on T cells following their priming in gut- and skin-associated lymph nodes in vivo. 
After intraperitoneal administration of a model antigen TCR-transgenic T cells activated in 
MLN upregulated their expression of α4β7 and CCR9, whereas priming in peripheral 
lymph nodes resulted in induction of the skin-tropic homing molecules P- and 
E-Selectin ligands [Campbell and Butcher, 2002; Johansson-Lindbom et al., 2003; 
Stenstad et al., 2006]. Factors that influenced the efficiency of tissue-specific T cell 
generation in vivo included the route of antigen administration and the use of adjuvant. 
In an ovalbumin-specific TCR-transgenic model, oral administration of SIINFEKL - a 
peptide epitope of ovalbumin - led to an efficient upregulation of α4β7 and CCR9 on 
responding adoptively transferred transgenic T cells in MLN while intraperitoneal 
administration of antigenic peptide induced comparable expression levels only after 
co-administration of adjuvant [Johansson-Lindbom et al., 2003]. In these experiments 
suitable adjuvants for enhancing gut-specific imprinting of adoptively transferred T cells 
upon intraperitoneal antigen administration were alum, the TLR3-ligand polyI:C and the 
TLR4-ligand LPS. 
 
These in vivo-effects of systemic TLR3/4 stimulation to enhance antigen-specific imprinting 
of a gut-phenotype on responding T cells in MLN are in contrast with our findings that 
CpG-DNA impairs gut-imprinting by MLN-derived DC in vitro. However, effects of systemic 
TLR9 instead of TLR3/4 stimulation on T-cell imprinting in mesenteric lymph nodes have 
not been described yet. Others have shown for humoral but not cellular immune responses 
that subcutaneously delivered vaccines containing antigen and polyI:C or LPS stimulated 
the induction of both systemic and mucosal immune responses with high levels of specific 
serum-IgG and fecal-IgA [Enioutina et al., 2008]. In contrast, vaccines containing TLR9 
ligands could induce systemic immune responses but failed to induce mucosal humoral 
immunity. Furthermore, the TLR3/4 adjuvant-dependent augmentation of a gut-homing 
phenotype on T cells in MLN in these experiments might be caused by altered DC-
migratory behavior and not maturation-induced direct effects upon the imprinting 
process itself. Turnbull and colleagues have shown in rats that systemic administration 
of the TLR4 ligand LPS resulted in dramatically enhanced DC emigration from the 
intestinal lamina propria and the liver into draining lymph nodes [Turnbull et al., 2005]. 
Unlike their counterparts from spleen, accumulated DC in mesenteric lymph nodes did 
not express the maturation markers CD80/86 but could have allowed for enhanced 
gut-imprinting of transferred T cells in MLN upon systemic TLR stimulation in the 
reports described above just by their increased frequency. In contrast, systemic LPS 
had no effect on DC numbers and distribution in PP. Thus, further studies will need to 
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address the divergent effects of TLR-adjuvants on tissue-specific T cell imprinting in 
vivo. 
 
Generally speaking, requirements for imprinting a tissue-specific phenotype upon T 
and B lymphocytes by DC in vivo differ from those of in vitro-experiments. First of all, 
unlike the in vivo-situation, DC do not need a maturation stimulus for effective induction 
of tissue-specificity on T and B cells in vitro. However, that might be explained by the 
fact that DC used for in vitro-experiments often have already undergone maturation 
during the preceding isolation procedure [Johansson-Lindbom et al., 2003]. 
Furthermore, recent studies have shown that in vitro-activation by intestinal DC or 
addition of retinoic acid is sufficient to instruct expression of α 4β7 and CCR9 on 
lymphocytes whereas in vivo tissue-specific stroma cells, but not DC alone, allowed the 
mesenteric lymph nodes to induce the generation of gut tropism [Hammerschmidt et 
al., 2008]. Peripheral lymph nodes transplanted into the gut mesenteries failed to 
facilitate the generation of gut-homing T cells, even though gut-derived DC entered the 
transplants and primed T cells. In contrast PLN-derived DC that failed to induce α 4β7 
and CCR9 in vitro readily induced these factors in vivo upon injection into MLN-afferent 
lymphatics. The group concluded that in vivo, gut-homing T cells could only be 
generated in a permissive lymph node environment that was determined by resident 
stroma cells and DC. These resident stroma cells might produce negative signals that 
impair the generation of gut-homing T cells in transplanted and in situ PLN. 
 
In addition, Svensson et al. demonstrated that antigen dose not only played a central 
role in regulating various aspects of T cell differentiation including cytokine production 
and cytolytic activity but also in the induction of tissue-specific homing receptors 
[Svensson et al., 2008]. Activation of TCR-transgenic T cells by MLN-derived DC 
pulsed with a low antigen dose or administration of a low antigen dose in vivo led to 
efficient generation of α 4β7pos CCR9pos T cells, whereas pulsing of MLN-DC or in vivo 
administration of a high antigen dose resulted in reduced α 4β7 and CCR9 surface 
expression levels. Together, these results suggested that a negative signal is 
generated at higher antigen doses that could inhibit RA-induced expression of α4β7 and 
CCR9 downstream of retinoic acid receptor signaling. Similar dose-dependent 
regulatory effects of maturational stimuli such as TLR ligands upon DC-imprinting 
properties are conceivable but remain to be determined. 
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4.2.2 The role of retinoic acid in TLR-attenuated T cell imprinting of gut 
specificity  
The mechanisms by which dendritic cells from different anatomical sites generate 
tissue-specific T and B cells are currently the subject of intensive investigation. A 
breakthrough was made by Iwata et. al in 2004, when they found that the ability of 
intestinal DC to generate α4β7pos CCR9pos gut-specific T cells lies in their selective ability 
to produce retinoic acid. We have demonstrated that following activation with 
CpG-DNA, dendritic cells from peripheral and intestinal lymph nodes show increased 
intracellular levels of RALDH2 mRNA, a transcript coding for the key enzyme in RA 
synthesis. These findings are unexpected as CpG stimulation at the same time 
attenuates the capability of these cells to imprint a gut phenotype upon co-cultured T 
cells. Little is known about the regulation of the enzyme in dendritic cells and other cell 
populations. Uematsu and colleagues recently reported that RALDH2 mRNA 
expression in lamina propria-derived DC was enhanced upon TLR5 stimulation while 
TLR4 activation failed to induce the enzyme in splenic DC [Uematsu et al., 2008]. It 
was beyond the scope of this work to analyze the levels of RA produced by dendritic 
cells or to assess the formation and release of metabolites after CpG stimulation. 
 
In subsequent experiments in this work, we demonstrate that CpG-activated dendritic 
cells significantly reduced DC-independent upregulation of α 4β7 on anti-CD3ε/CD28-
activated T cells. These findings suggested that in response to TLR9 stimulation, DC 
produce an additional factor that inhibited RA-mediated upregulation of the gut-homing 
receptor α4β7 on co-cultured T cells. Compatible with these findings, Svensson et al. 
suggested a model in which competing signals generated during DC/T cell interactions 
play a central role in regulating tissue-homing receptor expression on responding 
T cells, and that the relative intensity of these signals is dependent on the DC source 
and antigen dose [Svensson et al., 2008]. Dudda and colleagues expanded this model 
to a point that tissue-selective homing receptor expression on T cells is governed by 
inductive as well as suppressive signals from both DC and tissue microenvironments at 
the site of antigen-priming [Dudda et al., 2005]. So far retinoic acid and the vitamin D-
metabolite calciferol have been identified as positive or negative signals, respectively, 
for imprinting a gut-specific phenotype upon T cells. Calciferol is generated at uniquely 
high concentrations in keratinocytes, macrophages and dendritic cells in the skin 
[Sigmundsdottir et al., 2007] and therefore is highly unlikely to account for impaired gut-
imprinting ability of in vitro-CpG-stimulated MLN-derived DC in our experiments. Other 
factors have been proposed to influence tissue-selective imprinting of lymphocytes. In 
vivo neutralization of the co-stimulatory molecule CD134L (also called OX40L), which 
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was expressed by a subset of intestinal DC, inhibited the expression of α4β7 by MLN-
primed T cells in a transfer model of murine colitis [Malmstrom et al., 2001]. In addition, 
others recently described a surprising capacity of intestinal DC to store and carry RA, 
suggesting that DC deliver epithelial-derived RA to the MLN rather than to produce it by 
themselves [Saurer et al., 2007]. However, doubt has been raised about this study’s 
experimental settings and further experiments are required to assess the proposed 
‘RA-storing capacity’ of DCs [Iwata, 2009]. 
 
The instrinsic factors that regulate the very expression of α4β7 on T cells remain poorly 
understood. Recently, DeNucci and colleagues have raised a very interesting aspect in 
this concern. For the α4β7-integrin, the α 4-subunit pairs with β 7. But α4 can also form 
heterodimers with β1. The group now demonstrated, that β1 regulates the expression of 
α4β7 through preferential pairing with the α4-subunit in murine CD4pos T cells [DeNucci 
et al., 2010]. β1 dominates the excessively expressed β7 for α4-pairing, thus controlling 
the amount of unpaired α4 that could form α4β7 heterodimers. Increasing the abundance 
of the α4-subunit in relation to β1 is crucial in the RA-mediated upregulation of α4β7 on T 
cells. Furthermore, they demonstrate that high abundance of the β 1-subunit can 
potently suppress RA-induced upreglation of α4β7. Our data suggest that upon CpG-
stimulation in vitro, DC produce additional soluble factors that inhibit RA-mediated 
upregulation of α4β7 on T cells. We now hypothesize that CpG-activated DC might 
induce β1 upregulation in T cells, thereby impeding the formation of the α4β7-
heterodimer. Further experiments will need to verify this hypothesis. Other recent 
reports have highlighted the role of metalloproteinase-dependent shedding in the 
regulation of surface homing molecules like L-Selectin after TLR stimulation [Morrison 
et al., 2010]. It is hence possible that the diminished RA-mediated upregulation of α4β7 
on T cells upon CpG stimulation is not regulated on the RA production or α4β7-
synthesis level but by the turnover and degradation of the gut-homing integrin on the 
cell surface. 
 
Thus, the identification and role of different soluble factors produced by dendritic cells 
or the tissue microenvironment of induction sites that drive T cell homing and the 
molecular mechanisms, especially in our setting of impaired gut-specific imprinting after 
CpG-DNA stimulation, still have to be defined in detail. However, in our case the 
search can be focused on DC-released factors as imprinting was also diminished in 
CpG-ODN-activated co-cultures of purified MLN-DC and T cells; that is to the exclusion 
of MLN microenvironment such as stroma cells and matrix components. 
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4.2.3 The imprinting of dendritic cells  
Although DC targeting for enhanced antigen delivery and presentation has become a 
prominent focus of both infectious and cancer vaccine research, few studies have 
systematically examined the potential of manipulating peripheral DC for the purpose of 
vaccine-induced mucosal immunity. Based on the well-recognized plasticity of the DC 
system, such studies ought to investigate whether DC could be modulated toward 
“mucosa-type” DC and whether mucosa-borne DC maintain this phenotype during 
immunotherapy or vaccine/adjuvant administration, respectively. In this context, it will 
be fundamental to understand how dendritic cells are themselves imprinted with the 
ability to subsequently induce different tissue-specific homing phenotypes on T and 
B lymphocytes.  
 
So far, it was demonstrated that based on conventional DC markers like CD8α, CD11b, 
CD11c and B220, there seem to be few differences in the ability of DC subsets from a 
given lymphoid tissue to generate tissue-tropic effector cells [Agace, 2006]. 
Johansson-Lindbom and colleagues demonstrated that DC can be imprinted with the 
ability to generate tissue-specific T cells before entering a lymph node. Furthermore, 
MLN-DC that express CD103, which make up about 40% of dendritic cells in 
mesenteric lymph nodes, are more potent to induce α4β7 and CCR9 on responding T 
cells in vitro when compared to CD103neg MLN-DC [Johansson-Lindbom et al., 2005]. 
These CD103pos MLN-DC seem to originate from the intestinal lamina propria and have 
migrated to the MLN upon antigen uptake where they make up the T cell gut-imprinting 
DC population [Jang et al., 2006]. These reports indicate that the tissue-
microenvironment where dendritic cells have encountered antigen and from where they 
afterwards have migrated rather than the identity of the draining lymph node have a 
role in imprinting DC with the ability to generate tissue-tropic T and B cells. However, 
as mentioned above, Hammerschidt et. al reported that in vivo stroma cells, but not 
DC, allow the MLN to induce the generation of gut tropism as PLN transplanted into the 
gut mesenteries failed to support the generation of gut-homing T cells, even though 
lamina propria-derived DC entered the transplants and primed T cells; furthermore DC 
that failed to induce α4β7-integrin and CCR9 in vitro readily induce these factors in vivo 
upon injection into MLN afferent lymphatics. The authors suggested that under 
physiological conditions, stroma cells and DC may cooperate in shaping a lymph node 
environment that in the MLN is characterized by high levels of RA, thereby favoring the 
induction of gut-homing molecules. 
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Taken together, these results clearly disprove the formerly mentioned possibility that 
subsets of pre-imprinted DC precursors from the bone marrow selectively localize to 
distinct peripheral tissue and thereby facilitate T cell tissue-tropism but rather 
demonstrate that the ability of DC to imprint a distinct tissue-specific phenotype upon 
T and B cells is regulated dynamically and can be reconditioned during their lifetime. 
Regardless of whether dendritic cells are imprinted with the ability to induce tissue 
tropism at the site of antigen uptake or in the draining lymph nodes by stroma cells, the 
factors used in this process remain to be determined. In a recent porcine study, 
monocyte-derived non-mucosal DC were analyzed for their capacity to imprint mucosal 
homing receptor expression on lymphocytes following targeting with selected 
immunomodulatory and adjuvant factors. Saurer et. al demonstrated that these DC 
when pre-treated with RA promoted up-regulation of α4β7-integrin and CCR9 mRNA 
expression on activated lymphocytes in vitro [Saurer et al., 2007]. They proposed a 
novel role for RA as mucosal immune modulator with epithelia cells being the possible 
source of RA in the intestinal mucosa. However, these RA-treated DC did not totally 
the function of resemble intestinal-borne DC and thus further studies will be needed to 
deepen our knowledge about the process of DC imprinting. 
 
 
4.3 TLR ligands influence future perspectives for vaccine 
design, cancer immunotherapy and HIV treatment 
As our understanding of the mechanisms that control the generation of tissue-tropic 
T and B lymphocytes steadily grows, the potential for using this knowledge for 
therapeutic purposes becomes evident. At the onset of this work, vaccination and 
cancer immunotherapy were two of several scenarios in which manipulating the 
tissue-homing receptor profile of lymphocytes could have clinical application and might 
be influenced by already utilized TLR-adjuvants.  
 
Many pathogenic bacteria such as Salmonella enterica subsp. enterica serovar 
typhimurium and Vibrio cholerea but also viruses like HIV invade our body at mucosal 
surfaces and therefore protective mucosal immune responses to vaccinations are often 
desired [Neutra and Kozlowski, 2006]. Today, most vaccines are still administered 
intramuscularly or subcutaneously, delivering the vaccine antigen to non-mucosal sites. 
Adjuvants that boost the antigen-specific immune response but also induce the 
expression of mucosal homing receptors on responding T and B cells at the site of 
vaccination might enhance vaccine efficacy for such pathogens. Conversely, vaccines 
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that target those distinct DC subsets such as CD0103pos DC in the intestinal lamina 
propria, that are physiologically able to generate gut-tropic lymphocytes, could be used 
to increase lymphocyte localization to desired intestinal sites of infection. 
 
Furthermore, the α4β7-integrin has recently been implicated to play a vital role in HIV 
pathogenesis. Several reports have demonstrated before that HIV infection leads to the 
destruction of most CD4pos T cells in gut-associated lymphoid tissues, leaving a 
damaged and thus compromised tissue in its wake [Haase, 2005; Picker, 2006]. Arthos 
and colleagues have now shown that HIV-1 binds to the α4β7-integrin through an 
interaction with the viral envelope glycoprotein gp120, which enhances infection of 
T cells by the virus [Arthos et al., 2008]. Thus, pharmacological modulation of the 
expression of the α4β7 integrin by TLR ligands may in the future serve as a novel 
therapeutic approach in the treatment of HIV. 
 
Two main pillars of cancer immunotherapy are DC immunization and T cell 
immunotherapy where ex vivo antigen-loaded DC or primed tumor-specific T cells, 
respectively, are adoptively transferred. Regarding DC immunization, the route of DC 
administration appears crucial in dictating the homing receptor expression pattern of 
responding lymphocytes. Only DC that were injected intraperitoneally were able to 
generate gut-tropic T cell responses, regardless of the origin of adoptively transferred 
DC [Dudda et al., 2004; Dudda et al., 2005]. As mentioned above, together these 
reports indicate that DC are re-imprinted either at the site of immunization or by 
dominant soluble factors and/or stroma cells in the draining lymph nodes at the time of 
T cell priming. Identification of these DC imprinting factors may allow effective 
conditioning of the immunization site before DC transfer or even ex vivo generation of 
‘intestinal’ DC. In T cell immunotherapy we are facing problems by the inefficiency of in 
vitro-primed and expanded T cells to localize to the relevant tumor site and associated 
draining lymph nodes [Dudley and Rosenberg, 2003]. The identification of the factors 
including TLR adjuvants that regulate the induction of homing receptors on 
lymphocytes may thus allow for the in vitro-generation of tumor-specific T cells with an 
enhanced ability to target distinct tumors; in our case especially tumors of the intestinal 
tract. 
 
In this work we demonstrate that immunostimulants like TLR ligands that have been 
widely and successfully used in immunotherapy, can have significant impact on the 
tissue-tropism of a subsequently triggered immune response. Thus, stimulation of TLR, 
here shown for TLR9 ligands, can result in downregulation of the gut-homing receptors 
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α4β7-integrin and CCR9 on bystander naïve lymphocytes as well as on memory T and 
B cells with afterwards impaired ability to enter intestinal lymphoid tissues and lamina 
propria in short-term homing experiments. The process of imprinting tissue-tropism is 
affected as well, as DC stimulated with TLR9 ligands failed to induce high levels of 
α4β7-integrin on responding T cells in vitro. These findings point out the difficulty to 
mount effective mucosal immune responses by using these adjuvants and could 
explain why we face inefficient therapy results in treating intestinal tumors with TLR9 
adjuvant while subcutaneous marker tumors responded satisfyingly to the same 
regimen. However, in other experimental settings, TLR ligands proved more than once 
that they can be powerful tools as vaccine adjuvants and in antitumor therapy and are 
too valuable to be given up for intestinal/mucosal immunotherapy. 
 
Although many homing receptors that are involved in T cell tissue tropism have been 
identified, future studies need to address the cellular and molecular mechanisms that 
regulate their in vivo expression. Solving the following outstanding issues will be central 
to utilize our new insights in tissue-specific homing of lymphocytes for immunotherapy 
and to overcome the obstacles illustrated for intestinal immunotherapy in this work: 
(1) First and foremost, the current understanding of the mechanisms that drive 
generation of tissue-tropic T and B cells as well as our findings are based on murine 
models. Confirmation that similar mechanisms apply for humans are urgently required. 
(2) It is essential to identify the anatomical sites where DC themselves are imprinted 
with the ability to induce tissue specificity on lymphocytes, the molecular mechanism 
underlying this process and the particular influence of commonly used adjuvants like 
TLR ligands. 
(3) It is important to require a better understanding of the molecular signals generated 
by dendritic cells that regulate expression of the homing receptors on responding T and 
B cells. Then, undesired signals could be overwritten and lymphocytes reprogrammed 
to designated target tissues. 
(4) We still need to investigate whether the ability to generate tissue-specific 
lymphocyte subsets is restricted to the intestine and the skin or is a property of all 
lymph nodes.  
(5) Last, it will be necessary to determine crucial effects of inflammation and systemic 
infection on site-specific induction and function of tissue-homing receptor expression. 
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4.4 TLR ligands in inflammatory bowel disease 
Inflammatory bowel diseases (IBD) are a group of idiopathic disorders of chronic 
inflammation of the GI tract supposedly due to inappropriate mucosal immune 
responses to normal intestinal microbes. IBD are traditionally divided into two subtypes, 
ulcerative colitis (UC) and Crohn’s disease (CD), which share the common pathway of 
uncontrolled intestinal inflammation. Hereby, CD primarily affects the small intestine 
and the terminal ileum while UC is mainly limited to the large intestine. A key element 
in the pathogenesis of both UC and CD is enhanced leukocyte recruitment from the 
blood circulation which provides a potential target for therapeutical inhibition. 
 
4.4.1 Aberrant homing in inflammatory bowel diseases 
The exact pathogenesis of IBD is still poorly understood. Common theories share the 
importance of mutations of innate PRR like NOD2 that lead to defective microbial 
sensing by epithelial and antigen-presenting cells [Kobayashi et al., 2005]. Failure to 
clear commensal microbes through such innate immune mechanisms leads to a 
compromised barrier function, bacterial colonization of the epithelium and subsequent 
activation of the acquired immune response [Eksteen et al., 2008]. The resulting 
inflammation consists of T cells and macrophages in CD and is strongly polarized 
towards a TH1/ TH17 immune response with production of pro-inflammatory cytokines 
like TNF-α, IL-12/IL-23 and IFN-ɣ/IL-17 [Fuss et al., 2006]. UC, on the other hand, is 
characterized by an infiltrate of neutrophils in addition to T cells and an excess of IL-13 
and IL-5 resembling a modified TH2 immune response [Fuss et al., 2004].  
 
Regardless of the underlying cause, both UC and CD are associated with massive, 
inappropriate influx and accumulation of immune cells into the gut. The gut-specific 
endothelial adhesion molecules MAdCAM-1 [Briskin et al., 1997] and 
CCL25 [Papadakis et al., 2001] are upregulated on mucosal vessels in IBD resulting in 
sustained recruitment of lymphocytes. As the inflammation establishes, signals that 
drive organ specificity become diluted by generic inflammation-associated processes 
[Eksteen et al., 2008]. Dysregulated immune responses to commensal bacteria, an 
abundance of TLR ligands and a sustained overproduction of pro-inflammatory 
cytokines up-regulate the expression of additional adhesion molecules such as ICAM-1 
and VCAM-1 on the endothelium of mucosal venules, thereby promoting continuous 
leukocyte recruitment into the inflamed tissue [Nakamura et al., 1993]. The increased 
local secretion of cytokines changes the microenvironment of the gut in favor of 
maturation and activation of dendritic cells. DC then emigrate into intestinal lymphoid 
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tissues, creating a positive feedback loop between gut tissue and lymphoid organs by 
redirecting additional lymphocytes to the intestinal compartment [Bell et al., 2001]. 
 
An additional feature of IBD is the capacity of chronic gut inflammation to trigger 
inflammation in extra-intestinal sites. These extra-intestinal manifestations of IBD occur 
when lymphocytes infiltrate the joints, eyes, skin, lungs or liver. It has been suggested 
that extra-intestinal complications arise because chronic intestinal inflammation leads 
to the generation of activated circulating gut-effector lymphocytes that somehow bind to 
tissue vessels outside the GI tract. Indeed, patients with IBD-associated autoimmune 
hepatitis and/or primary sclerosing cholangitis (PSC) showed anomalous expression of 
MAdCAM-1 and CCL25 in liver endothelium [Hillan et al., 1999]. Accordingly, 20 % of 
intrahepatic T cells in PSC patients had a mucosal phenotype with high expression of 
α4β7 and CCR9 [Eksteen et al., 2004]. Recruitment of these lymphocytes to the liver in 
response to aberrantly expressed gut-homing molecules, the possible encounter with 
their cognate antigen and their subsequent activation results in hepatitis and liver 
injury. However, the signals responsible for inducing the expression of MAdCAM-1 and 
CCL25 in the liver of patients with IBD are currently unknown. Extension of this model 
of aberrant lymphocyte recirculation to other extra-intestinal manifestations of IBD 
could explain their tissue distributions as well as point to new therapies that are based 
on modulating tissue-specific lymphocyte homing [Eksteen et al., 2008]. 
 
 
4.4.2 Anti-adhesion molecule therapy in inflammatory bowel disease 
The crucial role of adhesion molecules in inflammatory disorders makes them 
interesting targets for drug development. Several therapeutic compounds directed 
against trafficking of lymphocytes towards the gut mucosa have been designed 
recently, and are being further developed as a novel class of drugs that modulate 
lymphocyte migration and hopefully thereby alter course of the local inflammatory 
reaction in the intestinal wall of patients with Crohn’s disease or ulcerative colitis. 
Several experimental and first clinical studies have shown promising results of the new 
class of therapeutics. 
 
In IBD, anti-adhesion therapy focuses on two pathways: the α 4β7 integrin/MAdCAM-1 
and the LFA-1/ICAM-1 interaction. In a murine model of spontaneous ileal 
inflammation, the SAMP1/Yit mouse, which shares histological features with human 
ileal CD, prophylactic antibody blockade of MAdCAM-1 prevented the development of 
ileitis [Matsuzaki et al., 2005]. In ongoing clinical studies, a specific α4β7 integrin 
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antibody, LDP02, showed success in treatment of patients with clinically present 
IBD [Marshall, 2001; van Assche and Rutgeerts, 2002]. Natalizumab, a humanized 
monoclonal α 4-integrin IgG4 antibody that not only blocks the α 4β7/MAdCAM-1 
interaction but also inhibits the inflammation-induced α 4β1-VCAM-1 binding, proved 
efficient in therapy of patients with active CD [Ghosh et al., 2003]. ICAM-1 is another 
endothelial adhesion molecule that is upregulated and hence gains importance during 
inflammation. In the murine dextran sulphate sodium-induced colitis model, inhibition of 
ICAM-1 with antibodies or small inhibitory RNA (siRNA) reduced experimental colitis 
[Bennett et al., 1997; Taniguchi et al., 1998]. SiRNAs are antisense oligonucleotides 
that hybridize to a sequence-specific target RNA molecule, most often mRNA, and 
consecutively prevent the translation of the protein encoded by this RNA. SiRNA 
targeting ICAM-1 has shown efficacy in open-label studies in patients with UC and 
chronically active CD [Eksteen et al., 2008]. However, other studies could not 
convincingly show efficiency of anti-ICAM antisense oligonucleotides [van Assche and 
Rutgeerts, 2002]. Taken together, these studies suggest that anti-adhesion molecule 
therapy is an attractive concept for the treatment of IBD. 
 
 
4.4.3 Murine colitis models and CpG therapy 
Several recent studies investigated the role of immunostimulatory CpG-DNA motifs in 
the pathogenesis and treatment of IBD. As impaired mucosal barriers, dysregulated 
intestinal immune responses against commensal bacteria and overproduction of pro-
inflammatory cytokines were postulated to contribute in the pathogenesis of IBD, 
Rachmilewitz and colleagues speculated that known cell-survival-promoting effects and 
immunostimulatory properties of CpG-DNA could inhibit damage to the colonic mucosa 
and limit exposure of subepithelial tissue to commensal bacteria and inflammatory 
products. These combined effects could thereby result in the inhibition of chronic 
intestinal inflammation [Rachmilewitz et al., 2002]. Indeed, they could demonstrate that 
subcutaneously or intragastrically injected CpG-DNA could prevent – when given 
prophylactically – and ameliorate – when given after onset of the disease – clinical and 
chemical signs of colitis in a murine model. These results were reproducible in different 
models of chemically-induced colitis (dextran sulphate sodium-induced and 
hapten-induced colitis) as well as in an IL-10 knockout model of spontaneous colitis. 
Treatment with CpG-DNA resulted in lower levels of colonic pro-inflammatory cytokines 
such as IL-6, IL-1β and TNF-α, pro-apoptotic caspase-3 and 9, decreased epithelial 
cell death and preserved colonic mucosal architecture. These effects were independent 
of the nature of the associated CD4pos T cell response as the different involved murine 
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colitis models were driven by both TH1 and TH2-weigthed adaptive immune responses. 
Hence the authors concluded that survival-promoting and immunostimulatory effects on 
innate immunity by CpG-DNA limits mucosal damage and invasion of commensal 
bacteria and thereby reduces the subsequent mucosal inflammation driven by adaptive 
immunity [Rachmilewitz et al., 2002]. 
 
Later, it was demonstrated that the beneficial effects in IBD patients of treatment with 
probiotic bacteria [Hart et al., 2003] is mediated by their immunomodulating DNA 
[Rachmilewitz et al., 2004]. Mice with experimental colitis treated with probiotics 
showed significant improvement in their symptoms. This effect was totally abrogated in 
TLR9-deficient mice while mice lacking functional TLR2 and 4 showed normal 
response to the treatment. Administration of ɣ-irradiated probiotics ameliorated the 
experimental colitis as did the viable probiotics making it unlikely that bacterial 
metabolites or their competitive inhibition of commensal microbes were responsible for 
their protective effects on the colonic mucosa. Subcutaneous and intragastric but not 
rectal administration of irradiated probiotics was effective in ameliorating the 
experimental colitis indicating that probiotic DNA acts systemically and was mainly 
absorbed in the small intestine. Rachmilewitz et al. concluded that immunomodulating 
DNA motifs from commensal bacteria may play a physiological role in the maintenance 
of mucosal homeostasis, limit bacterial invasion into colonic tissue and reduce resulted 
inflammation [Rachmilewitz et al., 2004]. Subsequent studies identified type I IFN as 
mediators of the anti-inflammatory effect by CpG-DNA in murine models of 
experimental colitis [Katakura et al., 2005; Lee et al., 2006]. 
 
These promising results raised hope that the immunomodulating properties of CpG-
DNA could soon be facilitated in clinical trials [Bradbury, 2002] and were further 
augmented by reports that CpG-DNA inhibited the ex vivo production of the 
pro-inflammatory cytokines TNF-α and IL-1β by inflamed colonic mucosa of patients 
with active ulcerative colitis [Rachmilewitz et al., 2006].  
 
In contrast, Obermeier et al. found divergent effects of immunostimulatory 
oligonucleotides in a chemically-induced model of murine colitis. When CpG-DNA was 
injected intraperitoneally, only prophylactic treatment could ameliorate the colitis while 
treatment in a chronic state of disease aggravated its symptoms [Obermeier et al., 
2002; Obermeier et al., 2003]. Pretreatment with CpG-DNA but not LPS reduced levels 
of IFN-ɣ, IL-6 and IL-12 in MLN during the experimental colitis while these 
pro-inflammatory cytokines were elevated by CpG-treatment after the onset of acute 
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colitis. The authors hypothesized that the commensal bacterial DNA-induced immune 
response perpetuates established murine experimental colitis and that pre-treatment 
with CpG-DNA may have lead to ‘desensitization’ with suppressed production of 
inflammatory cytokines as well as IL-10-induced tolerance towards bacterial DNA. 
Further studies consolidated Obermeier and colleagues’ theory that CpG-DNA derived 
from luminal bacteria contributes to the perpetuation of chronic late-stage intestinal 
inflammation. They demonstrated that eight weeks after the onset of dextran sulfate 
sodium-induced colitis in TLR9-deficient mice, intestinal inflammation was significantly 
lower and pro-inflammatory cytokine production was markedly reduced when 
compared to colitis in wild-type mice [Obermeier et al., 2005]. Treatment of wild-type 
mice suffering from chronic chemically-induced colitis with adenoviral oligonucleotide 
that are known to block CpG DNA effects, resulted in a significant amelioration of 
disease with a reduced production of IFN-ɣ but stable levels of TGF-β and IL-10 in 
colonic tissue.  
 
More recent studies by the same group provided data supporting the concept that 
bacterial CpG DNA derived from the normal gut flora may contribute essentially to the 
homeostasis between effector and regulatory immune mechanisms in healthy 
individuals to protect them from chronic intestinal inflammation [Obermeier et al., 2005]. 
They used the murine SCID transfer model in which colitis was induced by transfer of 
naïve splenic TH cells into recipients with severe combined immunodeficiency (SCID) 
that are characterized by an absolute absence of functional T cells. In contrast, TH cells 
from CpG-ODN treated donors did not induce significant intestinal inflammation in 
SCID recipients. Additionally, TH cells from TLR9-deficient mice induced markedly more 
severe colitis in SCID recipients than cells from wild-type controls, suggesting similar 
protective role of ‘endogenous’ bacterial DNA leading to a less ‘aggressive’ phenotype 
of these cells. Cotransfer of CpG-treated and naïve TH cells protected recipient 
animals from colitis, indicating regulatory activity. Attenuated, CpG-treated cells 
showed reduced proliferation and produced less IFN-ɣ, IL-5 and IL-6 after anti-CD3 
stimulation, but there was no difference in regulatory T cell surface markers between 
‘aggressive’ and attenuated cell pools. Recent reports showed that these protective 
properties of CpG-DNA were independent from a pre-existing bacterial flora indicating 
non-antigen specific effects and that TGF-β and type I IFNs as well as IL-10 
independent mechanism were involved [Bleich et al., 2009]. 
 
Taken together, these findings point out the critical role of bacterial CpG-DNA in the 
pathogenesis of chronic intestinal inflammation. Constant exposure of a healthy 
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organism to commensal bacterial DNA may contribute to the homeostasis of the 
intestinal immune system regulating the delicate balance between effector and 
regulatory mechanisms. To which extent these CpG-DNA motifs perpetuate 
established intestinal inflammation and when is the critical time point in the course of 
diseases that CpG-ODNs turn from friend to foe, remains to be clarified. However, this 
demonstrates the multifaceted host response toward CpG motifs of bacterial DNA and 
how a single TLR stimulus may change the susceptibility to complex disorders as IBD 
[Obermeier et al., 2005]. 
 
Different theories of the mechanism how CpG-DNA realizes its protective effect in 
intestinal inflammation have been postulated. Rachmilewitz et al. suggest diverse 
immunomodulatory effects of CpG-DNA, on the one hand enhancing innate immunity 
and its epithelia barrier function to prevent pathogens from reaching deeper layers of 
the intestinal mucosa and on the other hand reducing production of pro-inflammatory 
cytokines in the colonic mucosa [Katakura et al., 2005; Rachmilewitz et al., 2006]. 
Obermeier and colleagues hypothesize that bacterial DNA-motifs might induced 
regulatory properties in T cell subsets [Obermeier et al., 2005; Bleich et al., 2009]. In 
this work we demonstrate that CpG-DNA exposure results in reduced surface 
expression of the gut-homing integrin α4β7 on T cells in vivo and in vitro. Short-term 
homing experiments confirmed poor migration to intestinal lymphoid tissue, the small 
intestine and the colon by these lymphocytes. Although previous studies with murine 
models of experimental colitis did not address expression patterns of gut-specific 
adhesion molecules on lymphocytes nor their distribution and/or accumulation in the 
inflamed colon, it is tempting to speculate that the impaired capability of T cells to 
migrate to the intestinal tract may have contributed to the protective effect of CpG-DNA 
in murine experimental colitis. Further studies will be needed to elucidate the role of 
lymphocyte migratory behavior in amelioration of murine colitis after CpG-treatment. 
Nevertheless, these finding emphasize the potential of CpG-DNA motifs as novel 
compounds in the treatment of IBD. 
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4.5 Summary 
Effective immune surveillance requires that immune cells are recruited and positioned 
in specific tissue compartments where they are able to carry out their functions. This is 
achieved for lymphocytes primarily through the selective expression of adhesion 
molecules and chemokine receptors, which allow them to bind to their endothelial 
ligands in vascular beds of particular effector organs. Among these migratory 
molecules, also called homing receptors, are the α4β7 integrin and the chemokine 
receptor CCR9 that mediate lymphocyte homing to the gastrointestinal tract. 
Expression of the correct access code of homing receptors by T cells is crucial for 
efficient tissue-specific immune responses but also induces autoimmune diseases and 
allergy. Thus, interfering with T cell homing is emerging as a promising therapeutic 
strategy.  
 
In recent years, the factors involved in the regulation of T cell homing have been the 
subject of intense research. In the first part of this study, we focused on the effect of 
innate immune activation by Toll-like receptor agonists, such as immunostimulatory 
CpG DNA, on the expression patterns of the gut-homing receptor α 4β7 on naïve 
lymphocytes. We demonstrate that in vivo stimulation of mice with CpG DNA leads to a 
decrease of approximately 60 % in surface expression of α 4β7 on lymphocytes in 
peripheral and mesenteric lymph nodes. This effect was not dependent on the route of 
CpG administration. In vitro experiments showed that downregulation of the gut 
adhesion molecule on lymphocytes is mediated by dendritic cell (DC)-released 
cytokines including interleukin-6 and is not dependent on direct cell-cell interaction. In 
subsequent short-term homing experiments these CpG-stimulated lymphocytes were 
markedly impaired in their ability to enter intestinal sites as they failed to efficiently 
recirculate to mesenteric lymph nodes and Peyer’s patches.  
 
Several reports have shown that signals derived from DC contribute to the selective 
generation of tissue-tropic T cells in secondary lymphoid organs. A key factor in this 
process appears to be the DC-delivered vitamin A metabolite, retinoic acid. However, it 
remains unclear how DC themselves are imprinted in their local environment with the 
ability to induce different tissue-specific homing phenotypes on T and B lymphocytes. 
In the second part of this study we demonstrate that stimulation of mesenteric lymph 
node-derived DC with the TLR9 ligand CpG attenuates their ability to imprint gut 
specificity upon antigen-specific T cells. Unexpectedly, following activation with CpG 
DNA, DC from peripheral and intestinal lymph nodes show increased intracellular 
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levels of RALDH2 mRNA, a transcript coding for the key enzyme in retinoic acid 
synthesis. Furthermore, these CpG-stimulated DC reduced upregulation of α4β7 on 
activated T cells, suggesting that in response to unspecific innate immune activation, 
DC produce an additional factor that inhibits retinoic acid-mediated upregulation of the 
gut-homing receptor α4β7 on T cells. 
 
Systemic administration of the TLR9 ligand CpG-DNA induces a state of systemic 
inflammation. Our data now show that in this inflammatory state, downregulation of the 
α4β7 integrin critically alters migration patterns of lymphocytes. Naïve T cells are then 
impaired in their capacity to enter intestinal secondary lymphoid organs and imprinting 
of gut-homing specificity on intestinal antigen-experienced T cells by dendritic cells is 
markedly attenuated. Thus, during systemic inflammation, the gut is deprived of locally 
activated T cells and further lymphocyte influx. As the largest peripheral immune 
compartment, the gastrointestinal system constitutes a huge lymphocyte reservoir. 
Thus, we hypothesize that it may provide an enormous pool of lymphocytes that are 
recruited during infection.  
 
Future studies will need to specify the cellular and molecular mechanisms that regulate 
the in vivo expression of the homing receptor α4β7. Solving this key issue should 
increase our understanding of tissue-specific immune and inflammatory processes in 
the gastrointestinal tract. Therapeutic modulation of organ-selective trafficking patterns 
of lymphocytes will allow tissue targeting of immune responses against local tumors 
and therapeutic re-routing of pathogenic T and B cells in gut-specific autoimmune and 
inflammatory diseases such as ulcerative colitis and Crohn’s disease. Furthermore, 
recent studies have identified the integrin α4β7 as a coreceptor of HIV and modulating 
α4β7 expression may serve as a novel therapeutic approach in this disease.  
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4.6 Zusammenfassung 
Eine effektive Immunüberwachung setzt voraus, dass Abwehrzellen in spezifische 
Gewebskompartimente rekrutiert und dort positioniert werden, wo sie ihre spezielle 
Funktion ausüben können. Für Lymphozyten wird dies in erster Linie durch die 
selektive Expression von Adhäsionsmolekülen und Chemokinrezeptoren gewährleistet. 
Diese ermöglichen den Lymphozyten ihren endothelialen Liganden in den Gefäßbetten 
bestimmter Effektororgane zu binden und in diese einzuwandern. Innerhalb dieser 
Migrationsmoleküle, auch Homing-Rezeptoren genannt, vermitteln das α4β7 Integrin 
und der Chemokinrezeptor CCR9 die gezielte Migration von Lymphozyten in den 
Gastrointestinaltrakt. Die Expression des richtigen Musters an Homing-Rezeptoren auf 
T-Zellen entscheidet sowohl über das Zustandekommen einer effizienten 
gewebsspezifischen Immunantwort als auch von Autoimmunerkrankungen und 
Allergien. Dementsprechend zeichnet sich die Beeinflussung der zielgerichteten 
T-Zell-Migration als ein vielversprechender zukünftiger therapeutischer Ansatz ab. 
 
In den letzten Jahren waren die Faktoren, die an der Regulation des 
Migrationsverhaltens von T-Zellen beteiligt sind, Gegenstand intensiver Forschung. Im 
ersten Teil dieser Arbeit untersuchten wir, wie eine Aktivierung des angeborenen 
Immunsystems durch Toll-like-Rezeptor-Agonisten, wie zum Beispiel 
immunstimulatorische CpG-DNA, das Expressionsmuster des gastrointestinalen 
Homing-Rezeptors α4β7 auf naïven Lymphozyten beeinflusst. Wir zeigen, dass in vivo-
Stimulation mit CpG-DNA bei Mäusen zu einer 60-prozentigen Abnahme der 
Oberflächenexpression von α4β7 auf Lymphozyten in peripheren und mesenterialen 
Lymphknoten führt. Dieser Effekt war nicht abhängig vom Applikationsweg für CpG-
DNA. Fortführende in vitro Experimente haben gezeigt, dass die Runterregulation des 
Adhäsionsmoleküls auf Lymphozyten durch Zytokine vermittelt wird, die von 
dendritischen Zellen (DC) sezerniert werden. Dieser Prozess involviert Interleukin-6 
und ist nicht abhängig von direktem Zell-Zell-Kontakt. In anschließenden Migrations-
Experimenten waren CpG-aktivierte Lymphozyten stark in ihrer Fähigkeit 
eingeschränkt, in intestinales Gewebe einzuwandern, da sie nicht in der Lage waren, 
effizient zu den mesenterialen Lymphknoten oder Peyer’schen Plaques zu migrieren.  
 
Mehrere Arbeiten haben gezeigt, dass von DC stammende Signale zur selektiven 
Bildung von gewebsspezifischen T-Zellen in sekundär-lymphatischen Organen 
beitragen. Ein Schlüsselfaktor in diesem Prozess scheint der von DC bereitgestellte 
Vitamin-A-Metabolit Retinolsäure zu sein. Jedoch bleibt es unklar, wie DC ihrerseits in 
Discussion 
93 
ihrer lokalen Umgebung die Fähigkeit erlangen, verschiedene gewebsspezifische 
Migrations-Phänotypen auf T- und B-Zellen zu prägen. Im zweiten Teil dieser Arbeit 
zeigen wir, dass die Stimulation von DC aus mesenterialen Lymphknoten mit Toll-like-
Rezeptor-Liganden deren Fähigkeit einschränkt, Darm-Spezifität auf T-Zellen 
einzuprägen. Unerwarteterweise reagieren DC auf eine Aktivierung durch CpG-DNA 
mit einem gesteigerten intrazellulären Level an RALDH2 messenger RNA; einem 
Transkript, das für das Schlüsselenzym der Retinolsäure-Synthese kodiert. Weiterhin 
verringern diese CpG-stimulierten DC die Hochregulation von α4β7 auf aktivierten T 
Zellen. Dies legt nahe, dass DC in Reaktion auf einen unspezifischen Stimulus des 
angeborenen Immunsystems, einen weiteren Faktor sezernieren, der die durch 
Retinolsäure vermittelte Hochregulation von α4β7 auf T-Zellen blockiert. 
 
Systemische Anwendung des Toll-like-Rezeptor-9-Liganden CpG-DNA induziert einen 
Zustand systemischer Entzündung. Unsere Daten legen nun nahe, dass während 
diesem entzündlichen Zustand durch die Runterregulation des α4β7 Integrins, die 
Migrationsmuster von Lymphozyten entscheidend verändert werden. Naive T-Zellen 
sind nun in ihrer Fähigkeit eingeschränkt in intestinale sekundärlymphatische Organe 
einzuwandern und das Prägen von Darm-Spezifität auf antigenerfahrenen T-Zellen 
durch lokale DC ist deutlich vermindert. Dementsprechend ist das Magen-Darm-
System während der systemischen Entzündungsphase von lokal aktivierten als auch 
neu eingewanderten T-Zellen abgeschnitten. Da das gastrointestinale System das 
größte periphere Immunkompartiment darstellt und auf diese Weise einen enormen 
Pool an Lymphozyten bereithält, nehmen wir an, dass diese während einer 
systemischen Infektion rekrutiert werden können. 
 
Zukünftige Arbeiten werden die zellulären und molekularen Mechanismen präzisieren 
müssen, die die Expression des Homing-Rezeptors α4β7 regulieren. Die Lösung dieser 
Schlüsselfrage wird unser Verständnis von gewebsspezifischen Immun- und 
Entzündungsvorgängen im Magen-Darm-System entscheidend verbessern. Die 
therapeutische Modulation organspezifischer Migrationsmuster wird uns die Erzeugung 
zielgerichteter Immunantworten gegen lokale Infektionen und Tumoren sowie die 
therapeutische Umleitung von pathogenen Lymphozyten in chronisch-entzündlichen 
Erkrankungen wie Colitis ulcerosa und Morbus Crohn erlauben. Des Weiteren wurde in 
aktuellen Studien α4β7 Integrin als Korezeptor des HI-Virus identifiziert, so dass die 
Modulation der α4β7 Expression als neuartiger therapeutischer Ansatz bei der 
Bekämpfung von HIV dienen könnte.  
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6 APPENDIX 
6.1 Abbreviations 
A 
AP-1  Activated protein 1 
APC  Allophycocyanin 
APC  Antigen-presenting cell 
 
B 
B16-FL  B16 melanoma cell line expressing Flt3-L 
 
C 
Cardif  CARD adapter inducing IFNβ 
CCR  Chemokine receptor 
CD  Crohn’s disease 
cDNA  Copy-desoxyribonucleic acid 
CFSE  Carboxyfluorescein diacetate succinimidyl ester 
CLA  Cutaneous lymphocyte antigen 
CpG   Oligonucleotide with cytosine-(phosphate)-guanine motifs 
 
D  
DC  Dendritic cell 
DMEM  Dulbecco's modified Eagle´s medium 
DMSO  Dimethyl sulfoxide 
DNA  Desoxyribonucleid acid 
ds  Double-stranded 
 
E 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
E-Lig   E-selectin ligand  
 
F 
FACS  Fluorescent-activated cell sorting 
FCS  Fetal calf serum 
FITC  Fluorescein isocyanate 
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FL-DC   Flt3L-derived dendritic cells 
Flt3-L  Fms-like tyrosine kinase 3 ligand 
Foxp3  Forkhead box p3 
FSC  Forward scatter 
 
G 
GI  Gastro-intestinal 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GM-DC   Dendritic cells differentiated with GM-CSF and IL-4 
 
H 
HBSS Hank's balanced salt solution 
HEV High endothelial venules 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HRP Horseradish peroxidase 
 
I 
IBD Inflammatory bowel disease 
IF Interferon 
IL Interleukin 
IMDM Iscove's modified Dulbecco's medium 
IFNaR Interferon-α receptor 
ip intraperitoneally 
IPS-1 IFN-β promoter stimulator 1 
IRF Interferon regulatory factor 
 
L 
LFA-1 Lymphocyte function-associated antigen 1 
LP Lamina propria 
LPAM-1 Leukocyte Peyer’s patches adhesion molecule 1 
LPS Lipopolysaccharid 
LRR Leucine-rich repeat 
 
M 
mAb  Monoclonal antibody 
MACS  Magnetic-activated cell sorting 
MAdCAM-1 Mucosal addressin cell adhesion molecule-1 
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MAPK  Mitogen-activated protein kinase 
MDA5  Melanoma differentiation associated gene 5 
mDC  Myeloid dendritic cell 
MLN  Mesenteric lymph node  
MHC  Major histocompatibility complex 
mRNA  Messenger ribonucleic acid 
MyD88  Myeloid differentiation primary response gene 88 
 
N 
nd Not determined 
NEAA Non-essential amino acids 
NF-κB  Nuclear factor-κB 
ns Not significant 
 
O 
ODN Oligodesoyxnucleotide 
ON Oligonucleotide 
 
P 
PAMP Pathogen-associated molecular pattern 
PCR Polymerase chain reaction 
pDC Plasmacytoid dendritic cell 
PE Phycoerythrin 
PerCP Peridinin chlorophyll protein 
PLN Peripheral lymph node 
PP Peyer’s patches 
PGN Peptoglycans 
PNAd Peripheral lymph node addressin 
PFA Paraformaldehyde 
PRR Pattern-recognition receptor 
PSC Primary sclerosing cholangitis 
PYD Pyrin domain 
 
Q 
qRT-PCR Quantitative real-time PCR 
 
R 
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RA Retinoic acid 
RALDH Retinol aldehyd dehydrogenase 
RIG-I Retinoic acid-inducible gene-I 
RPMI Roswell Park Memorial Institute 
RNA Ribonucleic acid 
RT Room temperature 
 
S 
SEM Standard error of the mean 
SLO Secondary lymphoid organs 
ss Single-stranded 
SSC Sideward scatter 
 
T 
TH cell T-helper cell 
TIR Toll/IL-1 receptor 
TIRAP TIR domain-containing adapter molecule 
TLR Toll-like receptor 
TMB Tetramethylbenzidine 
TGF Tumor growth factor 
TNF Tumor necrosis factor 
TRAM TRIF-related adapter molecule 
Treg cell Regulatory T cell 
TRIF TIR-containing adapter inducing IFNβ 
 
U 
UC Ulcerative colitis 
 
V 
VLE Very low endotoxin 
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